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ABSTRACT 
Dementia is the progressive decline in cognitive function due to 
damage or disease in the body beyond what might be expected from 
normal aging. Based on neuropathological and clinical criteria, 
dementia includes a spectrum of diseases, namely Alzheimer's 
dementia, Parkinson's dementia, Lewy Body disease, Alzheimer's 
dementia with Parkinson's, Pick's disease, Semantic dementia, and 
large and small vessel disease. It is thought that these disorders result 
from a combination of genetic and environmental risk factors. 
Despite accumulating knowledge that has been gained about 
pathophysiological and clinical characteristics of the disease, no 
coherent and integrative picture of molecular mechanisms underlying 
neurodegeneration in Alzheimer’s disease is available. Existing 
drugs only offer symptomatic relief to the patients and lack any 
efficient disease-modifying effects. The present research proposes a 
knowledge-based rationale towards integrative modeling of disease 
mechanism for identifying potential candidate targets and biomarkers 
in Alzheimer’s disease. Integrative disease modeling is an emerging 
knowledge-based paradigm in translational research that exploits the 
power of computational methods to collect, store, integrate, model 
and interpret accumulated disease information across different 
biological scales from molecules to phenotypes. It prepares the 
ground for transitioning from ‘descriptive’ to “mechanistic” 
representation of disease processes.  
The proposed approach was used to introduce an integrative 
framework, which integrates, on one hand, extracted knowledge 
from the literature using semantically supported text-mining 
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technologies and, on the other hand, primary experimental data such 
as gene/protein expression or imaging readouts. The aim of such a 
hybrid integrative modeling approach was not only to provide a 
consolidated systems view on the disease mechanism as a whole but 
also to increase specificity and sensitivity of the mechanistic model 
by providing disease-specific context. This approach was 
successfully used for correlating clinical manifestations of the 
disease to their corresponding molecular events and led to the 
identification and modeling of three important mechanistic 
components underlying Alzheimer’s dementia, namely the CNS, the 
immune system and the endocrine components. These models were 
validated using a novel in-silico validation method, namely 
biomarker-guided pathway analysis and a pathway-based target 
identification approach was introduced, which resulted in the 
identification of the MAPK signaling pathway as a potential 
candidate target at the crossroad of the triad components underlying 
disease mechanism in Alzheimer’s dementia. 
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CHAPTER 1. Introduction to Scientific 
Challenge 	  
1.1. Complexity of the human brain 	  
The human brain is the most complex organ in the human body that 
processes thought, action, memory, cognition and feeling. More than 
thousand years ago, the Persian polymath – Avicenna – whose book 
“Canon of Medicine” provides a complete system of medicine 
(known as systems medicine today; 
http://en.wikipedia.org/wiki/Avicenna) extensively described the 
brain function, brain diseases and a five-cell profile of human head 
including common sense, retentive imagination, and cognitive 
faculties such as thinking, estimation and memory, both separately 
and interconnected [1],[2].      
That ancient five-dimensional anatomy of the human brain has been 
nowadays transformed into a more modern schema with seven scales 
(Figure 1). 
Today, the complexity of the human brain can be viewed from two 
perspectives: anatomical complexity and functional complexity. 
Anatomically, brain has approximately 1011 neurons that 
communicate together via about 1014 synapses [3]. Surprisingly, 
there is no quantitative information on the number of brain structural 
parts in the public domain but as I report in details in Chapter 5, 
currently the total number of brain anatomical parts based on known 
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Figure 1. A schematic representation of dimensions of 
complexity in the functioning brain. With advancements in 
neurology, a more complex picture of the interconnected brain 
structure and its functioning appears, which poses the challenge of 
dealing with high-dimensional, high-order data sets at various 
biological levels and scales. (Taken from 
[http://questioneverything.typepad.com/]; last accessed: 22.10.2013).  
different cell types amounts to 737. From the interconnectivity of 
such a complex anatomy then arises high-order functioning of the 
brain, which has been recently characterized based on anatomical 
and functional connectivity and synchronisation of their interactions 
[4]. Advanced neuroimaging technologies have revealed the 
existence of functional connectivity profiles of different brain 
regions, defined and visualized as complex functional networks [5]. 
Such a complexity is inherited by neurological diseases as well. 
Therefore, understanding the complexities of the brain is essential 
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for understanding pathologies of brain disorders, including 
neurodegenerative diseases.	  
1.2. Neurodegeneration and dementia 	  
Since this work is focused on neurodegeneration and dementia, 
provisioning their definitions will be helpful for understanding the 
rest of the chapters in this thesis. The term neurodegeneration has 
been defined as “any pathological condition in which the nervous 
system or nerve cell loses its function, structure, or both [6]. The 
neuronal cell degeneration and death is quite devastating (due to 
limited brain’s ability to replace lost neurons) and observed in the 
progressive neurological disorders such as Alzheimer’s disease.  
Dementia by definition is “the loss of intellectual functions, such as 
thinking and memory, which interferes with daily function” [7]. It 
should be noted that the term dementia does not indicate a disease in 
itself, but rather a group of symptoms that are dependent on a 
particular condition and result in cognitive decline and significant 
deterioration of memory.  	  
1.3. Research motivation 
Despite the tremendous advancement of the technology in 
contemporary times, there is little known about the complexity of the 
brain and its disorders resulting from neurodegeneration; hence, 
brain and central nervous system disorders remain the world's 
leading cause of disability with no proper diagnosis and very limited 
symptomatic treatment options. This very fact is reflected in Figure 
2: while modern science has been successful in reducing the 
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mortality of patients suffering from cancers or cardiovascular 
diseases during the past decade, it has failed to control the high death 
rate associated with neurodegenerative diseases (NDDs) such as 
Alzheimer’s disease (AD). Unfortunately, this high rate of mortality 
has been coupled with a wave of high prevalence and incidence of 
Alzheimer’s disease, at least in the US population when compared to 
other NDDs. Moreover, although the worldwide prevalence of AD is 
estimated to quadruple by 2050, currently there exists no means to 
prevent, slow down, or cure AD. A very recent study indicates that, 
despite of reduced total mortality of people aged 55-74 years old in 
developed countries, total neurological deaths (due to nervous 
diseases and Alzheimer’s) increased significantly over the period 
1979-2010 [8]. Thus, the social pressure is rising as patients ask their 
physicians “why does research take so long? Why don’t we have 
effective therapies for such a devastating disease?” [9].      
Since 1960, many features of this fatal disease have been elucidated 
and many potentially disease-modifying compounds have made their 
way to initial human clinical trials. However, more than 200 AD 
drug candidates have failed to date [10]. These failures on the side of 
clinical application – despite significant successes on the side of 
molecular findings - uncover the fact that there is a deep 
“translational gap” between basic research and clinical application in 
Alzheimer’s disease. Some authors have attributed these problems to 
the failure of the translation of research in animal studies or the use 
of wrong animal model [11]. But repetitive failure of amyloid-
targeting clinical trials has led to growing skepticism that the 
hypothesis on which AD trials are based might not be valid [12]. 
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Indeed there are important questions about pathogenic mechanism of 
AD to be answered; for instance, “are different pathways leading to 
the manifestation of AD?”, “are plaques and tangles secondary 
events or downstream effects?”, or “what role is the dimension of 
time playing in the pathophysiology of AD?”. The current situation 
urges for a better understanding of the disease mechanism as it 
progresses over time and highlights the pressing need for correct and 
precise prediction of efficient mechanistic targets right at the 
beginning of the drug discovery pipeline. 
 
	  
Figure 2. Changes in selected causes of death between 
2000 and 2008. The figure shows the overall mortality (in 
the given timeframe of 8 years) in selected disease areas. Note 
that there is substantial controversy about speaking of a “AD 
mortality”, as AD is not the cause of death but rather an 
accompanying condition.  
(Taken from [http://www.alzheimersanddementia.com /article/ 
S15525260(13)00076-9/abstract]; last accessed: 22.10.2013). 
Chapter	  1.	  Introduction	  to	  Scientific	  Challenge	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  	  
Currently no coherent and integrative picture of molecular 
mechanisms underlying neurodegeneration in Alzheimer’s disease is 
available. The AD research community is now beginning to realize 
that AD is a complex multifactorial disease and other non-amyloid 
targets, pathways, and processes should be investigated to identify 
novel treatment strategies [13]. Existing drugs only offer 
symptomatic relief to the patients and lack any efficient disease-
modifying effects [14].	  
1.4. The goal of this thesis 
The goal of the research presented in this thesis is: 
a. to propose an integrative knowledge- and data-driven 
approach for identification of novel target candidates by 
addressing the problem of complexity underlying the 
neurodegenerative mechanisms in Alzheimer’s disease.  
b. to demonstrate that knowledge-based computational 
models and maps of Alzheimer’s disease progression 
enable the identification of mechanistic pathways and 
improve the understanding of the correlations between 
genotypes and phenotypes at the molecular level. 	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CHAPTER 2. Complex Biology Underlying 
Neuro-degeneration in Alzheimer’s Disease 	  
2.1. Classification of neurodegenerative disorders 
(NDDs) 
Neurodegeneration represents a large group of heterogeneous 
disorders in which the neuronal damage and death occurs within 
specific anatomical and functional areas of the brain. The exact 
number of NDDs is not clear but it is estimated to be a few hundred 
[15]. Due to the inherent anatomical and functional complexity of the 
brain, classification of NDDs is a challenging and complicated task, 
which has so far remained controversial. This is because many 
NDDs show clinical and pathological overlap with one another and 
several regions of the brain are affected simultaneously. For 
example, multiple system atrophy (MSA) in which several areas of 
brain are affected by degeneration of neurons, parkinsonism is a 
prominent feature but it may be accompanied with other symptoms 
such as sever ataxia or autonomic failure, depending on the affected 
area of the brain. Another example is the clinical overlap between 
Parkinson’s disease with dementia and Alzheimer’s disease 
dementia. Since classification of these two neurodegenerative 
diseases is merely based on their clinical signs, early diagnosis of 
Parkinson’s disease (PD) is hampered. The extent of clinical overlap 
between these two conditions is so much greater than chance that 
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even some authors propose that AD and PD belong to a spectrum of 
neurodegenerative disorders with common disease mechanism but 
triggered by different etiological factors [16]. Moreover, even many 
diseases with neurodegeneration as their major element such as 
epilepsy, multiple sclerosis and schizophrenia are not classified as 
degenerative. To date, categorization of neurodegenerative disorders 
is still based on clinical features (symptomatology) or the topography 
of lesions (as revealed by imaging techniques). Accordingly, 
Przedborski and coworkers (2003) have proposed a high-level 
classification for NDDs (Figure 3).   
Traditionally, the current nosology of NDDs follows the “one 
disease, one pathology” paradigm which is based on the notion of a 
discrete and clear correlation between disease states and certain 
pathological markers. For instance, early findings in autopsies of AD 
patients showed the presence of amyloid plaques and neurofibrillary 
tangles and similarly, abnormal protein aggregates of Lewy bodies 
were identified in the postmortem brains of Parkinson’s patients. 
However, this kind of nosology poses several problems. 
Firstly, the progressive nature of NDDs highlights the point that 
neurological changes are “time-dependent” and for this reason, it is 
difficult to distinguish disease stages or decide about the associated 
neuropathology. Due to this long “latency period” in NDDs 
generally, and in dementias particularly, which can take several 
decades as long as 22 years before the diagnosis of dementia, 
clinically it is not possible to operationalize poor cognitive 
performance in elderly [17]. Secondly, problems relate to labeling 
the disease when more than one possible diagnosis exists for a set of 
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symptoms. Disease labeling may change over time as the disease 
progresses and this can be misleading for patients [18].  
 
 
Figure 3. High-level classification schema for grouping 
NDDs based on anatomical structure. This schema reflects the 
conventional anatomically guided classification system, which does 
not take into consideration the disease mechanism. Reproduced from 
[15]. 
As mentioned before, the overlapping symptomatology of NDDs 
suggests that single pathological markers can poorly correlate with 
clinical symptoms and perhaps, multiple markers or molecular 
features can better represent separate NDD etiologies. Recent 
initiatives have been launched to develop a new taxonomy of 
diseases based on their underlying molecular and environmental 
causes rather than on physical signs and symptoms [19],[20]. 
Therefore, NDDs should be seen as a spectrum of diseases with 
overlapping symptoms and mixed pathologies.     
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2.2. Dementias and Alzheimer’s disease 	  
2.2.1. Nosology 
Today, several classification systems for dementia subtypes exist, 
taking into account the etiological specifications, anatomic location, 
course of disease and prognosis (http://www.ninds.nih.gov/disorders/ 
dementias/detail_dementia.htm). Figure 4 summarizes all three 
classifications in a single schema with detailed categorization based 
on subcortical subtypes. This schema integrates the entire concept of 
“clinical vs. histopathological vs. mechanism-based classification”. 
The limitation of this classification schema is that it does not provide 
sufficient granularity at the etiological level.    
In contrast, an etiology-based classification schema provides a better 
granularity and more complete list of dementia subtypes. Table 1 
depicts this classification system [22]. However, this classification 
system is heavily biased towards anatomical etiology of dementias 
and does not include the knowledge of molecular basis underlying 
dementias. 
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Figure 4. An integrated classification system for grouping 
dementia subtypes. Reproduced from [21]. 
 
The lack of proper classification of diseases with high resolution at 
the molecular and mechanism level has led to the ignorance of 
disease heterogeneity. Unfortunately, disease heterogeneity is not 
considered in the design and conduct of clinical trials and 
consequently, the likelihood of success in clinical trials for an 
effective drug will probably reduced. For this reason, Kola and Bell 
(2011) have called for reformation of the human disease taxonomy 
by moving away from traditional diagnostic-based criteria to 
molecular-based stratification of patients with multiple disease 
subtype [23].   
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Table 1. Etiology-based classification system for dementia 
subtypes based on anatomy 
Etiology-
based 
dementias 
Primary cortical Alzheimer’s disease  
Frontotemporal dementia  
Pick’s disease  
Primary progressive aphasia  
Agryophilic grain disease  
Lewy body dementia Diffuse 
Mixed 
Cerebral 
Primary 
subcortical 
Parkinson’s disease  
Corticobasal degeneration  
Progressive supranuclear 
palsy 
 
Multiple system atrophy  
Lewy body dementia Transitional 
Brainstem 
Cerebrovascular  Vascular dementia Large/small vessel strokes 
Multiple lacunar infarcts 
Binswanger disease 
CADASIL 
Cerebral amyloid 
angiopathy 
Structural/traum
atic injury 
Brain tumors  
Limbic encephalitis  
Traumatic brain injury  
Dementia pugillistica  
Chronic subdural hematoma  
Normal pressure 
hydrocephalus 
 
Postanoxic state  
Postoperative cognitive 
dysfunction 
 
Toxic exposure Substance induced dementia  
Medication induced dementia  
Alcohol dementia  
Inhalant induced dementia  
Wernicke-Korsakoff 
syndrome 
 
Toxic metal exposure  
Wilson’s disease  
Toxic gas exposure  
Nutritional 
deficiency 
Vitamin B12 deficiency  
Folate deficiency  
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Niacin deficiency  
Thiamine deficiency  
Infectious 
disease 
Bacterial Bacterial manengitis 
Whippie disease 
Viral Viral manengitis 
Herpes simplex 
encephalitis 
HIV-associated dementia 
Progressive 
Leukoencephalopathy 
Sleeping sickness 
Neurosyphillis 
Lyme disease 
Fungal Fungal manengitis 
Cryptococcal meningitis 
Prion disease Creutzfeldt-jakob disease 
Kuru 
GSS syndrome 
Fatal familial insomnia 
Parasitic diseases  
Organ failure Uremic encephalopathy  
Hepatic encephalopathy  
Endocrine 
disease 
Diabetes mellitus  
Hypothyroidism  
Hyperparathyroidism  
Cushing syndrome  
Addison disease  
Neurologic/ 
metabolic 
disorders 
Huntington’s disease  
Multiple sclerosis  
Marchiafava-Bignami 
disease 
 
Ataxia syndrome  
Inherited storage diseases Adrenoleukodystrophy 
Metachromatic 
leukodystrophy 
Cerebrotendinous 
xanthomonasis 
Inflammatory 
disease 
Collagen vascular diseases Behcet syndrome 
Sjörgen syndrome 
Systemic lupus 
erythematosus 
Vasculitides Granulomatous angiitis 
Lymphomatoid 
granulomatosis 
Polyarteritis nodosa 
Wegener granulomatosis  
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2.2.2. Epidemiology of dementias and AD 
Epidemiological estimates indicate that the prevalence of AD is 
increasing worldwide. According to the World Health Organization 
in 2001, about 37 million people worldwide had been afflicted by 
dementia out of which 18 million suffered from AD by that time. 
The latest numbers come from the Alzheimer World Report, which 
estimated 35.6 million people with dementia in 2010, the numbers 
nearly doubling every 20 years, to 65.7 million in 2030 and 115.4 
million in 2050 [24]. The global burden of annual incidence of 
dementia is shown in Figure 5. It is noteworthy that in most studies 
the term ‘dementia’ has been used interchangeably with ‘AD’. 
 
 
 
 
 
 
 
Figure 5. The global burden of annual incidence of 
dementia. (Taken from [http://www.who.int/mental_health/ 
publications/dementia_report_2012/en/]; last accessed: 01.11.2013).  
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Epidemiological studies report that the incidence rate of new cases 
increases with age, almost doubling with every five-year increase in 
age (Figure 6). 
 
 
 
 
 
 
 
 
 
 
Figure 6. Projection of the incidence rate of dementia cases 
from 10 studies. As shown in a number of studies, the prevalence 
of Alzheimer's disease doubles with every five-year increase in age. 
(Taken from [http://www2f.biglobe.ne.jp/~boke/ adupdatecu.htm]; 
last accessed: 22.10.2013) 
 
Interestingly, the incidence of dementia is lower in men but women 
enjoy a longer survival time than men for both AD and vascular 
dementia [25].  	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2.2.3. Risk factors for AD 
Increased risk of AD has been associated with a large number of 
factors. The main risk factor for AD is advancing age, given that it is 
driven by lifelong accumulation of molecular damage. Mayoux and 
Stern have recently analysed the AD incidence data published in 24 
studies and estimated the age-specific incidence of AD as illustrated 
in Figure 7 [26]. The age of onset in most AD cases is usually 65 and 
above, which is considered as “sporadic” but onset before this age 
suggests involvement of a strong genetic component. Among genetic 
factors, the E4 allele of the APOE gene is the only confirmed risk 
factor for AD, which has been shown to be specific for up to 90 
percent of dementia cases [27].  
 
	  
Figure 7. The annual incidence rate (per 100 person-years) 
for Alzheimer disease. This graph is an estimate of the data 
collected in 24 published studies. 
 
Accumulating epidemiological evidence indicates that various risk 
factors contribute to exacerbation of neurodegenerative diseases 
Chapter	  2.	  Complex	  Biology	  Underlying	  AD	  	   17	  
including gender, poor education, endocrine conditions, oxidative 
stress, inflammation, stroke, hypertension, diabetes, smoking, head 
trauma, depression, infection, tumors, vitamin deficiencies, immune 
and metabolic conditions, and chemical exposure [28]. Such risk 
factors lead to manifestation of co-morbid conditions in patients with 
neurodegenerative diseases. For instance, it is observed that 
dementia incidence is modulated by factors linked to treatment of 
other diseases such as diabetes [29]. Similarly, retrospective studies 
of clinical and autopsy data revealed that patients with rheumatoid 
arthritis exhibit a reduced prevalence of AD [30]. Reports also 
suggest that patients who take anti-inflammatory drugs or suffer 
from inflammatory diseases like arthritis have reduced risk of 
developing AD. In general, AD is associated with several major co-
morbidities including hypo- and hyper-thyroidism, sleep apnea, 
osteoporosis, glaucoma, and rheumatoid arthritis [31]. Hence, 
identification of those co-morbidities that have strong etiological link 
to the disease may open up new intervention strategies to indirectly 
modify the trajectory of the disease.   
Other major risk factors that modify the risk of AD include 
hypertension, myocardial infarction, coronary heart disease, diabetes, 
atherosclerosis, smoking, high cholesterol concentrations and a 
history of stroke (Table 2) [26]. Of the above-mentioned risk factors, 
age and gender and genotype can not be changed but others can be 
modified to prevent the disease.  
 
Chapter	  2.	  Complex	  Biology	  Underlying	  AD	  	   18	  
Table 2. List of major factors that modify the risk of 
Alzheimer’s dementia and their probable mechanism of 
effect. Adopted from [26]. 
 
 
2.2.4. Disease course of AD 
Since AD is a progressive disease, it typically takes 10 years from 
diagnosis to death [32]. Some people on a course of healthy aging 
show only age-related changes in cognition but some other gradually 
move to mild cognitive impairment (MCI), which is the beginning of 
transition to AD. Figure 8 illustrates the natural history of AD based 
on clinical cognition tests. 
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Figure 8. Natural history of Alzheimer’s dementia 
progression based on declining cognitive function over 
time. All AD patients decline similarly through the stages of 
cognitive and functional loss as well as the stage of behavioral 
problems, although at different rates. (Taken from 
[http://www.medscape.org/viewarticle/456034_2]; last accessed: 
22.10.2013) 
 
2.2.5. Diagnosis of AD 
Clinically, AD is diagnosed based on the presence of characteristic 
cognitive, behavioral, and neuropsychiatric symptoms such as 
problems with memory or speech. For research purposes, the 
diagnosis of AD is performed using diagnostic criteria developed and 
published by the DSM-IV-TR and NINCDS-ADRDA working group 
[33]. Given the insufficient diagnostic specificity of conventional 
criteria against other dementia subtypes (23-88%), this framework 
offers revised AD and non-AD diagnostic criteria using not only 
“core diagnostic criteria” but also “supportive features”. The core 
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diagnostic criteria takes into consideration features of early and 
significant episodic memory impairment whereas supportive features 
include test for medial temporal lobe atrophy, abnormal 
concentrations of cerebrospinal fluid (CSF) biomarkers, specific 
patterns on functional neuroimaging with PET and check for 
autosomal dominant mutations.  
CSF biomarkers are not routinely used for evaluation of AD and PET 
biomarkers are extensively being developed to be used as preclinical 
diagnostic markers. To date, there is no molecular and imaging 
biomarkers that could predict onset or progression of AD. However, 
the most popular diagnostic tests in clinic for AD are obtaining 
history of the onset of the patient’s symptoms and their progression, 
physical examination including visual signs, speech, reflexes, eye 
movement, etc., laboratory studies such as blood test, radiological 
studies using ‘functional’ and ‘structural’ imaging, and finally 
neuropsychological tests including the most commonly used tests 
namely Mini-mental State Examination (MMSE) and the Mini-Cog. 
These tests assess mental skills of patient using several items such as 
recall, time and place orientation, writing skills and mental 
calculations.	  
2.2.6. Biomarkers of AD 
Over the past decades, validated and disease-specific biomarkers 
have been introduced to explain the neuropathology of AD. These 
biomarkers play an important role in supporting the challenging task 
of definite diagnosis of AD and can be grouped in two categories: 
pathophysiological and topographical markers [34].  
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Pathophysiological biomarkers include CSF measures of reduced 
amyloid-beta, increased total tau, increased phosphorylated tau, and 
amyloid PET scanning. In contrast, topographical image-based 
biomarkers are less specific but identify the regional patterns of AD 
pathology and include medial temporal lobe atrophy and reduced 
glucose metabolism in temporal lobe regions. Interestingly, these 
imaging biomarkers have been shown to accurately map to the Braak 
stages of neurofibrillary tangle deposition [35].   
In 2010, a hypothetical model of the major biomarkers of AD was 
published in which the temporal evolution of AD biomarkers in 
relation to each other and to the onset and progression of clinical 
symptoms was described. The authors have revised their model using 
the latest biomarker data and proposed that the two major 
proteinopathies underlying AD biomarker changes, Aß and tau, may 
be initiated independently in sporadic AD (Figure 9) [36]. In this 
proposed integrative model, subcortical tauopathy is the first AD 
pathophysiological process to arise in many individuals and is 
detectable only by immunostaining methods. This tauopathy, 
however, does not by itself lead to AD. Amyloid-beta 
pathophysiology arises later and independently from pre-existing 
tauopathy. Acceleration of the initial slowly developing subcortical 
tauopathy occurs after concentrations of Amyloid-beta biomarkers 
become abnormal (biomarker abnormality in Figure 9). Changes in 
imaging biomarkers then occur, followed last by onset of overt 
clinical symptoms. 
 	  
Chapter	  2.	  Complex	  Biology	  Underlying	  AD	  	   22	  
	  	  	  	  	  	  	  	  	  
Figure 9. Model integrating tauopathy and amyloid-beta 
pathophysiology. The threshold for biomarker detection of 
pathophysiological changes is denoted by the black horizontal line. 
The grey area denotes the zone in which abnormal 
pathophysiological changes lie below the biomarker detection 
threshold. In this figure, tau pathology precedes A-beta deposition in 
time. A-beta deposition then occurs independently and rises above 
the biomarker detection threshold (purple and red arrows). This 
induces acceleration of tauopathy and CSF tau then rises above the 
detection threshold (light blue arrow). Later still, FDG PET and MRI 
(dark blue arrow) rise above the detection threshold. Finally, 
cognitive impairment becomes evident (green arrow), with a range of 
cognitive responses that depend on the individual’s risk profile (light 
green-filled area). (Adopted from [36]) 	  
2.2.7. Stages of AD 
There are different descriptions for staging in AD. Perhaps the 
Clinical Dementia Rating (CDR) system was the first staging scale 
for dementia that was developed by Hughes et al. in 1982. CDR is a 
five-point scale as shown in Table 3. 
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Table 3. Representation of the CDR scale for rating 
cognitive performance 
CDR-0 No dementia 
CDR-0.5 = Very 
mild 
Memory problems are slight but consistent; 
some difficulties with time and problem 
solving; daily life slightly impaired. 
CDR-1 = Mild Memory loss moderate, especially for recent 
events, and interferes with daily activities. 
Moderate difficulty with solving problems; 
cannot function independently at community 
affairs; difficulty with daily activities and 
hobbies, especially complex ones. 
CDR-2 = 
Moderate 
More profound memory loss, only retaining 
highly learned material; disoriented with 
respect to time and place; lacking good 
judgment and difficulty handling problems; 
little or no independent function at home; can 
only do simple chores and has few interests. 
CDR-3 = Severe Severe memory loss; not oriented with respect 
to time or place; no judgment or problem 
solving abilities; cannot participate in 
community affairs outside the home; requires 
help with all tasks of daily living. 
 
In 1987, Reisberg introduced the Functional Assessment Staging 
(FAST) system with the focus on levels of functioning and daily 
living activities versus cognitive decline [37]. Table 4 summarizes 
seven stages of the FAST system. 
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Table 4. Representation of the FAST system for 
measurement of cognitive performance 
Stage 1: Normal adult No functional decline 
Stage 2: Normal older adult Personal awareness of some 
functional decline. 
Stage 3: Early Alzheimer's 
disease 
Noticeable deficits in demanding 
job situations. 
Stage 4: Mild Alzheimer's Requires assistance in complicated 
tasks such as handling finances, 
planning parties, etc. 
Stage 5: Moderate 
Alzheimer's 
Requires assistance in choosing 
proper attire. 
Stage 6: Moderately severe 
Alzheimer's 
Requires assistance dressing, 
bathing, and toileting. Experiences 
urinary and fecal incontinence. 
Stage 7: Severe Alzheimer's Speech ability declines to about a 
half-dozen intelligible words. 
Progressive loss of abilities to walk, 
sit up, smile, and hold head up. 
 
The Global Deterioration Scale/Functional Assessment Staging 
(GDS/FAST) system, developed by Auer and Reisberg in 1997 (also 
known as Reisberg scale), is widely used to characterize the stages of 
AD on a seven-stage granularity basis (Table 5) [38].  
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Table 5. Details of the Reisberg rating scale 
Diagnosis Stage Signs & Symptoms 
No 
Dementia 
Stage 1:  
No Cognitive 
Decline 
In this stage the person functions 
normally, has no memory loss, and 
is mentally healthy.  
No 
Dementia 
Stage 2:  
Very Mild 
Cognitive 
Decline 
This stage is used to describe 
normal forgetfulness associated 
with aging; for example, 
forgetfulness of names and where 
familiar objects were left. 
No 
Dementia 
Stage 3:  
Mild Cognitive 
Decline 
This stage includes increased 
forgetfulness, slight difficulty 
concentrating, decreased work 
performance. People may get lost 
more often or have difficulty 
finding the right words. Average 
duration: 7 years before onset of 
dementia 
Early stage Stage 4:  
Moderate 
Cognitive 
Decline 
This stage includes difficulty 
concentrating, decreased memory 
of recent events, and difficulties 
managing finances or traveling 
alone to new locations. People 
have trouble completing complex 
tasks efficiently or accurately and 
may be in denial about their 
symptoms. Average duration: 2 
years 
Mid-stage Stage 5:  
Moderately 
Severe 
Cognitive 
Decline 
People in this stage have major 
memory deficiencies and need 
some assistance to complete their 
daily activities (dressing, bathing, 
preparing meals). Memory loss is 
more prominent and may include 
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major relevant aspects of current 
lives. Average duration: 1.5 years 
Mid-stage Stage 6:  
Severe 
Cognitive 
Decline 
(Middle 
Dementia) 
People in Stage 6 require extensive 
assistance to carry out daily 
activities. They start to forget 
names of close family members 
and have little memory of recent 
events. Many people can 
remember only some details of 
earlier life. They also have 
difficulty counting down from 10 
and finishing tasks. Incontinence 
(loss of bladder or bowel control) 
is a problem in this stage. Ability 
to speak declines. Personality 
changes, such as delusions 
(believing something to be true 
that is not), compulsions 
(repeating a simple behavior, such 
as cleaning), or anxiety and 
agitation may occur. Average 
duration: 2.5 years 
Late stage Stage 7:  
Very Severe 
Cognitive 
Decline (Late 
Dementia) 
People in this stage have 
essentially no ability to speak or 
communicate. They require 
assistance with most activities 
(e.g., using the toilet, eating). They 
often lose psychomotor skills, for 
example, the ability to walk. 
Average duration: 2.5 years 
 
Reisberg and coworkers (2008) have recently provided a 
comparative overview of the above-mentioned staging scales in 
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which the typical time course of normal brain aging, MCI, and AD 
have been mapped to the range of stages in different scales [39].  
It is worth of note that a different staging system based on the 
distribution pattern and packing density of amyloid deposits in 
autopsied brains (i.e. neuropathological staging) was proposed by 
Braak and Braak in 1991, which distinguished six stages [40]. This 
system was able to differentiate initial, intermediate, and late phases 
of the disease in both symptomatic and non-symptomatic individuals. 
This staging schema was revised in 2006 by Braak et al. using more 
advanced techniques with focus on tau hyperphosphorylation, as 
summarized in Table 6. [41]. 
 
Table 6. Updated schema for diagnosis of stages in 
Alzheimer’s disease  
Stage I Lesions develop in the transentorhinal region 
Stage II Lesions extend into the entorhinal region 
Stage III Lesions extend into the neocortex of the fusiform 
and lingual gyri 
Stage IV The disease process progress more widely into 
neocortical association areas 
Stage V The neocortical pathology extends fanlike in 
frontal, superolateral, and occipital directions, and 
reaches the peristrate region  
Stage VI The pathology reaches the secondary and primary 
neocortical areas and, in the occipital lobe, extends 
into the striate area 
 
Given the importance of predictive measures for identification of 
individuals at the risk of developing mild cognitive impairment, 
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characterization of the long preclinical stage of AD opens a crucial 
window of opportunity to intervene with therapy; to this end, 
recently preclinical stages of AD have been described and 
recommended by the National Institute on Aging (Figure 10) [42].  
 
	  
Figure 10. Graphic representation of the proposed staging 
framework for preclinical AD. Note that some individuals will 
not progress beyond Stage 1 or Stage 2. Individuals in Stage 3 are 
postulated to be more likely to progress to MCI and AD dementia. 
Abbreviations: Ab, amyloid beta; PET, position emission 
tomography; CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose, 
fMRI, functional magnetic resonance imaging, sMRI, structural 
magnetic resonance imaging. (Adopted from [42]) 
 
The emerging concept of preclinical AD has great implications for 
identification of predictive biomarkers as well as development of 
disease-modifying treatments. For instance, it is critical to define a 
biomarker that best predicts progression from the preclinical to the 
clinical stages of AD dementia. The long latency period of AD 
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within the preclinical phase opens up a new opportunity for potential 
intervention with disease-modifying therapies. However, more 
studies should be conducted to determine the robustness of the above 
model in terms of the number of individuals transitioning from pre-
clinical to clinical phase of AD. Besides, robust predictive 
biomarkers and preventive disease-modifying treatments are still 
missing and deserve more investigation.     	  
2.3. Biology/Etiology of AD 
2.3.1. Anatomical patterns of pathology in AD 
Decline in cognitive abilities, learning difficulties and memory 
impairment, particularly the loss of episodic memory, are hallmarks 
of early AD. The first pre-requisite for understanding the pathology 
of AD is to understand the neuroanatomy of human memory and 
cognition because such functional tasks are crucially dependent on 
networks of brain areas and regional connectivity circuits. The 
primary brain region damaged during the course of AD is “limbic 
system”, which consists of several structures, most importantly, 
hippocampus, cingulate gyrus, limbic cortex, amygdala, olfactory 
bulbs, fornix, mamillary body, septum and habenular commisure 
(Figure 11).  
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Figure 11. Neuroanatomy of the limbic system and 
surrounding structures in the human brain. (Taken from 
[http://jobspapa.com/diagram-the-limbic-system-and-surrounding-
structures.html]; last accessed: 22.10.2013) 
 
The pathology associated with AD begins in the entorhinal cortex 
where a decline in its volume is observed. This region plays an 
important role in relaying information between the hippocampus and 
neighboring cortices. The atrophy then spreads to hippocampus and 
moves out to the temporal and parietal cortices. Degeneration of 
entorhinal cortex occurs progressively during aging but its 
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pathological conversion to MCI and to AD begins long before 
manifestation of clinical symptoms [43]. 	  	  
2.3.1.1. Neuroanatomy of human memory and learning 
It is long known that the medial temporal lobe is involved in 
processing memory. The hippocampus is a central structure for 
memory function and plays an important role in both spatial and 
episodic memories [44]. In coronal section, the hippocampus looks 
like an S-shaped structure and is composed of the cornu ammonis 
and the dentate gyrus. The cornu ammonis is further divided into 
four fields, namely CA1 to CA4 (Figure 12) [45]. 
              
Figure 12. Neuroanatomy of the hippocampus, including 
CA layers. 
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As shown in the figure above, the hippocampus contains three layers 
of densely packed neurons designated CA1, CA2, and CA3. These 
layers can be distinguished based on differences in the density of 
pyramidal cells. CA1 region (also called the Sommer sector) is 
important in neuropathology because the first signs of neuronal death 
due to cerebral hypoxia are observed in this area. Dentate gyrus 
mainly consists of granule cells and is primarily affected during 
normal aging as well as very late phase of AD [46].    
On a cellular network level, the hippocampus has several important 
connections to other brain regions through neural pathways (Figure 
13). The entorhinal cortex is considered the gateway to the 
hippocampus because neurons forming the so called “perforant 
pathway” collect input from many other brain regions and deliver to 
the dentate gyrus of the hippocampus. “Mossy fibers” connect 
granule cells of the dentate gyrus to pyramidal cells of the CA3 area. 
The input is finally sent to the CA1 area for further processing. CA1 
pyramidal cells provide output via subiculum to the entorhinal cortex 
and prefrontal cortex. It has been shown that the dentate gyrus and 
the CA3 networks are involved in pattern recognition whereas the 
CA1 network is involved in learning the environment. The CA1 
region is particularly vulnerable to pathological effects of AD and 
such vulnerability has direct impact on the hippocampal-neocortical 
memory system [47].  
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Figure 13. Schematic representation of the neural 
connections between brain regions. a) Interconnection of 
anatomical regions that support episodic memory, highlighting the 
connections between the hippocampal system, diencephalic 
structures and neocortical regions. b) Diagrammatic representation of 
the unidirectional and bidirectional network connectivity of critical 
structures of the temporal lobe system, diencephalic nuclei and 
neocortical association areas involved in memory processing. c) The 
anatomy of the CA, depicting the trisynaptic pathway as the principal 
feedforward neural circuit involved in the processing of information 
through the hippocampus. Abbreviations: Ant, anterior thalamic 
nuclei; CA, cornu ammonis; DG, dentate gyrus; EC, entorhinal 
cortex; MB, mamillary bodies; Med, medial thalamic nuclei; MTT, 
mamillothalamic tract (bundle of Vicq d'Azyr); SN, septal nuclei. 
(Taken from [47]) 
 
Classically, memory systems of human brain are divided into long-
term and short-term (working) memory. Figure 14 illustrates further 
classification of human memory systems mapped to corresponding 
anatomical brain regions. In AD, both episodic and semantic 
memories are impaired. The role of semantic memory in episodic 
future thinking has been recently reviewed by Bartsch and Butler 
[48].  
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Figure 14. The classic view of memory systems based on a 
temporal scale. Episodic memory represents memory of specific 
events in time and space. Episodic autobiographical memory is 
usually regarded as part of episodic memory although it also 
comprises semantic memory, which includes facts, meanings, 
concepts and knowledge about the external world and refers to 
general factual knowledge. The different memory systems can 
interact and overlap with each other on a temporal scale (for 
example, episodic memory transfers into semantic memory over 
time) and content-wise (procedural learning can be modulated by 
declarative memory). (Taken from [47]). 	  
2.3.1.2. Neuroanatomy of human cognition 
Cognitive functions can be divided into two broad groups: basic and 
higher-level cognitive functions [49].  
Basic cognitive functions include “attention”, “working memory”, 
“long-term memory”, and “perception”.  
Higher-level cognitive functions include “speech & language”, 
“decision-making” and “executive control”. 
These cognitive functions are processed and regulated by neural 
circuits that interact at the interfaces of the cerebral cortex, thalamus, 
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and basal ganglia. Solari and Stoner (2011) have collated, integrated, 
and visualized the accumulated connectivity data obtained from 
many published studies of primate cerebral cortex on 
neuroanatomical circuitry of cognition and integrated these 
fragmented studies into a single framework [50].   
Based on this integrative model, the authors hypothesized that 
cognitive function follows a pattern of information flow among 
seven neural circuits. The seven circuits described are consolidated 
long-term declarative memory, short-term declarative memory, 
working memory/information processing, behavioral memory 
selection, behavioral memory output, cognitive control, and cortical 
information flow regulation (Figure 15). 
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Figure 15. Summary diagram of proposed flow of cognitive 
information. Generally information flows from left to right 
through the color coded circuits. Long-term memory is split into 
perceptions and associations. Cortical neuron x (Cx), 
Parahippocampal gyrus (PH), Hippocampus (H), Specific thalamus 
(Ts), Layer 1 projecting thalamus (TL1), Intralaminar thalamus (Ti), 
Cerebellum (C), Striatum (S), External segment globus pallidus 
(Gpe), Internal segment globus pallidus (Gpi), Substantia nigra par 
reticulata (Snr), Basal forebrain (BF). (Taken from [ 
http://www.frontiersin.org/files/cognitiveconsilience/ index.html#]; 
last accessed 01.11.2013) 
 
To map cognitive functions to specific brain regions, functional brain 
imaging or electroencephalography can be utilized aiming at 
localization of function [51]. This has led to construction and 
representation of topological brain architecture in form of 
connectivity maps or networks (Figure 16). The nodes of these 
networks are usually inferred during tasks that manipulate one or 
more of cognitive functions. 
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Figure 16. Structural and functional brain networks can be 
studied in four steps. 1: Define the network nodes as 
electroencephalography or multielectrode-array electrodes, or as 
anatomically defined regions of histological, MRI or diffusion tensor 
imaging data. 2: Estimate a continuous measure of association 
between nodes. This could be the spectral coherence between two 
magnetoencephalography sensors, or the connection probability 
between two regions of an individual diffusion tensor imaging data 
set, or the inter-regional correlations in cortical thickness or volume 
MRI measurements estimated in groups of subjects. 3: Generate an 
association matrix by compiling all pairwise associations between 
nodes to produce an undirected graph. 4: Calculate the network 
parameters of interest in this graphical model of a brain network and 
compare them to the equivalent parameters of a population of 
random networks. Taken from [51]. 
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Alterations in the configuration of these connectivity networks 
reflect neural network function or dysfunction because cognitive and 
behavioral functions result from large-scale network interactions. For 
instance, fMRI-based connectivity networks distinguished between 
the Salience Network connectivity associated to behavioral variant 
frontotemporal dementia and the Default Mode Network 
connectivity associated to AD. While the former map represented 
atrophy in frontoinsular, cingulate, striatal, thalamic and brainstem 
nodes, the latter highlighted an atrophy specific to posterior 
hippocampus, medial cingulo-parieto-occipital regions and the dorsal 
raphe nucleus [52]. Therefore, functional and structural network 
mapping methods provide the opportunity to identify anatomically 
predictable patterns of neurodegeneration in the human brain.	  
2.3.2. Main hypotheses on the pathology of dementia 
Since the early description of Alzheimer’s disease made by Alois 
Alzheimer in 1906, and despite remarkable findings and insights into 
this disease, still the accurate mechanism of AD pathogenesis 
remains unclear. Several independent hypotheses have been 
proposed to address the pathogenesis in AD from different angles 
including apolipoprotein E (ApoE) genotyping [53],[54],[55], 
hyperphosphorylation of tau protein [56],[57], oxidative stress 
[58],[59], abnormal cell cycle [60],[61], inflammation [62],[63],[64], 
and Amyloid-beta metabolism [65],[66],[67]. In a recent review by 
Dong et al., these hypotheses have been systematically introduced 
and discussed [68]. Although all these hypotheses are important, 
none of them alone can explain the heterogeneity of pathological 
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abnormalities observed in AD. Here, I focus on three most popular 
hypotheses and briefly explain their proposed mechanisms. 	  
2.3.2.1. Amyloid hypothesis 
The hallmark of this hypothesis is the clinical observation of amyloid 
plaques and tangles in brains of deceased patients. According to this 
hypothesis, the imbalance between production and clearance of the 
amyloid-beta protein in the brain parenchyma leads to the deposition 
of toxic oligomers of this peptide, amyloid-beta aggregation, 
formation of tau filament aggregates and ultimately neural 
degeneration. Consequently, in both familial and sporadic AD 
production of total amyloid-beta or its 42 variant clearly increases 
but it is unclear whether the clearance of amyloid-beta in sporadic 
AD is disturbed [69]. Figure 17 summarizes downstream events that 
are shared between familial and sporadic AD as proposed by the 
amyloid hypothesis.  
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Figure 17. Diagrammatic representation of the amyloid 
cascade hypothesis in both sporadic and familial AD. An 
increase in production of either total Abeta or the amyloidogenic 
Abeta1–42 isoform is well established in familial AD, but only 
limited evidence exists for a specific disturbance in Abeta clearance 
in sporadic AD. In both familial and sporadic AD, soluble Abeta is 
thought to undergo a conformational change that renders it prone to 
aggregation into soluble oligomers and the larger insoluble fibrils 
found in plaques. Fibrillar Abeta deposited in plaques might be 
neurotoxic; however, synaptic loss and clinical progression of the 
disease mainly correlate with soluble Abeta levels. Soluble Aβ 
oligomers might inhibit LTP in the hippocampus and, hence, disrupt 
synaptic plasticity. Tau phosphorylation and subsequent 
neurofibrillary tangle formation, as well as inflammation and 
oxidative stress, are regarded as downstream events. Abbreviations: 
Aβ, amyloid-β; AD, Alzheimer disease; APOE, apolipoprotein E; 
APP, amyloid precursor protein; LTP, long-term potentiation. 
(Taken from [69]) 
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The amyloid hypothesis explains the pathology mechanism as shown 
in Figure 18. The beta-amyloid precursor protein (APP) is cleaved by 
beta-site APP-cleaving enzyme (BACE) and the gamma-secretase 
complex. Consequently, the large domain of APP (CTF-beta) is 
secreted and binds to the complex of gamma-secretase, presinilin 1 
or 2 (PS1, PS2). These all bind to each other and form a core 
complex required for gamma-secretase activity. The final products of 
gamma-secretase cleavage activity are amyloid-beta protein and the 
APP intracellular domain (AICD). The function of this peptide is not 
well understood [70].     
	  
Figure 18. Cartoon representation of the molecular details 
underlying amyloidogenesis. a) Amyloidogenic processing of 
beta-amyloid precursor protein (APP) by beta-site APP-cleaving 
enzyme (BACE) and the gamma-secretase complex. b) Various 
proposed sites of intramembrane proteolysis by gamma-secretase. 
The amino-acid sequence around the cleavage sites of APP is shown 
(numbers refer to the sequence of Abeta; shaded amino acids are in 
the transmembrane domain). (Taken from [70]) 
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Consequent failure of Alzheimer’s drugs targeting amyloid-beta 
[71], on the one hand, and discovery of amyloid-independent 
neuronal injuries in demented patients [72], on the other hand, have 
recently led to calls for reconsideration of the amyloid cascade 
hypothesis [73],[74]. To this end, concerns have been raised that 
current anti-amyloid interventions in demented patients are too late 
[75]. New findings suggest that the pathological process in 
autosomal dominant AD begins more than 20 years prior to onset of 
dementia [76] and CSF levels of amyloid-beta increase up to 10 
years before onset of late-onset AD [77]. Despite disappointing 
results from clinical trials of anti-amyloid compounds, Michael W. 
Weiner from Elan in his review article believes that “the research 
highlights of 2012 provide new support for the central role of 
amyloid in AD pathogenesis.” [78]. Whether the amyloid-beta 
cascade is primary cause or secondary effect in pathogenesis of AD 
remains controversial.	  	  
2.3.2.2. Inflammation hypothesis 
Neuroinflammation is a prominent feature of all neurodegenerative 
diseases. Frank-Cannon et al. (2009) provide a comprehensive 
review on neuroinflammation evidence in neurodegenerative 
diseases [79] but here I will focus on the role of inflammation in AD 
pathology. 
First evidence of systematic inflammation involvement in the 
etiology of AD came from a meta-analysis study in 1996, which 
concluded - based on 17 epidemiological studies - that administration 
of non-streoidal anti-inflammatory drugs (NSAIDs) might reduce the 
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risk of AD [80]. Later, clinical observations showed that microglia 
accumulate surrounding amyloid plaques [81]. Thus, 
neuroinflammation is believed to be an early consequence of the 
amyloid beta deposition. Accordingly, aggregates of amyloid-beta 
activate microglia, partly through Toll-like receptors (TLRs), and 
these receptors activate transcription factors such as NFKB and AP-
1, which in turn induce production of the reactive oxygen species 
(ROS) and drive the expression of inflammatory cytokines [82]. 
The rationale behind the inflammation hypothesis of AD is based 
upon the observation that both acute and chronic systemic 
inflammation were found to be clinically associated with accelerated 
cognitive decline in patients with AD [83]. A recent study shows that 
blockade of the IL-12/IL-23 pathway in a mouse model of AD led to 
a reduction in cerebral amyloid load and improvements in cognitive 
function [84]. Known molecular and cellular mediators of 
inflammation in AD pathology are summarized in Table 7.   
 
Table 7.  List of well-known mediators of inflammation in 
AD reported in biomedical literature 
Cellular mediators Microglia 
Astrocytes 
Oligodendrocytes 
Neurons 
Molecular mediators The complement system 
Cytokines and chemokines 
Toll-like receptors 
Cyclooxygenases and Arachidonic Acid 
Metabolites 
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Although Heneka and O’Banion suggest that inflammatory 
mediators may stimulate APP processing, and thus, anti-
inflammatory treatment strategies should be considered for AD 
patients, still the precise molecular mechanism underlying this effect 
is not well understood [85].	  	  
2.3.2.3. Infection hypothesis 
The first report on direct visualization and isolation of infectious 
agents from postmortem brain tissue of AD patients appeared in 
1986. In this study, MacDonald identified Borrelia spirochetes in 
subculture of autopsy brain tissues from two patents with dementia 
[86]. Since then, there have been reports that hypothesized systemic 
infections may contribute to the pathogenesis of sporadic AD. 
Mawanda and Wallace (2013) now provide a comprehensive 
overview of infectious agents associated with AD and examine the 
latest status of the infectious AD etiology hypothesis [87]. These 
infectious agents include herpes simplex virus type 1 (HSV-1), 
Chlamydophila pneumonia, Borrelia burgdorferi, Helicobacter 
pylori, prions, and other infectious agents. I refer readers to the 
review paper mentioned above for more in-depth information.  
Regarding the mechanism of action of infectious agents associated to 
AD, two possibilities have been proposed: either infectious agents 
directly infect the brain or indirectly promote the pathogenesis of AD 
through various effects of systemic infections [88]. Following 
infection, in addition to the inflammatory response, there is a 
systemic response (i.e. acute-phase response). Launch of this 
response is dependent on the synthesis of pro-inflammatory 
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molecules such as IL-1 beta, IL-6 and TNF. In a series of studies 
with transgenic mice, it was shown that the amyloid-beta protein has 
many of the characteristics of a prion, providing evidence for the 
existence of Abeta prions [89]. The hypothesis that AD might be a 
prion-type disease with possible capability of being spread by 
infectious particles was first raised by Morales and coworkers [90]. 
They injected brain extracts of AD patients into the brains of normal 
mice and were able to induce amyloid-beta deposition as well as the 
typical AD symptoms in control animals. At present, research on the 
impact of systemic infection on chronic neurodegeneration is 
ongoing and aims at better understanding of the communication 
routes between the peripheral immune system and the brain [91].	  	  
2.3.3. Clinical heterogeneity of AD 
Heterogeneity in presentation and progression of AD has long been 
demonstrated (e.g. [92],[93] and [94].  
There have been three hypotheses to explain such heterogeneity in 
AD: “subtype hypothesis” (distinct clinical variants), “phase 
hypothesis” (variation in the stage of the disease), and 
“compensation hypothesis” (variation in the origin and progression 
of the disease). Subtypes of AD have been classified based on the 
relative density of neurofibrillary tangles into “typical AD”, 
“hippocampal sparing AD”, and “limbic-predominant AD”. 
However, it has been shown that these subtypes are different than 
neurofibrillary tangle-predominant dementia, which might be more 
than a mere variant of AD [95]. Moreover, left parietal atrophy is 
associated with language symptoms in younger age of onset and 
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faster cognitive decline, which is indicative of a ‘language variant’ of 
AD, whereas right parietal atrophy is associated with visuospatial 
symptoms, suggestive of a ‘visuospatial variant’ [96]. The high 
degree of heterogeneity that is observed amongst AD patients can be 
also be attributed to the varying rates of disease progression. In a 
study of 80 AD cases, neuropathological heterogeneity was shown to 
be more consistent with the phase hypothesis [97]. Komarova and 
Thalhauser (2011) have quantified such temporal variations by 
mapping the variations onto the GDS/FAST staging system, and 
found that there is a large heterogeneity in the duration of stages in 
AD. 
Understanding the neurobiological basis of this heterogeneity 
requires strategies that link cognitive and behavioral variations to the 
regional damage of brain cells. Imaging biomarkers have emerged as 
useful means for capturing variations in the distribution of the 
pathologic changes. They can also help clinicians distinguish AD 
from other dementia syndromes.	  	  
2.3.4. Treatment options for AD 
Despite many years of research and gain of substantial insights into 
the pathology of AD, no disease-modifying drugs yet exist for AD. 
Early treatment studies focused on the inhibition of cholinesterases 
(AChEs) and its positive, but unspecific, effects on memory 
function. Tacrine, introduced in 1992, was the first such inhibitor, 
which was followed by three other inhibitors with better safety 
profiles, namely donezepil, rivastagmine and galantamine. Based on 
their demonstrated ability to stop cognitive decline for 6 to 12 
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months, these drugs were used to treat mild to moderate AD patients. 
The second wave of AD treatment began with memantine in 2003, 
which is an NMDA receptor antagonist and is the first drug approved 
for the treatment of moderate to severe AD. Interestingly, 
investigational drugs target almost all amyloid processing steps, as 
illustrated in Figure 19. 
    
	  
Figure 19. Main steps of sequential cleavage of amyloid 
precursor protein (APP), leading to generation of beta 
amyloid and/or other products with existing therapeutic 
interventions mapped to each stage. A: the cleavage sites for 
alpha-, beta- and gamma-secretase. B: ectodomain shedding of APP 
by alpha-secretase. C: Subsequent intramembrane proteolytic 
cleavage of C83/CTFα by gamma-secretase. D: ectodomain shedding 
of APP by beta-secretase. E: Subsequent intramembrane proteolytic 
cleavage of C99/CTFβ by gamma-secretase. F: Abeta 
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oligomerization and deposition leading to neurodegeneration, both 
directly and through tau hyperphosphorylation. In dashed boxes, 
disease modifying drugs that interfere with each particular step. 
(Taken from [98]) 
 
However, these treatments neither stop the neurodegeneration nor 
reverse the progression of AD. They have only symptomatic effects 
for a short term; e.g. they may improve over the baseline or delay to 
decline cognition but neurodegeneration inevitably continues its 
downward trajectory after 6 to 9 months. Besides, about 30-40% of 
AD patients do not respond to approved AChE inhibitors at all [99].  
Accordingly, in the absence of disease modifying drugs that are able 
to slow or stop the disease, the current challenge of pharmacology is 
to develop the new generation of drugs that prevent AD. In this 
paradigm, it is expected that disease-modifying medications reduce 
the slope of decline or at least stabilize a patient’s condition [100]. 
There are currently over 70 experimental compounds in preclinical 
and clinical trial phases, targeting mostly amyloid cascade or 
downstream responses such as inflammation and apoptosis [101]. 
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CHAPTER 3. State-of-the-art Computational 
Approaches to Disease Modeling 	  
3.1. Biological models and their types 
In the philosophy of science, a “model” is an idealized structure that 
we use to represent the world, via relations between the model and 
real world target systems. The model is used by scientists to gain 
understanding of a complex real-world system via an understanding 
of simpler, hypothetical system that resembles it in relevant respects 
[102]. In biology, “a model is description of a system” and a system 
is “any collection of inter-related objects” that act as elemental units 
of the system on which observations can be made [103]. Since 
biological systems in the real world experiments are considered as 
complex, models of biological systems have been classified in the 
literature under the mathematical models. According to Barillot et al. 
(2012), two forms of mathematical models for biological systems 
exist: “data-driven models” versus “knowledge-based models” [104]. 
In data-driven models, the structure of model is inferred from the 
biological data whereas in knowledge-based models prior knowledge 
is compiled and incorporated into a model by human expertise. 
Accordingly, models can be categorized based on their types: 
(a) quantitative or qualitative;  
(b) statistical or mechanistic;  
(c) static or dynamic;  
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(d) discrete or continuous;  
(e) deterministic or stochastic.  
These models are usually represented in the form of different 
formalisms as follows: 
-Differential equation models 
-Power law models 
-Boolean models 
-Petri-net models 
-Rule-based models 
-Flux balance analysis models	  
3.2. Modeling biological systems 
Emergence of advanced technologies that enable researchers to 
obtain comprehensive snapshots of biological systems at real time 
and with single molecule resolution has led to the generation of 
unprecedented amount of data. However, the one-dimensional view, 
while useful, will fail to deliver models that are generally predictive 
of complex system behavior. In silico modeling and simulation of 
complex biological systems provides an efficient way to organize 
and integrate multiple data types and ultimately, to generate multi-
dimensional views. Thus, systems biology can be called as 
“integrative biology” with the aim of predicting biological outcomes 
given the interaction of underlying components and elements [105]. 
Systems biology has emerged as a young discipline, which aims to 
investigate the structure and dynamics of biological systems (holistic 
approach) rather than the characteristics of the isolated parts 
(reductionist approach) [106]. Modeling complex biological systems 
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requires a good understanding of their features, amongst which 
hierarchy, complexity, heterogeneity, context-dependency, and 
emergent property are the most important features [107]. In fact, 
these features arise from the enormous interactions amongst 
molecular constituents of cells. As mentioned above, the challenge of 
systems biology is to understand the structure and the dynamics of 
intra- and inter-cellular web of interactions that contribute to the 
function of a living cell. The sum of these interactions forms a 
‘network of networks’, which can be modeled and structurally 
analyzed. Barabasi and Oltvai (2004) were first to adopt the idea of 
network modeling from physics and introduce it to biology as 
‘network biology’ [108]. This notion can be traced back to the 
application of graph theory to representing biological networks by 
Watts and Strogatz in 1998 who characterized the ‘small world 
phenomenon’ and other network properties [109]. More recent 
features and properties of complex biological networks can be found 
in the book entitled “Network science: complexity in nature and 
technology” [110]. 
3.2.1. Bottom-up systems biology 
The bottom-up approach starts from constitutive parts and 
mechanistic details, and uses accurate formulating of each process to 
provide an interconnected view of biological interactions. The aim of 
this approach is to come up with an integrated map of pathway 
models representing the entire system. However, limitations of these 
approaches can be summarized as follows: i) complete dependency 
on experimental studies and data availability; ii) uncontrollable 
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enlargement of models by the incorporation of more data and 
processes; iii) vulnerable to experimental design and tools for model 
analysis. 
Since the bottom-up approach follows the first principles in biology, 
it is not surprising that it requires extensive quantitative data, which 
is not always available particularly when a model of complex disease 
such as AD is going to be built. An example of bottom-up approach 
is modeling of enzyme kinetics, which requires determination of 
kinetic parameters by in-vitro measurements. The Silicon Cell model 
takes advantage of the bottom-up approach to enable online in-silico 
experimentation, for example, about the effect of over-expression of 
an enzyme in the pathway on the productivity of the interaction of 
interest [111].  
Metabolic network models are often built using bottom-up 
approaches and typically include stoichiometry data. Computational 
stoichiometric models have been used to perform metabolic flux 
analysis as well as flux balance analysis including prediction of 
cellular phenotypes using extreme currents and extreme pathways 
[112]. 	  
3.2.2. Top-down systems biology 
The top-down approach originates from large experimental data sets 
or information that provide structure to the model and tries to unravel 
underlying biological mechanism by narrowing the analysis down to 
the bottom. In this approach, the flow of information occurs from 
‘omics’ level to pathway level. The top-down approach starts with 
data analysis and data integration to establish correlations among 
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molecules, followed by prediction and hypothesis generation. These 
hypotheses can be further tested in the lab and thereby, an iterative 
cycle is formed (Figure 20). The top-down approach uses various 
types of models at different phases of the characterization of the 
system; for example, in the component discovery phase, knowledge-
based qualitative static modeling can be applied and in the later 
phases Bayesian models may be used to decipher the regulatory 
dependencies.   
 
 
 
 
 
 
 
 
 
 
Figure 20. The cycle of modeling, hypothesis generation, 
and experimentation in systems biology. Systems biology is 
an integrated process, which begins with pattern observation in 
experimental data, continues with modeling/simulation of the 
observed pattern and leads to hypothesis generation. Generated 
hypotheses can be further validated by experiments.   
Limitations of this approach include difficulty of dissecting many 
entangled mechanisms, correlation-based rather than cause-and-
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effect-based, and lack of supporting knowledge for interactions. 
However, the advantage of this approach lies in its ability to identify 
network structures that underlie the system behavior through ‘reverse 
engineering’ of the system data. Such an ability allows for isolation 
of ‘mechanistic structures’ that explain the mode of action [113].  
The bottom-up approach has been already applied to amyloid-beta 
accumulation in AD with the aim of elucidating mechanism of 
neurotoxicity [114]. This approach has led to the identification of 
cartoon-like pathways and mechanisms influenced by amyloid-beta 
including pathways in neurons, astrocytes and microglia that are 
implicated in beta-amyloid toxicity. To date, all the endeavors in this 
direction have been limited to generation of molecular disease maps 
such as AlzPathway [115]. However, since bottom-up studies are 
often based on data derived from transgenic animal models, they do 
not provide an accurate representation of therapeutic effectiveness in 
humans [116]. Hence, an integrated top-down approach may provide 
clues to determine pathological pathways that are causally linked to 
the disease phenotypes, on one hand, and are central to disruption of 
neuronal networks underlying the memory and cognitive function, on 
the other hand.        	  	  
3.3. Network modeling of disease processes 
Since its introduction to the field of biomedicine, network modeling 
has been used to better understand the effects of molecular 
interactions on disease progression. Although network modeling of 
disease pathways has been called differently by different authors 
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such as “network systems biology” or “systems pathology” or 
“network medicine”, it essentially paves the way for transitioning 
from ‘descriptive’, ‘correlative’ associations between molecular 
signatures and clinical phenotypes to ‘mechanistic’, ‘causal’ 
associations. Molecular networks that represent molecular states of 
the perturbed biological system underlying disease (also known as 
‘disease maps’) provide a suitable framework for transitioning from 
descriptive to mechanistic mode by linking genetic information to 
disease processes and clinical phenotypes. 
Based on the nature of data, various types of human interactomes can 
be modeled (genetic networks, RNA networks, protein networks, 
regulatory networks, metabolic networks). There still exist important 
caveats when constructing such network models: interaction data 
remains incomplete, there is bias towards particular interactions, and 
the available data is noisy. However, current interactome models, in 
spite of their incompleteness or biasedness, open up new avenues of 
research towards an integrated understanding of the pathophysiology 
of diseases.	  
3.3.1. Properties of disease network models 
Properties of disease network models show fundamental differences 
compared to other network models such a social or technological 
network models. These properties can be classified into three types 
of modularity (Figure 21). 
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Figure 21. Comparative representation of three modularity 
concepts.	   	   a) Topological modules correspond to locally dense 
neighborhoods of the interactome, such that the nodes of the module 
show a higher tendency to interact with each other than with nodes 
outside the module. b) Functional modules correspond to network 
neighborhoods in which there is a statistically significant segregation 
of nodes of related function. c) A disease module represents a group 
of nodes whose perturbation (mutations, deletions, copy number 
variations or expression changes) can be linked to a particular 
disease phenotype, shown as red nodes. (Taken from [118]) 
 
While Zhu et al. (2007) provide a thorough review of the network 
models and their characteristics [117], I briefly touch the modularity 
feature of networks as follows.	  
3.3.1.1. Topological modularity 
Molecular interactions are mathematically represented by graphs 
whose topological characteristics have been subject of extensive 
research to find shared design principles. Initially it was thought that 
the independence of scale or scale-freeness is indicative of networks 
that evolve gradually based on preferential attachment of nodes [108] 
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and accordingly, attempts were dedicated to matching topologies of 
molecular interaction networks such as gene co-expression, protein-
protein interaction networks and metabolic networks to the 
topologies observed in other real-world networks (e.g. social 
networks). However, it was later figured out that properties of 
random network models are not consistent with properties of 
molecular networks in terms of statistical and biological meaning 
[119][120]. In parallel to these top-down analyses using degree 
distribution metrics, a bottom-up approach was utilized to find 
motifs and modules to describe the functional significance of 
biological networks but these descriptors are criticized for having no 
characteristic behavior when considered as a dynamic system [121].   
In the context of disease representation, topological metrics attempt 
to answer the question whether disease genes/proteins are distributed 
randomly in the interactome or whether there are correlations 
between their locations and their network topological features. One 
special topological feature is the emergence of high-degree nodes or 
“hubs”, which govern the regulatory processes in biological 
networks [122]. Based on biological role and dynamic behavior, 
hubs have been classified into “party hubs” and “date hubs”, which 
function inside modules and between modules, respectively [123]. 
Dense connections between nodes with the same functionality form 
the so-called ‘clusters’ and are observed in highly modular networks. 
These clusters provide the basis for introduction of the concept of 
functional modules [124].    
Although the current trend in topological network analysis is slowly 
moving from global to local analysis to couple topological properties 
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to biological knowledge, the main caveat associated to topological 
features is that they may not reflect the real biological modularity as 
a network model is assumed to be always incomplete. Given this and 
other above-mentioned reasons, for the rest of this thesis work, I am 
cautious to rely on topological metrics in my analysis and will only 
focus on the functional modularity concept.	  
3.3.1.2. Functional modularity 	  
A functional module is defined as “an aggregation of nodes of 
similar or related function in the same network neighborhood.” 
[125]. Functional modules carry out cellular functionality and are 
hierarchically organized [126]. The aim of functional module 
analysis techniques is to identify functional pathways that regulate 
sub-processes.  
Early functional analysis algorithms were focused on mapping out 
the gene ontology (GO) concepts to nodes and testing the enrichment 
of annotation terms iteratively. This approach, which suffers from 
the large linear output of annotations terms was further developed 
into the widely used gene set enrichment analysis (GSEA) approach. 
The main advantage of GSEA is that it is a ‘knowledge-based’ 
approach, in the sense that it focuses on manually curated gene sets 
that share common biological functions [127]. Modular enrichment 
analysis approach takes advantage of traditional ontological analysis 
but incorporates extra network discovery algorithms [128]. Since 
disease-specific networks generated and presented in this thesis work 
are large, the GSEA algorithm will be applied to perform functional 
analysis. 	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3.3.1.3. Disease modularity 
Disease modules are disease components or subnetworks whose 
dysregulation leads to disease phenotypes. In the context of network 
models of diseases, disease-related components are inter-related. The 
key difference of the disease modules compared to the topological 
and/or functional modules- despite their possible overlap- is that they 
are specific to the disease they represent, meaning that each disease 
can have its unique module. Since disease modules include disease-
modifying genes, they are likely to explain multiple disease 
phenotypes in both sporadic and hereditary diseases [118]. 
Disease module-based methods start with building a disease-specific 
cellular interactome, identifying subnetworks with most of the 
disease-associated genes, and validating the functional role of the 
module in the pathology of the disease using functional annotations 
or expression patterns [129][130]. Often the limitation of these 
methods is the low coverage of disease-specific maps in the vicinity 
of the known disease components. However, such methods help us 
dig into disease mechanisms and develop rationales and hypothesis 
that could be used to guide experimental research towards more 
objective outputs.	  
3.3.2. Applications of disease-specific network models 
Analysis of disease network models can provide a rationale approach 
to guiding systems interpretation in the context of prior physiological 
or pharmacological knowledge along with incorporation of both 
specific (target) and non-specific (off-target) effects. Besides 
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provisioning an integrative view, disease models can be used for 
biomarker and drug discovery purposes, as I briefly highlight below.	  	  
3.3.2.1. Disease mechanism discovery 
Despite the availability of huge body of information and knowledge 
on human diseases, the molecular mechanisms underlying complex 
human diseases remain largely unexplained. The challenge of linking 
clinical outcomes to their underlying molecular events has been long 
of interest to the scientific community and to the pharmaceutical 
industry as well. This is because it will help to obtain better 
understanding of the disease mechanism at molecular level. Thus, 
disease-specific models may be used to support translation of 
molecular findings into the development of new therapeutic 
strategies. 
Traditionally, disease-specific maps are built based on correlation 
network models. Such models are routinely built using high-
dimensional data such as protein-protein interactions or gene 
expression data by establishing pairwise relations (i.e. edges) for all 
variables (i.e. nodes) but they confound direct and indirect 
associations and do not distinguish between cause and effect. 
Alzheimer’s disease map [115] and Parkinson’s disease map [131] 
are good examples of disease-specific networks in the area of NDDs. 
In contrast, causal network models aim at representing response 
variables and covariates and, thus, the directionality of associations 
between cause and effect. When relationships between variables 
represent conditional dependencies (e.g. given disease symptoms, 
compute the probabilities of the presence of various diseases), the 
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model is a Bayesian network, which requires information on prior 
distribution. In the absence of such information, Biological 
Expression Language (BEL) offers an alternative. BEL is the state-
of-the-art causal network modeling language that integrates 
literature-derived ‘cause and effect’ relationships into a data-driven 
platform and produces casual network models (The Biological 
Expression Language [http://www.openbel.org]). The models 
developed by this means represent a high-resolution and 
comprehensive view not only on the core established pathways but 
also on peripheral events that lead to clinical readouts seen in 
patients. A prime example is development of mechanistic disease 
models for identification of patients with ulcerative colitis who could 
be potential responders to targeted anti-TNF therapy with Infliximab 
[132]. Based on the prior knowledge in the literature, a causal 
network model was constructed that described mechanistic 
knowledge underlying ulcerative colitis in the form of the “cause-
relationship-effect” pattern. Next, gene expression profiles of 
responders and non-responders were incorporated into the causal 
model and a mechanistic strength value was calculated on the gene 
expression network activity signature of TNF signaling for each 
patient in the population. The model demonstrated that non-
responders have different TNF signature compared to responders, 
which was due to sustained TNF-like downstream signaling in non-
responders after treatment with Infliximab, controlled by alternative 
upstream controllers (Figure 22). 
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Figure 22. Stratification of patient population based on 
disease mechanism. A BEL model was successfully built and 
applied to a cohort of patients with ulcerative colitis disease – based 
on TNF signature - to stratify responders from non-responders to 
Infliximab.   
 
It is noteworthy that a computer-readable disease model should be 
readily amenable to computational reasoning for disease mechanism 
discovery and furthermore, in the absence of models that represent 
normal cellular processes in healthy state, any attempt to derive 
mechanistic interpretations is inconclusive. Realizing this necessity, 
Westra et al. (2011) constructed a computable BEL model to capture 
normal, non-diseased biology of cell proliferation in lung cells [133].     
“Differential network analysis” (also known as “differential network 
biology”) methods have been devised and used for cross-species, 
cross-condition network analysis since the 1990s [134]. However, 
despite the fact that biological systems are highly dynamic and 
change depending on environment, tissue type, disease state or 
developmental stage, to date, almost all network models have 
represented the cellular interactions under single static condition 
(mostly under disease condition). Although conventional approaches 
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try to map out dynamic changes in gene expression or metabolic 
fluxes on static network models, they are unable to capture changes 
in wiring of the network model. To tackle this limitation, several 
studies have begun to use disease-specific models for modeling 
changes across disease states. A prominent example is the analysis of 
dynamic modules in the human protein interaction network that was 
shown to be useful for the prediction of breast cancer outcomes 
[135].  
Network perturbation amplitude (NPA) measurement is an up-to-
date and elegant approach that enables modeling of mechanistic 
network re-wiring and quantitative measurement of network 
perturbation in response to external stimuli [136]. The NPA scoring 
method integrates high-throughput experimental data (e.g. gene 
expressions) into curated literature-derived knowledge in the form of 
BEL models, provides an scoring function for quantification of 
causally affected biological processes, and quantifies the changes of 
disease state in comparison to control (non-perturbed) state. 
Although the applicability of this scoring function to other areas has 
not yet been demonstrated independently since its introduction in 
2012, it promises to compute the amplitudes of treatment-induced 
perturbations in biological networks. 	  
3.3.2.2. Drug-target identification 
Low productivity of drug discovery pipelines in recent years has 
been largely attributed to insufficient efficacy of failed drugs [137]. 
Failure of drugs in phase II and III clinical trials in fact reflects the 
poor understanding of the mode of action of such drugs at the 
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molecular level. Network-based knowledge of disease mechanism 
can be used to identify disease modules and prioritize drug targets. 
This approach is essentially a top-down approach, which aims at 
providing a network-based view of drug action (polypharmacology) 
while keeping the focus on node-based target prediction. Such 
methods have been successfully applied mostly to cancer and 
metabolic diseases [138],[139] and are currently under investigation 
for NDDs [140],[141].  
Earlier approaches considered topological characteristics of disease 
networks for target identification such as hub nodes, bridging nodes, 
etc. However, knockout studies revealed an unprecedented 
‘robustness’ in biological networks that leads to masking phenotypes 
due to functional compensation of neighboring pathways. For this 
reason, drug target prediction algorithms shifted towards the 
identification of perturbations rather than single genes [142]. The 
latest network-based target identification methods rely on targeting a 
particular group of proteins, being complexes, modules or pathways 
[143].   
Given the above background, two network-based strategies for target 
identification has been proposed [144]: 
1) “The central hit strategy”, which aims at targeting hubs, 
central nodes, or master-regulators of infectious disease 
networks [145] as well as cancer (e.g. in ovarian cancer 
[146]), and the goal is to selectively hit the network 
integrity of the infectious agent or the malignant cell; and 
2) “The network influence strategy”, which relies on the 
systems-level knowledge of both healthy and diseased states 
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to identify target candidates in polygenic complex diseases 
so that the ultimate object is to reverse the disease network 
malfunctioning to its normal functioning.   
Methods of the network influence strategy are much less developed 
than the single hit strategy as they deal with the dynamics of the 
disease network and it is a difficult task to overcome the robustness 
of networks. Beside nodes, edges of disease networks can be targeted 
to enforce the rewiring of the disease modules. The so-called 
“edgetic drugs” open up new opportunities to modify or modulate 
interactions of multifunctional proteins with a larger selectivity 
[147]. Current efforts in relation to targeting edges have been mostly 
concentrated on protein-protein interactions (PPIs) and it is expected 
that these efforts extend to signaling as well as gene interaction 
networks.	  	  
3.3.2.3. Biomarker discovery 
Disease-specific network models play a substantial role in both data-
driven and knowledge-driven methods of biomarker discovery. In the 
data-driven approach, similarities between data points (typically 
gene expression data) are computed in order to identify network 
clusters, which can suggest mechanisms of regulation. In contrast, 
knowledge-based approaches take advantage of the expert 
knowledge embedded in context-specific curated PPIs, functionally 
annotated pathways, and biomedical publications. Given the unique 
advantages of both data- and knowledge-driven approaches, 
therefore, a combined approach to network-based biomarker 
discovery is preferred [148].  
Chapter	  3.	  Computational	  Approaches	  to	  Modeling	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   67	  
Azuaje et al. (2012) suggest two integrative biomarker discovery 
strategies: a) linking network structure properties to clinical 
phenotypes, and b) identification of subnetworks with differential 
molecular response [149]. For instance, integration of gene 
expression profiles obtained from primary breast tumors into a 
protein interaction network model led to identification of sub-
network biomarkers that represent metastatic tumor progression 
[150]. The philosophy behind using subnetwork-based versus node-
based biomarker discovery is that molecular changes of individual 
nodes represent different outcomes in different network contexts of 
different patients. On the basis of the same philosophy, differential 
network analysis methods are being devised to identify subnetwork 
biomarkers (biomarker modules) by integrating stage-specific 
microarray data into disease-specific and control-specific PPI 
networks; for example, Liu et al. (2012) present a novel approach to 
predicting rewiring of network interactions in three stages of gastric 
cancer [151].    
The advantage of network-based biomarker discovery methods is 
that they have greatly facilitated the paradigm shift from “signature-
based biomarkers” to “multi-panel (multiplex) biomarkers”. By this 
means, gene expression information is linked to proteomics and 
pathophysiology of disease so that many different types of 
biomolecules (i.e. a panel of biomarkers) are being associated to 
pathological processes [152]. For instance, Dudley and Butte (2009) 
created two biomarker networks by linking genomic profiles from 
human diseases to detectable biomarker protein in blood plasma and 
in urine, respectively [153]. They found that in both networks, over 
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80% of the putative biomarkers are linked to multiple disease 
conditions. Thus, the vast combinatorial space of candidate 
biomarkers could be computationally investigated using a top-down 
approach, compared to the conventional bottom-up approach. 	  
3.3.2.4. Classification of diseases	  
The contemporary classification of human diseases is based on 
observational correlations between anatomical, symptomatic and 
epidemiological criteria, which does not take the etiological 
mechanism into account and thus, lacks sufficient sensitivity and 
specificity. This has led to the problem of misdiagnosis due to the 
overlap of symptoms. Consider Parkinson’s disease with dementia 
and Alzheimer’s disease dementia. Since classification of these two 
neurodegenerative diseases is merely based on their clinical signs, 
early diagnosis of Parkinson’s disease (PD) is hampered. The extent 
of clinical overlap between these two conditions is so much greater 
than chance that even some authors propose that AD and PD belong 
to a spectrum of neurodegenerative disorders with common disease 
mechanism but triggered by different etiological factors [154]. 
However, at the molecular level, these two conditions can be 
distinguished based on diagnosis between synucleinopathy from 
tauopathy.  
Another shortcoming of the current disease classification system is 
ignorance of inter-connected nature of many diseases, including 
comorbidities. Mechanistic disease models can be used to reveal 
inter-dependencies between the disease and risk mechanisms (Figure 
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23). Such interdependencies are reflected in comorbidities that co-
occur with the disease and increase the disease risk. 
           
	  
Figure 23. Deterministic factors involved in shaping the 
disease phenotype. Complex interactions between causative 
molecules, disease modifying molecules and environmental factors 
lead to an intermediate phenotype response (e.g. as comorbidity), 
which contributes to the manifestation of disease endophenotype.  
Thus, integrative disease modeling provides a systems-based 
network framework for incorporation of both conventional 
reductionism and non-reductionism approaches and allows for re-
definition of the current nosology [155]. In 2011, National Academy 
of Sciences committee recommended NIH to develop a new 
taxonomy of diseases based on their underlying molecular and 
environmental causes rather than on physical signs and symptoms 
[156]. The idea is to create a so-called Knowledge Network 
information system that integrates molecular data, medical histories, 
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and health outcomes of individual patients. In Europe, the Innovative 
Medicines Initiative (IMI) - Europe's largest public-private 
partnership aiming to improve the drug development process – 
launched a call that addresses the topic of developing an aetiology-
based taxonomy for human diseases. The aim of this call is to 
propose new etiological mechanism-based taxonomy in 
immunoinflammatory diseases and neurodegeneration with focus on 
AD and PD by developing knowledge frameworks that represent 
clinically relevant mechanistic knowledge of the pathophysiology 
underlying neurodegeneration.	  
3.3.2.5. Drug side-effect prediction 	  
Mapping drugs onto the target space of disease networks provides a 
system-wide view of the target landscape, which can be used for the 
investigation of polypharmacology as well as side effects of off-
targets. Network pharmacology has been proposed to aid selection of 
those compounds that maximize modulation of disease networks 
while minimizing side effects [157]. In a polypharmacological 
analysis, Keiser et al. (2009) computed chemical similarities among 
FDA-approved drugs and predicted new off-targets that explained 
drug’s adverse reactions [158]. In fact, both drug-target networks and 
drug-disease networks can be used for the prediction of side effects 
[159],[160]. A landmark paper by Campilus et al. (2008) showed that 
computing phenotypic side-effect similarities could predict targets 
that are shared between drugs and can be used for drug repositioning 
[161]. Mitzutani et al. (2012) analyzed correlations between drug 
target-binding profiles and side effect profiles in the context of a 
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drug-protein interaction network and found that correlated sets were 
significantly enriched with proteins that are involved in the same 
biological pathways [162]. In summary, network prediction methods 
may help to decipher novel side-effects when analyzing the disease-
specific mechanistic networks for identification of potential drug 
targets. 
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CHAPTER 4. Setting an In-Silico Strategy for 
Optimizing Early Drug Target Identification 
and Validation 	  
4.1. Target selection in drug discovery 
Target identification in drug development is a crucial step for follow-
up medicinal chemistry studies. A target in the context of drug 
discovery can be defined as disease-associated proteins that are 
functionally involved in the pathology of interest. Distinctions are 
typically made as to whether a target is ‘novel’, ‘established’, or 
‘validated’. Briefly, novel targets are proposed targets with 
speculative involvement in the disease process and no clear 
indication of its clinical benefit whereas established targets are those 
with a good scientific support on functionality in both normal and 
disease states but unknown clinical benefit. In contrast, validated 
targets have shown a clear clinical benefit with a well-understood 
mechanism of action.     
Specific biological hypotheses based on which targets are selected 
possess varying degrees of confidence, depending on the origin of 
those hypotheses. Given that targets have been historically identified 
on the basis of genetic studies or biological observations, Sams-
Dodd from Boehringer Ingelheim Pharma (2005) divides targets into 
three classes: “physiological targets” that characterize physiological 
effects at the level of whole organism in animal models;  “genetic 
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targets” that represent genetic mutations; and “mechanistic targets” 
that represent receptors, enzymes, or other biological molecules and 
are linked to molecular mechanism [163]. Accordingly, genetic 
targets are specific to those diseases that arise from a genetic 
mutation or the increased disease risk by a single gene. Moreover, 
the gene or its product must be the main modulator of the disease at 
the time of intervention. These two conditions for genetic targets 
imply that multifactorial complex diseases that develop over time 
can not be treated by such an approach. Instead, mechanistic targets 
go beyond the ‘single gene, single disease’ paradigm by engaging 
environmental factors in addition to causative biological 
components, and therefore, can be applied to multifactorial 
progressive diseases. Since mechanistic targets affect multiple 
molecular mechanisms, their validation is a complex task and 
depends on the availability of predictive models.    
In general, there are three complementary approaches to target 
identification: biochemical methods, genetic interaction methods, 
and computational prediction methods [164]. Amongst these three 
methods, computational target identification methods have the 
advantage of the least bias compared to other methods because they 
rely on a combination of experimental data generated by others. A 
high-priority task for computational target identification methods is 
to address the issue of clinical efficacy; i.e. in the absence of clinical 
data, a model is required to integrate both the experimental data and 
expert knowledge in the context of the disease of interest so that 
ultimately the clinical efficacy of a target can be predicted in silico in 
the form of a set of relevant hypotheses [165]. A success story in this 
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regard is the instrumental role of computational data integration and 
model analysis in identification of Aurora kinase A as the key target 
of dimethylfasudil in acute megakaryoblastic leukemia. In this case, 
integrating transcriptomic and proteomic data led to generation of 
testable hypothesis, which identified relevant target of 
dimethylfasudil [166].	  
4.2. Model-driven approach to target identification 
and validation for neurodegenerative diseases 
The pressing need for treatment of neurodegenerative diseases has 
not yet met due to complexity of disease mechanism and multiple 
unknown genes and pathways. The majority of existing treatments 
were discovered empirically and, for this reason, the mode of action 
of most of these drugs was unknown when they were introduced to 
the market. Consequently, the conventional target-based approach 
has not been much successful in the area of NDDs as was for other 
disease indications [167]. This fact is supported with the current and 
subsequent failures of Alzheimer’s drugs, as discussed in Chapter 1. 
Therefore, a better and deeper understanding of the 
neurodegeneration mechanism is needed, if the target-based 
approach continues to play its role in the CNS drug discovery and 
development. In response to this need, pharmaceutical industry has 
already taken steps towards applying systems biology approaches to 
deciphering disease mechanism and identifying therapeutic targets 
for CNS disorders, including NDDs, as discussed by Mei et al. from 
GlaxoSmithKline in their seminal review [168].  
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Normally, a research process starts with an exploration of the 
problem domain by collecting relevant data, information, and 
previous knowledge, which are often hidden in scientific 
publications. Accordingly, referring to the scientific literature is 
usually the first step towards drug target selection and validation 
process [169] because it provides a valid and proper framework for 
drug target identification purposes. When merged with network-
based disease models, the information extracted from text enhances 
the confidence about druggability of the candidate target(s). 
Moreover, it would be possible to generate informative profiles for 
each candidate target using information extracted from the text; i.e. 
literature-based annotation of target nodes on the network model of 
disease provides enormous insight about drug candidate efficacy and 
toxicity. Such profiles will be of high value for ranking or 
prioritizing target candidates. 
4.2.1. The overall strategy 
To address the motivation and mission of this research, and to 
improve our current understanding about pathophysiological 
mechanisms underlying AD, an “integrative disease modeling” 
approach is proposed, which takes advantage of the complementary 
nature of data-driven and knowledge-driven methods, combines 
them under a single framework, and produces knowledge-based, yet 
mechanistic disease models. The models generated by this approach 
could represent correlation or cause and effect, depending on the 
type of associations between pairs of variables in the network model. 
The general strategy is depicted in Figure 24.    
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Figure 24. Model-driven approach to integrating biological 
data. Proposed model-driven approach combines biomedical 
knowledge and data into a single disease model, which could 
represent correlations (left) or cause and effect (right).  
4.2.2. The methodology 
In the following, I discuss the workflow that was implemented 
according to the above strategy. It is a biphasic approach, meaning 
that knowledge-driven and data-driven methods are applied in two 
independent phases (Figure 25). Network models built from protein 
interaction data are used as model backbones or integration templates 
for addition of literature-derived information as well as overlay of 
experimental data. As discussed in Chapter 3, correlation-based 
networks including PPI networks have both advantages and 
disadvantages to be used as the model backbone: while PPI networks 
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lack the directionality on edges and suffer from incompleteness, their 
biggest advantage over the other types of networks is that they 
enable us to link data-derived information to literature-derived 
knowledge. Moreover, PPI networks offer the flexibility required for 
mapping other biological data types such as gene expression. 
 
	  
Figure 25.  Diagrammatic sketch of the workflow applied 
to the modeling approach. Domain-specific terminologies were 
plugged into the ProMiner software and the results of named entity 
recognition on PubMed abstracts were deployed in the SCAIView 
environment, appearing as highlighted text. The harvested 
knowledge from ontology-supported queries was manually 
integrated with protein interaction data using a brain-specific 
network model to isolate brain region-specific subnetworks for 
further analysis. 
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4.2.2.1. Knowledge-driven approach 
Text mining has been defined as “the computational discovery of 
new, previously unknown information, by automatically extracting 
information from different written sources” [170]. Text mining 
technologies have been broadly used for the identification of disease-
related knowledge on potential targets, biomarkers and the disease 
mechanism.  
Generally, text-mining methods consist of two steps [171]: 
information retrieval (IR) and information extraction (IE). IR is 
performed with the aid of search engines via two approaches: rule-
based (knowledge-based) and statistical (machine-learning). The 
former uses pattern recognition to find a meaningful biological 
pattern such as ‘<brain> and <pathway>’ whereas the latter uses 
classifiers to classify abstracts or sentences. IE relies on named entity 
recognition (NER), which enables detection and extraction of 
biological entities such as genes, SNPs, proteins, drugs, or other 
entities. Numerous tools have been developed on the basis of NER 
techniques: iHop [172] annotates a subset of PubMed sentences 
containing at least two proteins in conjunction with interaction-
specific keywords. AliBaba [173] aggregates results of a PubMed 
query and visualizes them as a graph. EbiMed [174] retrieves co-
occurring entities and ranks them by frequency. UKPMC [175] 
annotates and highlights entities in PubMed Central abstracts by 
using Whatizit [176]. GoPubMed [177] recognizes entities such as 
genes, gene ontology terms and MeSH terms. GeneView [178] is 
rather a recent NER-based tool, which recognizes a broader set of 
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entity types than genes but not gene ontology terms, provides search 
facilities using unique database identifiers and also finds 
relationships between proteins in text. ProMiner [179] is one of the 
systems for gene normalization, which performed very well in 
BioCreAtIvE I and II assessments, reaching an F-score of 0.8 for the 
recognition and normalization of human genes and proteins. The 
ProMiner system has been designed for the semi-automated 
generation of dictionaries and the recognition of spelling variants, as 
well as the disambiguation of acronyms and common word 
synonyms. ProMiner uses extensive dictionaries for various 
biological entities, including genes/proteins, SNPs, chemical names, 
disease terms, and any other relevant vocabulary.  
IE methods aim at extraction of relevant entities from the retrieved 
documents in a tabulated form. The simplest IE approach identifies 
co-occurrence of entities in the text whereas a more complex IE 
method attempts to extract relations between entities such as protein-
protein interactions, drug-target interactions or biological pathways. 
Several IE tools have been developed, which analyze search results 
and present summarized knowledge of semantics: MedEvi [180] 
provides concept variables of major biological entities (e.g. gene) to 
be used in semantic queries and prioritizes search results based on 
keywords that occur in original queries. EBIMED [181] extracts 
proteins, GO annotations, drugs and species from retrieved 
documents and identifies relationships between extracted concepts 
based on co-occurrence analysis. CiteXplore [182] provides 
integrated access to both literature and biological data and also 
contains abstract records from patent applications from the Europe 
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Patent office and from the Chinese Academy of Sciences. MEDIE 
[183] provides semantic search in the format of triples (subject, verb, 
object) and returns abstract sentences that match the queried 
semantic relations. PubNet [184] parses the XML output of standard 
PubMed queries and creates different kinds of networks. Nodes can 
be representatives of article, author or some database IDs and edges 
are constructed based on shared authors, MeSH terms or location. 
Ontology-based information extraction systems have been emerged 
as a subfield of IE, which make the use of ontologies and their 
explicit conceptualization to semantically guide the extraction of 
classes [185].  
The literature retrieval system used in this thesis is composed of two 
software components: the named entity recognition tool ProMiner 
and the knowledge discovery framework SCAIView [186]. The 
retrieval terminologies are incorporated into ProMiner, followed by 
ProMiner's annotation of all Medline abstracts using the dictionaries. 
The resulting entity annotations are stored in an Apache Lucene(TM) 
- based search index, together with the documents and their meta-
information. SCAIView incorporates the Lucene-based index and 
allows for searches that include exact matches, wildcard options, and 
Boolean operations. The document visualization within SCAIView 
provides highlighting for all the entity classes with tooltips 
containing available linkouts, descriptions, and depictions. The 
annotations are organized in the form of hierarchies (semantic trees) 
and can be navigated by the user via selecting full classes (e.g. 
‘genes’ or ‘diseases’), selecting certain subclasses (e.g. ‘Nervous 
Systems Diseases’), or singular dictionary entries (e.g. ‘Alzheimer’s 
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Disease’). For Boolean operations, either single entity class or 
complete tree classes could be selected. The system returns the 
results according to statistical ranking of found entities based on 
Kullback-Leibler divergence (relative entropy), meaning that the 
more relevant entities (e.g. gene names) appear in the top of the 
ranking list. 
Ontologies go beyond the mere providers of a common terminology 
for a knowledge domain by taking into consideration the semantic 
relationships among the concept classes. Such relationships help to 
model the knowledge domain in a well-organized hierarchy of 
concepts, which add to the value of ontologies when it comes to the 
real world applications. In contrast to philosophical ontologies, 
computational ontologies aim to represent a scientific knowledge 
domain in a machine-readable taxonomy-based manner with the 
maximum proximity to the natural language expressions in the real 
world. Computational ontologies form the basis for knowledge-
driven drug discovery approaches. To this end, I have integrated 
dictionary-based text mining technologies and ontological search 
capabilities to retrieve and extract relevant information for disease 
modeling and drug target identification (Figure 26). 
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Figure 26. Schematic workflow of ontology-driven 
literature search. Various resources were used to build ontologies 
and their controlled vocabularies, which ultimately were plugged 
into the SCAIView advanced search engine to allow for semantic 
search.   
 
The advantage of this approach is that a combination of domain 
ontologies and their dictionaries can be used in SCAIView to narrow 
down the search in the vast space of the knowledge cube. Therefore, 
the user is able to perform targeted, advanced search and export 
entities together with their annotation (Figure 27). The Entity View 
displays a table with the aggregated list of entities found in the 
documents ranked by relative entropy, as explained before. In the 
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Entity table, the following columns are shown by default: Entity, 
Relative Entropy, Reference Documents Count, Documents Count, 
and Link-outs to databases. However, this table can be expanded by 
adding more annotation columns to include additional information 
such as links to KEGG or Reactome pathways as well as Gene 
Ontology, InterPro family and domain information, ATC 
(Anatomical Therapeutical Chemical Classification) code, etc. The 
full table as well as selected entities can be exported the text file 
(CSV format). It is possible to export the list of all the extracted 
entities (e.g. gene names) along with their corresponding PubMed 
identifier so that there is a means for tracing back the reference from 
which the entity has been extracted. Exporting co-citations as well as 
PPIs out of the selected entities are other potential IE functionalities 
of SCAIView.   
 
 
Figure 27. Ontology-driven IR and IE using SCAIView 
facilitates targeted search.  
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The published knowledge in the literature contains complex 
biomedical information that can be represented as a multi-
dimensional cube. Controlled vocabularies derived from ontologies 
are used in combination to explore the knowledge cube in multiple 
dimensions and perform targeted search for informative documents.   	  
4.2.2.2. Data-driven approach 
With the availability of novel high-throughput methods, large 
amounts of data about the interactions among proteins are available 
in various databases. Aggregation of PPIs under a single interactome 
is necessary because there is a small overlap amongst PPI databases 
in terms of their data content [187],[188]. For this reason, several 
tools have been devised to capture, collect, and unify PPI data from 
existing PPI databases. For instance, BIANA (Biologic Interactions 
and Network Analysis) integrates multiple sources of biological 
information, including proteins and their relationships, and attempts 
to manage the biological information as a network where proteins are 
nodes and interactions are edges [189]. The PPI networks generated 
by means of such automatic methods, however, contain noise (e.g. 
incomplete parsing of data points, erroneous normalization of node 
names, etc.) and must undergo expert curation process. During this 
process, additional annotations on nodes and edges of the network 
model are performed using the knowledge-driven approaches. For 
instance, nodes that are already targeted by approved drugs can be 
highlighted or edges representing interactions in specific tissue or 
cell type can be filtered. The visualization, statistical analysis, and 
filtering of PPI networks is carried out in the environment of the 
Cytoscape software [190].   
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4.2.2.3. Model building workflow 
Both the information retrieved and extracted from the knowledge-
driven approach and the data aggregated from data-driven approach 
are subjected to a dedicated workflow with curation, quality control 
and model assembly steps (Figure 28). For instance, the protein 
interaction data are curated for any possible parsing error during the 
process of automatic data collection, aggregation and ID conversion. 
In this work at the reformatting step, all the protein IDs were 
converted into the official gene symbols as defined by HUGO Gene 
Nomenclature Committee (HGNC). By this means, mapping of other 
data layers such as gene expression levels or expressed biomarkers 
for the purpose of model analysis becomes feasible. Similarly, the 
textual information retrieved and extracted from publications 
undergo a manual curation and quality control process to avoid false 
positives and to ensure the true relevance of extracted information to 
the corresponding query. This step is particularly important as the 
current state-of-the-art IR and IE tools do not produce noise-free 
results and thus, intervention of human expert is still required.  
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Figure 28. Schematic workflow of model building. This 
workflow was used to construct context-specific models using 
curated, quality controlled data types. 
 
Once models are built, they are deposited in a dedicated 
knowledgebase together with proper documentation and meta-
information for the sake of future provenance. During analysis stage, 
functional validation of generated models is performed through 
pathway analysis. As explained in Chapter 3, GSEA methods are 
often used to determine enriched functional modules in the network 
model. Recovery of manually curated pathways from databases such 
as KEGG or BioCarta is another alternative. In the next chapters, I 
introduce a novel network validation method entitled “biomarker-
guided pathway analysis”, which takes advantage of the accumulated 
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knowledge about potential molecular biomarkers of disease and 
makes use of this observational information to guide the pathway 
analysis to the core molecular events already experimentally 
recorded for the pathology of the disease.    
Once the most significant pathway modules are identified in the 
context of tissue- or stage-specific disease network, these modules 
can be prioritized to identify candidate pathway modules as 
described in Chapter 10 (Figure 29). 
 
 
 
 
Figure 29. Workflow for validation, integration, and 
analysis of subnetwork models. Context-specific integrated 
models were subjected to validation by a variety of strategies such as 
biomarker guided analysis and pathway recovery test to establish the 
relevance and specificity of the model. Validated model is then used 
for identification of important disease processes supported by 
evidence attributes.  
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CHAPTER 5. Multi-scale Knowledge 
Representation using Ontologies 	  
Biological and medical ontologies are formal representations of 
biomedical knowledge. They have been proven very useful for the 
communication of biomedical information through controlled 
vocabularies, definitions and proper metadata annotation [191]. 
Numerous examples have demonstrated their value for data mining 
and knowledge discovery approaches. Ontologies have been used for 
automated reasoning [192], for large-scale annotation of entire 
genomes [193], for data mining in microarray data [194] and for 
semantic and ontological search in unstructured information sources 
such as scientific text [195],[196]. 
The biological domain has developed a large portfolio of widely 
accepted and widely used ontologies. However, relevant knowledge 
in the pharmaceutical sector has not yet been addressed by the public 
scientific community. Some proprietary efforts to organize the 
knowledge relevant for pharmaceutical industry exist. To our state of 
knowledge, the BioWisdom pharma ontology [197] is the only 
ontological resource representing a substantial part of the pharma 
world. This proprietary ontology comprises substantial evidence 
(extracted from literature) and incorporates a broad spectrum of 
public sources.  
Building context-specific disease models requires domain-specific 
knowledge to be incorporated into the model. Since disease models 
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may span from molecules to cells, tissues, organs and the entire 
physiology of human, there is a need to build up ontologies that map 
to these biological scales [198]. In the absence of such semantic 
resources for NDDs, I developed several ontologies to support the 
knowledge-driven approach for modeling mechanistic disease 
networks, with focus on Alzheimer’s disease (Figure 30). 
 
           
	  
Figure 30. Mapping ontology development efforts to 
various biological scales. Different ontologies and controlled 
vocabularies shown in this diagram were developed to support IE 
and IR process for building context-specific systems models. 	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5.1. Ontology life cycle 
The ontology-building life cycle is a common standard practice and 
is composed of the following five steps, as illustrated in Figure 31 
[199]. 
               
	  
Figure 31. The life cycle of ontology-building consisting of 
five substantial steps. A detailed description of the ontology-
building life cycle is outlined below. 
1) Defining ontology purpose and scope 
The first step in an ontology construction process is the definition of 
an ontology purpose and an ontology scope. In the ideal case, before 
the ontology building process begins, it should be clear why the 
ontology should be built. For defining an ontology purpose, the 
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ontology builder should identify motivating scenarios and 
competency questions. Also the motivating scenarios can help to 
identify the range of possible users. The set of competency questions 
should help to define ontology scope.  
2) Knowledge acquisition 
Knowledge acquisition consists of knowledge gathering from web, 
articles, books and other knowledge resources. An analysis of the 
collected knowledge should be performed with respect to the 
ontology scope.  
3) Conceptualization 
When enough knowledge is aggregated - the conceptualization 
process takes place, which consists of defining concepts and 
relationships between them. During this step, the superclass-subclass 
hierarchy of the ontology concepts is established. Parts of other 
existing ontologies can be reused and integrated into the ontology 
under development.  
4) Encoding 
During encoding step, the concepts are coded into the OWL (Open 
Web Ontology Language) structure format using specialized 
software tools, such as Protégé (Protégé Project 
[http://protege.stanford.edu/]).  
5) Ontology evaluation 
The last step is the evaluation of the ontology. Gangemi et al. (2006) 
have defined three measurements for quality assessment of 
ontologies:  
I. Structural measurement, which measures topological and 
formal semantics of the ontology; 
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II. Functional measurement, which tries to assess the coverage 
and applicability of the ontology to the knowledge domain 
of interest; 
III. Usability profile measurement, which aims to measure the 
extent of efficient accessibility of users to knowledge levels. 
Structural evaluation is performed by calculating features such as 
depth, breadth, and other topological features of the ontology. To 
evaluate the functional quality of the ontology in terms of measuring 
the boundaries of the knowledge domain it captures, precision, 
recall, and F-score values are calculated [200].  
Precision is the number of true positives (TP) divided by the sum of 
TP and false positives (FP).  
Recall is the number of TP divided by the number of results that 
should have been returned (FP + false negatives (FN)).  
The F-score = 2 x (precision x recall) / (precision + recall).  
These values are derived from the longest string match found 
between automatically annotated words using ProMiner and the 
human-curated gold standard annotation for each abstract in the 
selected corpus.	  	  
5.2. PLIO: Protein-Ligand Interaction Ontology 
The PLIO ontology was built in the course of a Master thesis as a 
groundbreaking effort to practice ontology-based IR and IE and 
calibrate the text-mining machinery and the IR system. This work 
has been published with equal contribution of the author of this 
thesis [201] and it is mentioned here for the sake of scientific 
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completeness of the work done for identification of novel targets at 
the molecular level. 
5.2.1. Purpose and scope 
PLIO is representing knowledge about the interaction of proteins and 
ligands (incl. drugs) and has a different scope and conceptual 
resolution than the Molecular Interaction ontology [202].  An 
important feature of PLIO is that it links directly from an ontology 
framework describing protein-ligand interactions to the mathematical 
formulas relevant for the computation of some of the entities 
represented in the ontology. To our knowledge, this is the first 
example for an ontology, which directly links from a knowledge 
representation to the mathematical building blocks that describe the 
leaves of the ontology in mathematical terms. It is noteworthy that 
we have adopted the top-level formal ontology structure during the 
construction of PLIO, i.e. the principle criteria of the top-level 
ontologies using the Basic Formal Ontology (BFO) upper level 
concepts was followed [203]. However, our attempt was 
concentrated on keeping the concept definitions close to expressions 
in natural language. Thus, the hierarchical structure of the ontology 
can serve as a robust navigation tree for terminology integration and 
text-mining applications.  
5.2.2. Structural characterization: 
Assessment of the quality of PLIO was based on both, structural and 
functional criteria. Table 8 summarizes the structural features of the 
ontology. 
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Table 8. Structural parameters of the PLIO ontology and 
their corresponding values 
 Diameter Depth No. of 
concepts 
No. of 
leaves 
Classes 371 13 371 271 
Properties 13 0 12 12 
   
5.2.3. Functional characterization: 
In order to assess the functional quality of the PLIO, three 
competency questions were sketched. Answering the competency 
questions requires sufficient ontological coverage to capture the 
concepts of the domain. Table 9 represents the competency questions 
that can be answered by the PLIO.  
 
Table 9. List of competency questions, the range of 
concepts that each question covers, and corresponding 
relations defined in the ontology 	  
Competency question 1 Concepts Relationships 
Find features which reflect 
protein-ligand interactions 
from the viewpoint of  
biophysics, 
chemoinformatics, 
molecular modeling, and 
experiments. 
a) Interaction descriptor  
b) Interaction type 
c) Thermodynamics of 
protein-ligand 
interactions 
d) Interaction detection 
e) Interaction simulation 
 
 
-Interaction “has_a” 
Interaction descriptor 
-Interaction “has_a” 
Interaction type 
-Interaction “described 
by” Thermodynamics of 
protein-ligand interactions 
 -Interaction “part_of” 
Interaction Detection 
-Interaction ”part_of ” 
Interaction simulation 
Competency question 2 Concepts Relationships 
Find features which reflect 
a certain kind of ligand 
a) Intrinsic activity 
b) Binding activity 
-Ligand “has_a” activity 
-Ligand “has_a” ligand 
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activity against its 
biological target. 
c) Biological activity 
d) Conformer 
binding site 
-Ligand “binds to” ligand 
binding site 
-Ligand “is_a” conformer 
-Ligand “has_a” 
conformation 
-Activity “is_a” intrinsic 
activity 
-Activity “is_a” binding 
activity 
-Activity “is_a” biological 
activity 
-Activity “has_a” activity 
landscape 
-Activity “has_a” 
structure-activity 
relationship 
-Activity “is_a” 
biotransformation ability  
-Activity “is_a” reaction 
ability 
Competency question 3 Concepts Relationships 
Find features which reflect 
the properties of protein 
and ligand binding site. 
a) Ligand binding site 
b) Ligand binding site 
properties 
-Ligand Binding site 
“has_a” binding site 
properties 
-Binding Site properties “is 
_a” physicochemical 
properties 
-Binding Site properties “is 
_a” geometrical properties 
 
 
After enrichment analysis of the training set, 81 concepts were 
enriched with synonyms and 25 new concepts were added to the 
protein-ligand interaction ontology. The terminology behind PLIO 
supports 1321 synonyms (on average 3.5 synonyms per concept). 
Evaluation of the terminology showed a satisfactory performance on 
an independent test corpus of 100 Medline abstracts (Table 10). 
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Table 10. Results of the ontology evaluation using NLP-
based approach 
 Precision Recall F-score 
Independent test set of 
100 abstracts 
0.94 0.72 0.8154 
  
5.2.4. Usability profile 
PLIO provides users with 1036 entity annotation axioms for all 
instances and classes.  The coverage of relevant information in the 
ontology has been increased by adding 75 formula annotations and 
several software hyperlinks. Through integration of PLIO in 
SCAIView, we could make the ontology easily navigable as a tree 
and – at the same time – visualize the markup of PLIO concepts 
tagged in PubMed abstracts. 	  
5.3. BMT: Biomarker Terminology 
During the past years, high-throughput technologies have been 
extensively employed for the study of molecular mechanisms 
underlying different diseases and this has led to the discovery and 
development of a large number of molecular biomarkers. Several 
definitions for biomarkers have been proposed amongst which the 
one by the US National Institutes of Health defines a biomarker as “a 
characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention”. 
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Biomarkers have been utilized throughout various stages of drug 
discovery and development. For example, biomarkers play an 
important role in drug target discovery and validation (e.g. as 
quantitative readouts for candidate drugs), in the monitoring of 
toxicity mechanisms (e.g. quantitation of indicators for unwanted 
side-effects), and non-invasive imaging of diseased organs. In the 
process of drug development, biomarkers are considered to be 
pivotal to informed decision-making as they are used to drive critical 
go/no-go decision in the early stages of drug development. 
For target identification purposes, potential biomarkers reported in 
the literature indicate measurable molecular activities under the 
disease condition, which provide more reliable evidence in-vivo at 
the protein level compared to inconsistent gene expression results. 
This has important implications in the study of NDDs because gene 
expression data are often obtained from the post-mortem brain, 
suffer from heterogeneity of cell-types and tissues mixed in the brain 
samples, and are not even disease stage-specific.  Hence, later in the 
course of this thesis, I introduce the novel concept of ‘biomarker 
guided pathway analysis’ by which I guide the disease model 
analysis for target identification in AD to core pathological processes 
underlying disease mechanism. A first step to finding supportive 
evidence for clinically important potential biomarkers is to search the 
accumulated data and knowledge generated from basic research. For 
efficient exploration of the suspected large amount of biomarker 
information contained in the biomedical literature, semantic search 
and information retrieval systems are of utmost importance. Hence, 
development of a biomarker terminology as a semantic resource for 
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systematic harvesting of AD-related potential biomarkers was 
performed and published [204].    
5.3.1. Purpose and scope 
Surprisingly, there exists no ontology for knowledge representation 
of the biomarker domain. The purpose of BMT was to capture all the 
key concept classes in the domain of biomarkers under a single 
classification schema to be used for text-mining applications. The 
scope of BMT covers six classes based on the conventional 
classification of biomarker types as well as the distribution analysis 
of the potential biomarker information in the literature. 
1. Clinical Management: annotates all terms indicating clinical 
investigations in patients, which includes the initial mentioning, 
the clinical study, and finally the treatment 
2. Diagnostics: annotates all diagnostics that are used, which 
includes the initial disease stage, the molecular identification, 
and blood diagnostics 
3. Prognosis: annotates all terms indicating any prognosis, 
outcome, or marker (e.g. clinical or biomarkers, adverse effects, 
resistance, response, disease progression or outcome) 
4. Evidence marker: annotates all changes in gene and protein 
abundance, spanning from expression to mutation, SNP 
variations to phosphorylation status 
5. Antecedent: annotates all risk factors mentioned for the relevant 
disease.  
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5.3.2. Structural characterization 
 The biomarker terminology contains 119 entity classes with 1890 
different synonyms. 
5.3.3. Functional characterization 
The BMT was evaluated against a gold standard list of Alzheimer’s 
disease genes. Genes were ranked based on frequency and evaluated 
against the Alzheimer’s gold standard. For the different selections 
recall, precision, F-score and rank have been estimated for 10, 30, 
and 50 % recall. In addition the maximal recall has been estimated 
(Table 11). 
 
 
 
Table 11. Performance evaluation for Alzheimer’s disease. 
Genes were ranked based on frequency and evaluated against the 
Alzheimer’s gold standard at different ranking positions.  
Selection Rank Recall Precision F-score 
Baseline: Genes / 
Proteins 
60 0.10 0.92 0.17 
230 0.30 0.73 0.42 
469 0.50 0.61 0.55 
Maximal F-score 728 0.67 0.52 0.59 
Baseline + Clinical 
Management 
61 0.10 0.90 0.17 
226 0.30 0.75 0.42 
465 0.50 0.61 0.55 
Maximal F-score 682 0.65 0.54 0.59 
Baseline + Evidence 
Marker 
62 0.10 0.89 0.17 
225 0.30 0.75 0.42 
464 0.50 0.61 0.55 
Maximal F-score 654 0.62 0.54 0.57 
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Baseline +Prognosis 63 0.10 0.87 0.17 
247 0.30 0.68 0.41 
541 0.50 0.52 0.51 
Maximal F-score 740 0.61 0.47 0.53 
Baseline + 
Diagnostics 
64 0.10 0.86 0.17 
237 0.30 0.71 0.42 
494 0.50 0.57 0.53 
Maximal F-score 520 0.52 0.57 0.54 
Baseline + Statistics 64 0.10 0.86 0.17 
227 0.30 0.74 0.42 
678 0.50 0.42 0.45 
Maximal F-score 377 0.41 0.62 0.49 
Baseline + Clinical 
Management 
+ Evidence Marker 
60 0.10 0.92 0.17 
224 0.30 0.75 0.42 
451 0.50 0.63 0.56 
Maximal F-score 555 0.57 0.59 0.58 
Baseline + Clinical 
Management 
+ Evidence Marker 
+ Prognosis 
61 0.10 0.90 0.17 
230 0.30 0.73 0.42 
568 0.50 0.50 0.50 
Maximal F-score 479 0.47 0.56 0.51 
5.3.4. Application scenarios 
To demonstrate the applicability of the biomarker retrieval 
terminology, the performance of retrieval for biomarker-related 
abstracts from Medline was tested in the field of Alzheimer’s 
disease. The system was able to successfully extract candidate 
biomarker genes/proteins relevant to the queried diseases (see table 
12 below). Genes retrieved by the selection of Clinical Management 
and Evidence Marker classes and not mentioned in the AD gold 
standard were checked manually by this author using the SCAIView 
environment. Such genes/proteins might be valuable for 
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identification of novel biomarkers because they represent the yet-to-
be identified biomarkers whereas those already matched with the 
gold standard are candidates that are better known as potential 
indicators of the disease. For this purpose, the abstracts must contain 
at least the information of the gene, which is altered (e.g. 
overexpression or mutation) in a particular state of AD and their 
therapeutic response state. Examples of such information with the 
corresponding PMIDs are given in Table 12. 
	  
Table 12. Examples of articles accepted to contain 
biomarker information. Example evidence for genes retrieved 
via SCAIView for Alzheimer’s disease but not found in the 
corresponding gold standards. 
PMID Gene Alteration Textual Evidence 
17387528 ACAD8 
HMGCS2 
SNP In a European screening sample of 115 
sporadic AD patients and 191 healthy 
control subjects, we analyzed single 
nucleotide polymorphisms in 28 
cholesterol-related genes for 
association with AD. The genes 
HMGCS2, FDPS, RAFTLIN, ACAD8, 
NPC2, and ABCG1 were associated 
with AD at a significance level of P < 
or = 0.05 in this sample.  
17531353 SLC17A7 Protein 
expression 
decrease 
Loss of VGLUT1 and VGLUT2 in the 
prefrontal cortex is correlated with 
cognitive decline in Alzheimer 
disease…We quantified VGLUT1 and 
VGLUT2 in the prefrontal dorsolateral 
cortex (Brodmann area 9) of controls 
and AD patients using specific 
antiserums. A dramatic decrease in 
VGLUT1 and VGLUT2 was observed 
in AD using Western blot 
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19863188 HPX 
SERPINF1 
Cerebrospi
nal fluid 
concentrat
ion 
Five differentially-expressed proteins 
with potential roles in amyloid-beta 
metabolism and vascular and brain 
physiology [apolipoprotein A-1 (Apo 
A-1), cathepsin D (CatD), hemopexin 
(HPX), transthyretin (TTR), and two 
pigment epithelium-derived factor 
(PEDF) isoforms] were identified. Apo 
A-1, CatD and TTR were significantly 
reduced in the AD pool sample, while 
HPX and the PEDF isoforms were 
increased in AD CSF 
 
For AD, out of 400 genes, 158 genes/proteins had at least one 
evidence in the literature as being a potential biological indicator of 
Alzheimer’s disease and thus were considered as true positives (~ 
40%). Evaluation of retrieved genes not existing in the gold standard 
for AD showed that almost half of these genes have probably the 
potential of being considered as candidate biomarkers. This indicates 
that automated text mining using biomarker terminology 
combinations increases recall for biomarker – specific information 
retrieval and makes it possible to systematically explore the 
biomarker space in an efficient way. As I explain in the next chapter, 
I have used the BMT utility to harvest and screen all potential 
biomarkers of AD reported in the literature.  
 
5.4. BRCO: Brain Region and Cell Type Ontology 
Modeling details of disease mechanism in NDDs is challenging due 
to the anatomical complexity of the human brain. To the state of our 
knowledge, preceding to this work, there was no semantic 
framework in the public domain for representing the heterogeneous 
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structure and anatomical granularity of the human brain spanning 
from the gross regions of the brain down to region-specific cell 
types. Building this semantic resource supported knowledge-driven 
model building with the aim of increasing model resolution and 
specificity at the molecular level while maintaining the link to the 
cell type and tissue level.  
5.4.1. Purpose and scope 
Currently there are two ontologies whose knowledge scope is close 
to the human brain anatomy, including Neuroscience Informatics 
Framework Standardized Ontology (NIFSTD) [205] and 
NeuroNames [206]. NIFSTD is a well organized and highly 
standardized ontology which covers a broad range of neuroscience 
domain, but for extensive knowledge retrieval related to a specific 
human brain region or cell type its usage is restricted by its limited 
terminology. On the other hand, although NeuroNames is considered 
as the largest source of brain region names, it does not cover the 
knowledge scope of human brain cell types. Moreover, both of these 
ontologies are not human-specific. In contrary, BRCO is a human-
specific brain anatomical ontology, which enables users to traverse 
through the brain partonomy to cellular level with a coherent 
granularity. 
5.4.2. Structural characterization 
The structural features of BRCO reflecting topological and logical 
properties were measured by means of context-free metrics including 
depth (related to the cardinality of paths in a graph), breadth (related 
to the cardinality of paths), tangledness (No. of multi-hierarchical 
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nodes/ No. of all the nodes, a measurement of organizational fitness), 
and fan-outness (related to the dispersion of leaf node sets). These 
features are summarized in Table 13. 
  
Table 13. Structural parameters of the BRCO ontology 
and their corresponding values 
 No. 
of 
roots 
No. of 
classes 
No. 
of 
syno
nyms 
Max. 
depth 
Average 
width 
Tangled-
ness 
Fanout
-ness 
BRCO 3 3238 9843 16 211.7 0.02 0.85 	  
High value of Fan-outness factor (0.85) illustrates that BRCO has a 
very broad coverage. Tangledness factor of 0.02 shows presence of 
relatively very few multi-hierarchical nodes, which indicate that 
BRCO is easy to maintain. 
5.4.3. Functional characterization 
Applying ProMiner, evaluation of the terminology showed a 
satisfactory result on an independent test corpus (Table 14), although 
more iteration of ontology enrichment with false negative concepts 
will probably lead to improvement of the complete match.  
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Table 14. Evaluation of functional aspect of the BRCO 
ontology using text-mining approach. Complete match 
indicates capture of the complete concept term whereas partial match 
refers to partially matching concept terms due to their combinatorial 
representation with other words in text. 
BRCO Precision Recall F-score 
Complete 
match 
0.71 0.69 0.69 
Partial match 0.81 0.80 0.80 
 
5.4.4. Application scenarios 
One particular scenario for the application of BRCO is generating 
brain region or cell-type specific gene signatures for NDDs based on 
information retrieved from both literature and microarray databases 
such as GEO. We used an expression profiling study in GEO 
database (GSE5281) characterizing gene expression levels between 
AD vs. normal aged human brains. This study considers 6 distinct 
brain regions with about 14 biological replicates per brain region. 
However, no detailed information on the outcome of the study can be 
found due to the poor description of the gene expression studies in 
the microarray databases. Hence, to further gain mechanistic insight 
into brain region- or tissue-specific biological processes for those 
dysregulated genes, BRCO was used to find lines of evidence from 
literature. Through the literature search, visual cortex (VCX) showed 
to be relatively spared from AD pathologies. Thus, we expect to see 
less expression differences between AD-affected VCX and healthy 
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ones, which are consistent with our observation that statistically 
significant genes identified by comparison of affected VCX and 
healthy ones showed significantly smaller logged fold-changes 
compared to other regions under investigation. The literature-derived 
enriched gene specific to other five regions were compared to their 
corresponding experimentally-derived regional enriched genes and 
common genes signatures were detected, as shown in Table 15. 
 
Table 15. Comparison of literature and experimental 
approach towards regional enriched genes under AD. The 
low number of overlapping genes indicates the wealth of un-
annotated data in microarray data repositories. 
Brain regions No. of 
enriched 
genes 
derived 
from 
literature 
No. of 
enriched 
genes derived 
from 
microarray 
data 
No. of 
overlapping 
genes 
Entorhinal 
cortex 
198 1932 32 
Hippocampus 1020 3839 266 
Middle 
temporal gyrus 
38 5421 17 
Posterior 
cingulate cortex 
14 3457 5 
Superior frontal 
gyrus 
43 979 3 
 
It is noteworthy that despite the great discrepancy observed between 
the literature-derived enriched genes and the genes derived from 
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expression profiling on the single gene level, we observed a better 
similarity at the level of the enriched biological processes (GO 
terms). 
Another application scenario was to demonstrate that BRCO 
ontological search could be used to find confirmatory statements as 
well as experimental evidence supporting the microglia involvement 
in AD pathology. Microglia are often found near damaged tissue in 
Alzheimer's disease patients, but their role in the pathology of AD is 
not well known. Until very recently, the only hypothesis regarding 
the involvement of microglial cells in Alzheimer's disease (AD) 
pathogenesis is centered around the notion that activated microglia 
are neurotoxin-producing immune effector cells actively involved in 
causing the neurodegeneration [207]. Table 16 lists documents 
retrieved based on nested-ontology search with “microglia” concept 
from BRCO and “Alzheimer’s Disease” concept from the disease 
ontology in SCAIView. It could be demonstrated that not only 
established knowledge statements of molecular mechanism within 
microglia under AD were successfully retrieved (proof of concept), 
but also experimental evidence regarding subclasses of microglia 
could be retrieved by such approach.  
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Table 16. Comparative study of established knowledge 
statements and knowledge gained by BRCO for the role of 
microglial cells in AD. The extra knowledge gained with the help 
of BRCO complement the established knowledge for the role of 
microglia in all the given three examples. 
Established knowledge 
recovered from literature 
Supporting knowledge gained 
from literature by BRCO 
Activated microglia have 
contradictory roles in the 
pathogenesis of AD, being either 
neuroprotective (by clearing 
harmful Aβ and repairing 
damaged tissues) or neurotoxic 
(by producing proinflammatory 
cytokines and reactive oxygen 
species). (PMID: 21763676) 
 
Microglial cells play an important 
role in mediating 
neuroinflammation in 
Alzheimer's disease (AD) by 
production of a series of 
proinflammatory mediators and 
clearance of Aβ peptides and 
senile plaques. 
(PMID: 21496499) 
 
Early microglial accumulation in 
Alzheimer's disease (AD) delays 
disease progression by promoting 
clearance of β-amyloid (Aβ) 
before formation of senile 
plaques. However, persistent Aβ 
Our findings using both Iba1 
and antiferritin 
immunostaining of microglial 
cells show that coincident with 
the appearance of tau pathology 
in DS subjects there is 
consistent presence of 
dystrophic microglial cells and 
conspicuous absence of 
activated microglia using both 
markers. (PMID : 21847625) 
 
These results suggest that 
MyD88 deficiency may reduce 
Aβ load by enhancing the 
phagocytic capability of 
microglia through fractalkine 
(the ligand of CX3CR1) 
signaling and by promoting 
apoE-mediated clearance of Aβ 
from the brain. (PMID : 
21763676) 
 
In mouse models of AD, bone 
marrow-derived microglia 
(BMDM) have been shown to 
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accumulation despite increasing 
microglial numbers suggests that 
the ability of microglia to clear 
Aβ may decrease with age and 
progression of AD pathology. 
(PMID: 18701698) 
delay or stop the progression of 
AD and preventing their 
recruitment exacerbates the 
pathology. (PMID: 21418002) 
 
5.5. HuPSON: human Physiology Simulation 
Ontology 
It is foreseen that modeling and simulations will provide a better 
understanding of the human's body functioning and its pathological 
processes and help to develop therapies and tools that can aid disease 
diagnosis, treatment and prevention. In order to support these 
actions, we developed, evaluated and published an initial version of 
the Human Physiology Simulation Ontology (HuPSON) [208] as a 
resource that supports meta-data annotation of simulation as well as 
fundamentals of modeling and links the systems biology work to the 
Virtual Physiological Human (VPH) [209] and the CellML 
initiatives [210]. This ontology has been published with the equal 
contribution of this author. 	  
5.5.1. Purpose and scope 
HuPSON provides a framework for: a) annotation of simulation 
experiments, b) text-mining based retrieval of information required 
for modeling, c) interoperability of algorithmic approaches used in 
biomedical simulation, d) comparability of simulation results and 
interoperability on different structural scales (human anatomy down 
to cells and molecules), and e) linking knowledge-based approaches 
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(such as ontologies) to simulation-based approaches (for instance, 
differential equation-based approaches).  
5.5.2. Structural characterization 
Structural features of HuPSON are summarized in Table 17. 1,067 
(36%) of these classes were added manually whereas the other 64% 
of classes were integrated from related ontologies. Relatively high 
values of class number, leaves and width / average width together 
with a fanout factor of 0.71 are indicative of a broad coverage of the 
ontology, whereas the depth values of 10 (max.) and 5.5 (avg.) are 
indicators of a relatively good specificity of types to the domain. 
 
Table 17. Structural parameters and their corresponding 
values calculated for HuPSON 
 No. 
of 
roots 
No. of 
classes 
No. of 
synonyms 
Max. 
depth 
Average 
width 
Tangled-
ness 
Fanout-
ness 
HuPSON 10 2920 7262 10 270 0.06 0.71 
	  
5.5.3. Functional characterization 
Calculation of the system performance resulted in recall, precision 
and F-score of around 0.66 in the test set. Furthermore, participants 
from different working groups participating in the VPH Network of 
Excellence were asked to provide queries typical for the VPH 
domain. Table 18 shows that both ontology-based queries resulted in 
more true positive hits than their PubMed counterparts. These 
abstracts are considered to represent an “information gain” compared 
to the PubMed query results. 
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Table 18. Functional evaluation of HuPSON through 
answering competency questions as compared to the 
baseline PubMed search 
Query expressed in 
free text 
Hits of SCAIView 
query 
Hits of PubMed 
query 
Search the literature 
for fluid structure 
interaction models of 
the aneurysm 
simulating the pressure 
and its link to rupture 
8 out of 9 abstracts 
TP 
0 out of 0 abstracts 
TP 
Find publications on 
velocity of blood flow 
and rupture outcomes 
of aneurysms 
29 out of 59 abstracts 
TP 
2 out of 3 abstracts 
TP 
 
5.5.4. Application scenario 
In order to show the applicability of HuPSON to independent 
domains, we applied it to Alzheimer’s disease by challenging the 
system to retrieve and semantically filter the published knowledge 
related to simulation and modeling within this domain. Structural 
imaging has been recently shown to be a valuable tool in differential 
diagnosis of most dementias. To identify studies reporting the 
application of image analysis models to the differential diagnosis of 
Alzheimer’s using MRI, we used the MeSH terminology in 
conjunction with HuPSON and performed a query in the SCAIView 
environment. 18 out of the 23 retrieved abstracts were relevant to the 
query and correctly identified such studies. From these documents, 
we were able to extract what specific model types are used in the 
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query context (e.g. “network diffusion models” and “logistic 
regression models”). This kind of information can help model 
developers choose an appropriate model for their research. it should 
be pointed out, that the combination of HuPSON with the AD 
disease ontology (see section 5.7) has the potential to contribute 
largely to the work done in the VPH-DARE project (see 
http://www.vph-dare.eu ) where blood and lymphatic circulation 
simulation plays a major role. 	  
5.6. CTO-NDD: Clinical Trial Ontology for 
Neurodegenerative Diseases 
For a complete disease modeling process, linking clinical outcomes 
to their underlying molecular events is essential. Gaining insight into 
the mode of action of NDD-specific drug targets that were 
successfully evaluated through clinical trials in human populations 
will help to decipher mechanistic details underlying those targets and 
to guide the modeling efforts for target ID in AD. NDD-CTO 
harmonizes clinical readouts and is therefore an essential resource to 
make clinical trial data interoperable. 
5.6.1. Purpose and scope 
Although clinical trials measure the outcomes of a particular 
treatment or a particular biomarker, the knowledge behind the 
molecular mechanism underlying the measured outcomes remains 
implicit or unknown. In fact, the challenge of linking clinical 
outcomes to their underlying molecular events has been long of 
interest to the scientific community. The purpose of developing 
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CTO-NDD was to organize the key concepts of clinical trials and to 
mine the literature for molecular events linked to clinical endpoints. 
Scope of the CTO-NDD is focused on NDDs and covers the 
following areas: Clinical Trial Readouts, Clinical Trial Study, 
Clinical Trial Measurement Units, Clinical Imagings, Clinical trial 
methods, Exploratory Clinical Trials, Multicentered Trials, Pilot 
Trials, Practical Clinical Trials, Preclinical Trials, The Randomized 
Blinded Trial. 
5.6.2. Structural characterization 
Structural features of CTO-NDD are summarized in Table 19. 
 
Table 19. Results of structural evaluation for the CTO-
NDD ontology 
 No. 
of 
roots 
No. of 
classes 
No. of 
synonyms 
No. 
of 
leaves 
Average 
width 
Tangled-
ness 
Fanout-
ness 
CTO-
NDD 
12 483 1451 373 80.6 0.51 0.77 
 
The high number of classes and leaves together with high values for 
avg. width and the fanout factor point towards a broad coverage of 
the ontology, whereas the values for depth can be used to show 
specificity of the types to the domain.  
5.6.3. Functional characterization 
Precision, recall, and F-score were calculated as listed in Table 20. 
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Table 20. Text mining-based evaluation of the CTO-NDD 
functional parameters 
 Precision Recall F-score 
CTO-NDD 0.79 0.70 0.74 
 
Moreover, quality of CTO-NDD was assessed against five expert 
questions (Table 21). The following table summarizes the 
competency questions as well as the percentage of knowledge-
domain coverage by CTO-NDD (the number of relevant documents 
divided by all the retrieved documents multiplied by 100). 
 
Table 21. Functional evaluation of CTO-NDD by 
answering five competency questions 
Competency question by expert Percentage correct 
answer by CTO-NDD 
Return references about clinical trials that 
use rating scales to measure treatment 
outcomes in Alzheimer's disease. 
78% 
Return references that report the application 
of using MRI for measuring clinical outcome 
of patients with relapsing-remitting and 
progressive multiple sclerosis. 
62% 
Return safety and efficacy studies 
mentioning receptor targets of drugs used 
for treatment of Parkinson's disease that 
have been shown to be effective in 
double-blind clinical trials. 
88% 
Return references of phase 3 clinical trials 
for treatment of epileptic seizures that met 
their primary endpoint. 
32% 
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Return the clinical readouts for trials 
aimed at treatment of Alzheimer and 
provide the values for readout 
measurements 
75% 
 
5.6.4. Application scenario 
A knowledge base was created for five NDDs (Alzheimer’s disease, 
Parkinson’s disease, Multiple sclerosis, Epilepsy, Amyotrophic 
lateral sclerosis (ALS)). The purpose was to collect data from 
completed trial documentations and classify them under biomarker 
and therapeutic categories based on endpoints, entities/disease 
phenotypes, and results from publications. The statistical content of 
the knowledge base concepts are shown in Table 22. 
 
Table 22. Summary of documentation statistics published 
on the results of completed trials for 5 NDDs  
Disease Total number of 
complete trial 
documentations 
Number of 
Biomarker 
documentations 
Number of 
therapeutic 
documentations 
Alzheimer’s 
disease 
276 57 219 
Parkinson’s 
disease 
317 8 309 
Multiple sclerosis 
disease 
237 21 216 
Epilepsy 217 1 216 
Amyotrophic 
lateral sclerosis 
(ALS) disease 
54 3 51 
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In the case of AD, the majority of clinical trials have measured safety 
and pharmacokinetics of therapeutics. Since existing clinical trials 
are performed with the aim of either biomarker discovery or 
treatment assessment, the information extracted from trial databases 
were grouped into Biomarker or Therapeutic classes and deposited 
into the knowledgebase. Table 23 exemplifies two entries of clinical 
trials in the knowledgebase for biomarkers and therapeutics of AD. It 
should be noted that NDD-CTO can be extended to capture relevant 
concepts measured in observational or epidemiological trials. 
 
Table 23. Examples of biomarker (B) and therapeutic (T) 
entries found in clinical trial databases. Endpoints as 
identified by the ontology concepts have been related to the results of 
each trial through literature mining.  
B/T Title Endpoints Entities/Disease 
phenotypes 
Results from 
publications 
B Anti-Oxidant 
Treatment of 
Alzheimer’s 
disease 
Safety/ 
Efficacy study 
-Mild to moderate 
Alzheimer’s disease 
-Vitamin E + C + alpha-
lipoic acid 
-Coenzyme Q (CoQ) 
-Beta42 and a-beta40 
protein 
-Probable Alzheimer's 
disease 
-Memory impairment 
Use of vitamin E and 
C supplements in 
combination was 
associated with 
reduced AD 
prevalence (adjusted 
odds ratio, 0.22; 95% 
confidence interval, 
0.05-0.60) and 
incidence (adjusted 
hazard ratio, 0.36; 
95% confidence 
interval, 0.09-0.99). 
(PMID: 14732624) 
 
T Alzheimer’s 
disease: 
therapeutic 
Potential of 
Efficacy Study -Transdermal estradiol 
drug 
-Medroxyprogesterone 
drug 
Women treated with 
estrogen demonstrated 
improved performance 
on a test of semantic 
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Estrogen -Placebo Patch drug 
- Estrogen 
- Cognition decline 
-17-ß-estradiol  
- Estrone 
- FSH 
- ApoE 
- Mild-to-moderate 
dementia 
memory (Boston 
Naming Test) 
compared with 
subjects who received 
a placebo. Estrogen 
appeared to have a 
suppressive effect on 
the insulin-like growth 
factor (IGF) system 
such that plasma 
concentration of IGF 
binding protein-3 was 
significantly reduced 
and plasma levels of 
estradiol and IGF-I 
were negatively 
correlated during 
estrogen treatment. 
(PMID: 11524467) 
 
 
CTO-NDD goes beyond describing the knowledge of clinical trial 
readouts such as: biological readouts, cognitive readouts, physical 
readouts, primary and secondary endpoint measures and also, 
describing concepts related to different study types performed during 
clinical trials. CTO-NDD captures numerical descriptions and 
metrics that are routinely used in clinical trial studies. It also 
described different methods used for predicting clinical trial 
outcomes. 
 
5.7. ADO: Alzheimer’s Disease Ontology 
Placing the context specific to disease characteristics and mechanism 
at the heart of any disease-specific model is a substantial criterion for 
correct and precise representation of disease-specific pathological 
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processes. In the absence of Alzheimer’s-specific semantic 
frameworks such as terminologies or ontologies, which could 
potentially support target identification through modeling the disease 
mechanism in this thesis, there was an apparent need to create such 
semantic resource.  
ADO was developed during the course of the Master thesis of 
Ashutosh Malhotra who was supervised by me in the course of this 
work. ADO has been published and made openly accessible to the 
AD research community [211].    
   
5.7.1. Scope and purpose 
Presently, the main online repository of ontologies, BioPortal 
(http://bioportal. bioontology.org/), contains only one generalized 
disease ontology, namely Human Disease Ontology 
(http://bioportal.bioontology. org/ontologies/1009, Last accessed: 22-
4-2012) that has been designed to link distant datasets through 
disease concepts. However, the broad coverage and the lack of depth 
in this ontology restrict its usage for specific disease domains such as 
AD. Extensive efforts have been undertaken to organize published 
knowledge related to AD in the form of AlzSWAN knowledge base 
(http://www.alzforum.org/), which is supposed to be the reference 
repository for AD-based information available on the web. Still, 
information density or scalability remains a challenge for AlzSWAN. 
A first draft of an ontology representing clinical features, treatment, 
risk factors, and other aspects of the current knowledge in the 
domain of AD was developed. The hierarchical structure of the 
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ontology thus can serve as a robust navigation tree for terminology 
integration 	  
 
5.7.2. Architecture and contents 
 
ADO covers a wide range of key concepts and aims to engineer 
knowledge specific to AD. Modeled heterogeneity in this semantic 
framework tries to touch all relevant concepts but the range varies 
from very general (main ontology classes) to more specific concepts 
(concepts located at the ontology bottom “leaves”). The main views 
(root concepts) in ADO covering aspects of AD knowledge domain 
include: “Clinical”, “Non clinical”, “Etiological” and “Molecular and 
cellular mechanism”. Each of these superclasses has its own 
subclasses (Figure 32, left). Subclasses mentioned under “Clinical 
(thing)” cover concepts that have contributed significantly to our 
understanding of the pathology, diagnosis and possible treatment 
options. Concepts defined under each subclass tend to be more 
domain-specific. For example, concepts representing stages of the 
disease are mentioned under clinical concepts (Figure 32, right). 
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Figure 32. Representation of views incorporated in ADO 
(left) and example of disease stage concept and its 
subclasses (right). The left figure shows the hierarchical 
representation and the right figure illustrates the relational 
representation of the ontology concepts. 
          
Chapter	  5.	  Multi-­‐scale	  Knowledge	  Representation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   121
Currently much of the focus of AD research is devoted to preclinical 
studies that are conducted, typically on animals and has potential to 
play a vital role in drug discovery and development process. 
Concepts mapping all aspects of “Non-clinical” studies (Ex-vivo, In-
silico, In-vitro and In-vivo) have also been incorporated into ADO, 
hence elaborating the knowledge related to animal models and 
bioassays used to better understand biological processes underlying 
Alzheimer’s disease. 
“Etiological view” forms the third root in ADO and it covers all 
aspects that might be responsible for the initiation of AD ranging 
from genetic factors and environmental influences to morphological 
changes whose effect varies from individual to individual. Clinical 
appearance of AD is also marked by anatomical changes as well as 
cellular and molecular cascades, which together manifest the 
neuropathological alterations observed in AD.  
Furthermore, in ADO, the “Molecular and cellular mechanism” view 
is designed to cover all entities and biological mechanisms that find a 
possible role in AD. Studying behavior of neurons and other brain 
cells at the cellular and molecular level during AD can provide 
insights into the processes that mark its progression. The semantic 
relationships ‘is a’ and ‘has a’ and ‘part of’ were used to define 
relation types between pairs of concepts. 
 
5.7.3. Structural characteristics 
The structural features of the ontology reflecting topological and 
logical properties were measured by means of context-free metrics 
including depth and breadth  (related to the cardinality of paths in a 
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graph), tangledness (related to multi-hierarchical nodes), and fan-
outness (related to the dispersion of nodes). Table 24 shows various 
parameters, which were considered in the structural evaluation of 
ADO. 
 
     Table 24. Structural characterization of ADO 
No. of   No. of   No. of        No. of    Max.     Avg.  Tangleness   Fan-
out- 
roots     classes   synonyms   leaves   depth   width                      ness 
factor 
    6    1486     2178           1221       12    302.91       0.16            0.82    
 
The comparably high value of the Fan-outness factor exhibits the 
broad coverage of our ontology consisting of 1486 distinct classes. A 
tangledness factor of 0.16 is indicative for the presence of relatively 
few multi-hierarchical nodes in our hierarchy, which further 
confirms the coverage of the designed ontology. 
5.7.4. Functional characteristics 
The functional dimension of the ontology reflects the main purpose 
of that ontology by specifying a set of contextual assumptions about 
an area of interest. Functional evaluation measures how widely and 
precisely ontological concepts represent the semantic space for the 
indicated knowledge domain. The boundary of the knowledge 
domain addressed by ADO was estimated by calculating its fitness to 
an existing knowledge source (i.e. PubMed). Using our state-of-the-
art text-mining environment, which takes ADO hierarchical structure 
and corresponding dictionary as input, we were able to evaluate 
ADO functionally on the prepared ‘test set’ (see Methods). As a 
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result, the functional metrics reported in Table 25 could be 
calculated. 
 
 Table 25. Results of the ontology evaluation using NLP-
based approach 
Test set corpus size                            Precision     Recall       F-score 
Independent test set of 200 abstracts   0.71            0.74            0.72 
 
The result of this evaluation shows that the ontology in its current 
form can capture a wide range of AD concepts in the knowledge 
domain of AD scattered throughout scientific publications. 
 
 5.7.5. Expert evaluation	  
The expert panel’s revision of the ontological “view” structure is 
considered as a genuine evaluation for disease ontologies. Following 
this, our ontology was manually curated by a clinician expert in the 
field who added certain clinically relevant concepts to ADO, 
increasing its pragmatic usability. 
Two competency questions defined by the expert clinician and one 
from a pharmaceutical expert were selected to evaluate the semantic 
performance of ADO and its capability to return appropriate answers 
as following:  
1. Return references linking amyloid beta to synaptic 
dysfunction in the mild stage of Alzheimer's disease. 
2. Return references that associate the t-tau protein to 
frontotemporal dementia and Alzheimer's disease. 
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3. Return references containing clinical evidences that 
correlate CSF levels of p-tau with CSF Abeta 42 and 
cognitive decline. 
To evaluate the above queries, we manually compared documents 
returned by ADO in SCAIView with documents returned by PubMed 
advanced search using the same queries. The results of this 
evaluation are summarized in Table 26. 
 
Table 26. Results of competency questions evaluation using 
ADO within SCAIView compared to non-ontological 
search of PubMed. 
Question 
No. 
No. of 
SCAIView hits 
in total 
Relevant 
SCAIView        
hits  
No. of PubMed       
hits in total 
Relevant PubMed 
hits 
  1 22 documents 19 
documents 
1 document 1 document 
  2 
 
  3                        
130 documents 
 
12 documents 
14 
documents 
out of top 20 
7 documents 
20 documents 
 
0 document 
7 documents 
 
0 document 
 
 
As shown in Table 26, querying SCAIView with the support of ADO 
in comparison to querying PubMed using comparable query 
formulations for all competency questions returns better results in 
terms of both sensitivity and specificity. These results indicate that 
ADO-supported information retrieval improves the chances for 
gaining better coverage with focused results in the same time as 
compared to naïve PubMed based searches.                               Also 
the knowledge gain in terms of concept recognition and enrichment 
is better when performing ontology based semantic search. To 
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validate this, we used the third competency question and performed 
the query in SCAIView under two conditions: using the MeSH 
dictionary (without using ADO) and using ADO in conjunction to 
the NDD terminology. The reason is that the same corpus is indexed 
behind SCAIView so that the condition for queries remains fairly 
comparable. We then checked the document retrieval under both 
conditions and it turned out that the ontology based search using 
SCAIView (along with all MeSH concepts included as subset), was 
able to highlight approximately 5 times more entities than was 
possible using the MeSH dictionary alone. In this direction, we tried 
to derive inferences about the enrichment of the knowledge space 
surrounding the basic answer with the help of ADO concepts, e.g. 
how entities addressed in the competency questions are linked to 
other biological entities and processes (highlighted in the abstracts 
using ADO) in AD context. 
Additional knowledge gained by means of ontological concept 
enrichment adds higher value to the original answer found by ADO. 
Although ontology based context modeling has been long 
acknowledged as a key aspect in a wide variety of problem domains, 
the full power of semantic search using a disease ontology comes 
with using a combination of the ontology with entity recognition, as 
shown by strategies discussed above. 
5.7.6. Application scenario 
Our motivation for development of ADO was to automatically 
extract domain specific knowledge related to AD, which can be used 
to gain further insights into the disease mechanism. To further 
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demonstrate the utility of ADO, we aimed at capturing knowledge 
beyond Medline abstracts. In an evaluation experiment independent 
from Medline, we used ADO to mine 650 AD-related electronic 
patient health records (EHRs) in order to systematically screen for 
other diseases or disorders that may exist simultaneously but 
independently in patients suffering from AD. In medical terms this 
concept is described as ‘comorbidity analysis’. An example for the 
annotation of relevant terms in electronic patient records using the 
ADO dictionary is shown in Figure 33. 
 
 
Figure 33. Comorbidity information captured in electronic 
health records using ADO. Risk factor concepts (comorbidities) 
included in ADO such as infection, and depression have been 
highlighted in text together with AD-related symptoms. 
 
After analyzing the results obtained by calculation of term 
frequencies, we found that hypertension, diabetes and stroke are 
disorders that are reported to frequently occur in patients already 
suffering from AD. Furthermore, using our NER-driven literature 
mining machinery, we extracted a list of top 300 genes associated to 
these three diseases in the literature and compared it to the list of top 
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300 AD genes extracted from the literature using the same 
methodology. After curation for their relevance to the indication 
area, we found 19 common genes between AD and diabetes, 14 
between AD and hypertension and 46 between AD and stroke 
(Figure 34). 	  
	  
Figure 34. Four major comorbidities frequently mentioned 
with AD in EHRs and number of genes reported in the 
literature to be commonly involved in Alzheimer’s and 
these comorbid diseases. A higher number of genes were 
retrieved for the overlap of AD with stroke (46) and head traumas 
(42) at the mechanistic level than diabetes (19) and hypertension 
(14).   	  
5.7.7. Perspective and future outlook	  
With the public release of ADO (http://bioportal. 
bioontology.org/ontologies/ ADO), the hope is to reach out to the 
broader AD research community and to continuously improve the 
quality of the ontology. Furthermore, the project team will continue 
to review articles, abstracts, and other resources relevant for the 
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domain and to update and maintain ADO. A potential application of 
ADO in the future would be improvement of AD-specific models 
through semi-automated model updating process using ADO-driven 
text-mining systems. Moreover, ADO can be used to construct BEL 
models of AD physiopathological aspects. 
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CHAPTER 6. Integrative Modeling of 
Pathological Components associated to 
Alzheimer’s Disease 	  
In this chapter, I describe the modeling activities related to the AD 
pathology, in response to the key scientific questions of this thesis: 
 
- “are different pathways leading to the manifestation of 
AD?”,  
- “are plaques and tangles secondary events or downstream 
effects?”, or  
- “what role is the dimension of time playing in the 
pathophysiology of AD?”. 
 
 As discussed in Chapter 2, the putative mechanisms underlying the 
AD pathology have been formulated in the form of three major 
hypotheses, including amyloidosis, inflammation, and infection. 
From the systems point of view, these pieces of information need to 
come together and generate a bigger picture of the AD mechanism. 
The amyloidosis hypothesis describes the dysfunction of the CNS 
most important organ, the brain, whereas inflammation and infection 
both form the two sides of the same coin of the immune system 
deregulation. A third perturbed component of the system, which has 
not yet been explicitly put forward as a hypothesis, is the endocrine 
system (what I call “hormone hypothesis”). Interestingly, this 
Chapter	  6.	  Integrative	  Modeling	  of	  AD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   130	  
component came into the picture after an unexpected observation of 
enriched hormone proteins and their receptors in the literature-
derived data. The importance of the endocrine component is that the 
nervous and immune systems communicate via multiple hormonal 
routes and mechanisms and their interactions provide a finely tuned 
regulatory system, which is disturbed under the disease condition. 	  
6.1. Exploratory data analysis 
Exploratory data analysis is an analysis approach – often with visual 
methods - that focuses on summarizing the main characteristics of 
data by identifying general patterns in the data and features of the 
data that might not have been anticipated. In fact, the purpose of 
performing exploratory data analysis is to find the right formulation 
of the scientific question or hypothesis. In contrast to confirmatory 
analysis, which involves testing a previously established hypothesis, 
exploratory data analysis involves a broad investigation to explore 
datasets for getting insights into potential new hypotheses. This 
approach, therefore, has important implications for analysis of large 
and high-throughput biological data; for example, biological 
networks have been used for exploratory data analysis to discover 
modular structures in high-throughput data [212] or pathway 
diagrams have been constructed to facilitate exploratory analysis and 
to enhance biological discovery in large datasets [213].        
Accordingly, to explore directions towards answering the scientific 
questions in this thesis and to obtain the very first intuition about the 
available data sources, data qualities and their information value, 
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both literature-derived and database-derived data, after passing 
through expert curation, were subjected to an initial analysis in order 
to get a preliminary insight into their knowledge content and how 
best this knowledge can be used in the modeling process. This 
section reports on the feasibility study on the NDD- and AD-related 
data and knowledge.	  
6.1.1. Molecular overlap between NDDs 
It is well known that NDDs share common disease features [214]. 
Thus, an entry point to understanding the molecular etiology of 
NDDs is analysis of existing knowledge about genes and proteins 
that they share. 
A spectrum of six NDDs - presenting ‘dementia’ as a common 
symptom – was surveyed in the literature using dictionaries for the 
Human Genes/Proteins and MeSH terms in the SCAIView literature 
mining environment, and finally, a list of genes/proteins associated 
to these NDDs was generated. For each disease, the output list was 
manually curated to ensure the association between the gene and the 
disease of interest. The overlap of genes was computed between 
pairs of diseases and presented as a matrix (Figure 35).  
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Figure 35. Matrix containing number of overlapping genes 
between six NDDs. 
 
 The results clearly show that AD shares a significant number of 
genes with Parkinson’s disease (350 genes), followed by Lewy body 
disease (180 genes) and Parkinson’s disease (155 genes). This 
implies that there exists a similar molecular etiology underlying 
these NDDs. The top-ranked common genes among these three 
diseases include APP, APOE, MAPT, SNCA, SNCB, CHAT and 
PRNP. 	  
6.1.2. Potential biomarkers of AD 
In general, there are two categories of biomarkers: “known valid 
biomarkers”, which have been measured experimentally with a well-
established performance and “probable valid biomarkers”, which 
have been measured in an analytic test system but more evidence on 
their performance is needed to be approved [215]. The second 
category represents a vast majority of proposed biomarkers in the 
literature (potential biomarkers), which report a measured indication 
under the disease conditions. This information can be used in guiding 
the pathway analysis as I propose in the next chapter. 
  Huntington 
Lewy 
body Pick 
Creutzfeldt
-Jakob Alzheimer Parkinson 
Huntington   58 39 25 124 100 
Lewy body 
 
  58 31 180 155 
Pick 
  
  27 124 80 
Creutzfeldt-
Jakob 
   
  72 43 
Alzheimer 
    
  350 
Parkinson 
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In order to obtain a list of potential biomarkers, the following query 
was performed with the help of SCAIView and the biomarker 
terminology: 
 (([MeSH Disease:"Alzheimer Disease"]) AND [BioMarker 
Terminology Node:"Evidence Marker"])      
The long list of retrieved potential AD biomarkers - comprising of 
1009 genes/proteins - was filtered for expression evidence and was 
subjected to manual inspection of sentences. Figure 36 depicts the 
workflow for identification of these markers. Finally, 366 proteins 
reported to potentially act as disease biomarkers were identified and 
underwent the process of pathway enrichment analysis.  
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Figure 36. Diagrammatic workflow used for identification 
of potential AD biomarkers in literature. The biomarker 
terminology was used to query for potential expressed biomarkers of 
AD in PubMed, which were subjected to filtration, manual curation 
and pathway enrichment analysis.  
Table 27 represents the top significant pathways that are enriched 
with potential biomarkers of AD. This exploratory pathway analysis 
indicates that experimentally measured indicators of AD initially 
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point to inflammatory and cell death processes under disease 
condition. 
 
Table 27. Results of pathway enrichment analysis for 
literature-derived list of potential AD biomarkers  	  
	  
6.1.3. Target receptors of the human brain 
Cell surface receptors and ion channels constitute targets for one-
third of the current medicinal drugs with G-Protein-Coupled 
Receptors (GPCRs) forming the largest group of drug targets (36% 
of the human targets) [216]. The International Union of Basic and 
Clinical Pharmacology Committee on Receptor Nomenclature and 
Pathway p-value 
Amyotrophic lateral sclerosis (ALS) 2.78E-13 
HIV-I Nef: negative effector of Fas 
and TNF 
1.52E-09 
Apoptosis 1.11E-07 
Antigen Dependent B Cell 
Activation 
1.14E-07 
Apoptotic Signaling in Response to 
DNA Damage 
3.71E-07 
Keratinocyte Differentiation 6.41E-07 
Cytokines and Inflammatory 
Response 
8.74E-07 
Prion diseases 9.81E-07 
Stress Induction of HSP Regulation 1.24E-06 
FAS signaling pathway (CD95) 1.30E-06 
Cytokine Network 2.68E-06 
Alzheimer's disease 2.99E-06 
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Drug Classification (NC-IUPHAR) has released guidelines for 
nomenclature and classifying these targets. They also provide the 
IUPHAR-DB database containing peer-reviewed pharmacological, 
chemical, genetic, functional and anatomical information on receptor 
and channel targets for human, rat, and mouse (http://www.iuphar-
db.org). 
Using the annotation fields of the IUPHAR-DB, I was able to 
download all the GPCR and ion channel receptors that were 
annotated to be expressed in the human brain tissue. After the 
manual check, 69 GPCRs and 4 ion channel receptors were identified 
to specifically express in the human brain, some of which have been 
already targeted by approved drugs  (Table 28).  
 
Table 28. List of curated receptors that are expressed 
specifically in the human brain 
GPCRs  KiSS1, MCH2, 5-HT4, RXFP4, PKR2, P2Y6, 5-
HT1B, FZD2, MCH1, A2A, H2, GPR116, RAIG1, α
2C-adrenoceptor, RAIG2, A1, H1, 5-
ht5a, PKR1, P2Y11, 5-
HT1F, NPBW1, NPFF2, NPFF1, GPR125, P2Y12, P
2Y2, α2B-
adrenoceptor, FZD1, GPRC6, sst4, RXFP2, A3, NTS
1, P2Y14, P2Y13, 
NOP, mGlu3, ETB, GPR158, GPR98, ghrelin, 5-
HT2B, 5-HT7, mGlu2, MT1, GLP-
1, BB2, ETA, H4, H3, LH, GABAB2, 
GPR126, GPR179, A2B, α1A-
adrenoceptor, DP2, P2Y4, α2A-
adrenoceptor, GPR56, FFA1, RXFP3, P2Y1, TP, RX
FP1, EP4, VPAC1, GPBA  
Ion channel 
receptors 
 5-HT3C, ZAC, 5-HT3D, 5-HT3E  
Chapter	  6.	  Integrative	  Modeling	  of	  AD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   137	  	  
6.1.4. Human brain interactome 
Given the complexity of the human brain structure and in the 
absence of brain-specific molecular interaction models, it seemed 
reasonable to build an interaction model that represents a good 
resolution of protein interactions at the level of brain regions or 
tissue types. Tissue specificity is an important aspect of many 
diseases, which is frequently ignored when disease process models 
are built. Knowing that proteins and pathways play different roles in 
diverse tissues and cell types, functionality and functional 
relationships of molecular interactions should be resolved when 
modeling disease processes for target ID is performed. The rationale 
is that disease phenotypes are caused by tissue-specific pathology 
and thus, building tissue-specific functional networks can support 
prioritization of disease genes and association of disease phenotypes 
to underlying molecular interactions [217]. As demonstrated in 
Chapters 8 and 9, the brain interactome has been applied to modeling 
brain-specific disease pathways that are associated to the damaged 
areas of the brain anatomy. Application of the brain interactome goes 
beyond disease modeling by mapping the pharmacological space of 
CNS drugs to this network and including drug-target and drug-drug 
interactions on top of that. Such a model – called as the Human 
Brain Pharmacome - can be constructed with the aim of 
polypharmacology analysis or feasibility study of drug repurposing.  
In order to construct a context-sensitive network model representing 
possible protein interactions in the human brain - regardless of 
normal or disease conditions - in a tissue-specific manner, a brain-
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specific PPI network representing 15 brain regions was reconstructed 
using the global human protein interaction network [218]. These 
regions have been annotated to the interactions using co-expression 
profiles and include amygdala, cerebellum peduncles, cingulate 
cortex, hypothalamus, medulla oblongata, occipital lobe, parietal 
lobe, pons, prefrontal cortex, subthalamic nucleus, temporal lobe, 
thalamus, caudate nucleus, cerebellum, and globus pallidus. Presence 
or absence of a particular interaction in a brain region has been 
indicated by numbers so that number 1 indicates the presence of that 
interaction in that particular brain region and number 0 indicates the 
absence of a particular interaction in a particular brain region. It 
appears that some interactions occur in several regions and some 
others are region-specific. 
The brain interactome has been constructed based on the PPI 
information from 21 databases and is composed of 7255 proteins and 
47882 interactions. Edges are manually annotated and supported by 
additional attributes including source interaction databases, 
supporting experimental methods and evidence, evidence sentence 
from the literature, and source PMIDs in the literature (if available). 
Figure 37 illustrates an example snapshot of edge annotations in the 
brain interactome, which has been visualized in the Cytoscape 
environment. 
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Figure 37. Visualization of annotated attributes in the 
brain interactome in Cytoscape environment. Protein-protein 
interactions are coded for their presence (1) or absence (0) in 
particular brain regions based on their co-expression and further 
substantiated with additional evidence and information from 
databases and publications.   	  
Since the brain interactome captures a large amount of PPI 
information in the form of a hairball network with a giant 
component, it is best suited for “top-down” analysis methods. 
Indeed, the attributes embedded in the annotation space of the brain 
interactome will be used to support such a top-down analysis by 
providing the possibility to filter down the network and create 
various facets of the interactome model based on brain regions, e.g. 
generation of subnetworks representing interactions occurring only 
in hypothalamus or in cingulate cortex or both.  
It should be noted that the quality of this network model can be 
improved as more data become available on protein-protein 
interactions. For example, the majority of this interactome is based 
on retrieved data from protein and literature databases, which change 
and update dynamically. Therefore, an automatic survey of new data 
Chapter	  6.	  Integrative	  Modeling	  of	  AD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   140	  
releases or newly published literature can facilitate regular update of 
both interactions and attributes of the network.  
 
6.2. Modeling of molecular processes underlying AD 
As a first step towards exploratory analysis of disease processes 
underlying AD at the molecular level, the first version of the PPI 
model representing amyloid hypothesis in AD was constructed. The 
purpose was to explore the knowledge space published around 
molecular mechanisms underlying AD, visualize this knowledge 
space as a network model, and analyze it for the kind of pathways 
that are over-represented or enriched in the pathology of AD.  
For this purpose, the literature in SCAIView were queried with the 
“MeSH: Alzheimer’s disease” key word and searching for the list of 
“Human Genes/Proteins” associated to AD. In order to provide the 
relevant set of proteins for construction of the network (known as 
‘seed proteins’), 35 AD susceptibility genes were acquired from the 
AlzGene database [219], which is considered to be the gold standard 
for AD-related genes. Out of 35 genes, 31 genes were mapped onto 
the genes retrieved from the literature. These seed proteins were used 
as input to the BIANA tool and after manual curation, a network of 
684 nodes and 893 edges was constructed (Figure 38).  
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Figure 38. A first AD-specific PPI network model 
constructed around AD genes from AlzGene database. 
Nodes in cyan represent hubs and nodes in red represent linker 
(inter-module) proteins.  
 
When submitted to the DAVID tool for functional annotation [220], 
the genes of this network showed significant enrichment for 72 
KEGG pathways. To obtain the modular distribution of pathways, 
the hits were sorted based on the gene memberships in annotated 
pathways (Figure 39). These results show that, in this distribution, 
intracellular signaling pathways that are involved in the cell cycle 
and cell proliferation processes (reflected in the cancer and MAPK 
signaling pathways) are dominant. But the interesting observation is 
the presence of immune system-related pathways, i.e. chemokine 
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signaling pathway as well as natural killer cell signaling. Another 
important observation is the prominent involvement of a hormone-
dependent signaling pathway, namely the insulin-signaling pathway.  
 
	  
Figure 39. Results of functional annotation of genes in the 
AD network model to KEGG pathways. Pathways in cancer 
and MAPK pathway are the predominant pathways in this AD model 
and may point to the dysregulation of immense intracellular 
signaling and perturbation of cell cycle. Alzheimer’s pathway also 
emerges as a part of the bigger picture and indicates the relevance of 
the model. 	  
Taken all the above observations together, the results of exploratory 
data analysis - as the very first attempt at making sense of available 
data - highlighted the involvement of ‘immune’ and ‘hormone’ 
signaling components in the core pathological processes related to 
AD pathway. It should be noted that because the model generated 
here is an initial draft for obtaining directions and insights into the 
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disease mechanism, its coverage is low and thus, the signal is weak. 
Although these results may not show a clear pattern relevant to 
disease mechanism and the signals are weak, they at least provide a 
hint and further direction for exploring	   relevant hypotheses, for 
example, on the role of the immune and hormone components in 
pathology of AD. In the next chapters, the role of immune and 
hormone signaling pathways in the AD pathology is investigated 
more concretely. 
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CHAPTER 7. Modeling of the Immune 
System Component associated to 
Alzheimer’s Disease 	  
7.1. Introduction 
Neurodegenerative dementia is the main clinical manifestation in a 
multitude of diseases such as Alzheimer’s, Lewy bodies, 
Huntington’s and Parkinson’s diseases. It is often a feature of other 
pathological conditions including Creutzfeldt-Jakob disease as well 
as a couple of neurodegenerative diseases and syndromes. Moreover, 
several arrays of evidence suggest that infectious agents can induce 
the pathogenesis of dementia in infected people [221]. Among these 
infectious agents, viruses have been hypothesized to play a role in 
the development of dementia and dementia praecox [222],[223].           
It has been shown that HIV infection can cause dementia in at least 
20% of all HIV infected patients [224],[225] and it appears that the 
AIDS dementia complex is confined to the later phases of systemic 
infection by the human immunodeficiency virus [226]. Jang et al. 
(2009) showed that mice infected by the highly pathogenic H5N1 
influenza also manifest neuropathological signs and they suggested 
that any neurotropic influenza virus that activates the immune system 
in the brain can potentially lead to Parkinson’s and Alzheimer’s 
diseases [227].  
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The common observation among virus-induced dementia cases is the 
prolonged inflammatory responses as well as long latency period 
[228]. Interestingly, this time-dependent progression of the disease 
also occurs in age-related neurodegenerative diseases including 
Alzheimer’s. For example it has been proposed that long-term 
accumulation of insults to the immune system leads to the persistent 
activation of microglial cells which mediate progressive 
neurotoxicity [229]. Indeed, several lines of evidence in animal 
models indicate that exposure to bacterial lipopolysaccharide (LPS) 
or selective neurotoxins induces microglial activation which can last 
for years and cause the progressive and cumulative loss of neurons 
over time [230],[231],[232]. Jang et al. observed a similar trend in 
H5N1 infected mice whose CNS showed persistent microgliosis and 
prolonged inflammatory response even after the infection had 
resolved. Although inflammatory responses accompanied by over-
activation of the immune system are hallmarks of neurodegenerative 
diseases [233], neither non-steroidal anti-inflammatory drugs 
(NSAIDs) nor highly active antiretroviral therapy (HAART) have 
led to a definitive therapeutic outcome [234],[235].  
On the other hand, emerging evidence suggest that the current 
amyloid hypothesis may not capture the causative mechanism 
underlying the Alzheimer’s dementia and a rethinking of the 
relationship between amyloid aggregation and neurotoxicity is 
required. Further support to this comes from the recent failures of 
anti-amyloid drugs including 11 investigational drugs for 
Alzheimer’s disease [236]. All these have triggered the idea that the 
Chapter	  7.	  Modeling	  of	  the	  Immune	  Component	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   146	  
popular amyloid hypothesis may not well explain the cause of the 
disease or even could be a secondary event [237].  
HIV-associated dementia, among the virus-induced dementia types, 
is the best-studied model, which may provide some evidence on 
existing alternate pathogenic pathways in dementia. To gain an 
insight into the disease mechanism underlying AIDS dementia 
complex, we adopt a knowledge-based analysis approach by 
integrating literature data and biological networks.	  	  
7.2. Methods 	  
7.2.1. Text mining and information retrieval 
We employed SCAIView and accordingly a sub-corpus of the 
MEDLINE abstracts related to the keywords “infection AND 
neurodegeneration”, and “HIV AND neurodegeneration” were 
defined and queried for the instances of the human genes/proteins. 
The first query is rather general and covers neurodegenerative effects 
of both viral and non-viral infectious agents (including microbes and 
fungi) whereas the second one retrieves entities, which are involved 
in HIV-associated neurodegeneration. The output for each query was 
a list of human Genes/Proteins named entities extracted from 
PubMed abstracts and ranked based on relative entropy measurement 
in descending order. 315 genes/proteins were retrieved for the first 
query and 143 genes/proteins for the second query. For each entity, 
the retrieved abstracts were manually checked for the correct 
relevance of the entity to the disease context and possible false 
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positives were removed. This led to a reduction of the number of 
genes and proteins to 170 and 88 genes/proteins, respectively. A 
third sub-corpus of abstracts using the keywords “virus AND 
infection” was defined and the results were compared to the human-
HIV interacting proteins from the VirusMINT database [238].	  	  
7.2.2. Calculation of overlapping probabilities 
When comparing two top ranking gene lists obtained from two 
different queries, the overlapping gene set should be tested for the 
probability of this being a chance event. We used the hypergeometric 
probability approximated by Fisher’s exact test as suggested by Fury 
et al. [239] to calculate the p-values for overlaps between gene lists 
(see Results).   	  	  
7.2.3. Data acquisition 
In order to check for the relevance of the results, all human proteins 
that interact with HIV proteins were downloaded from the 
VirusMINT database. After removing the viral proteins and 
duplicates, 173 proteins were obtained and normalized on their 
corresponding gene official symbols. Incipient (MCI) and acute 
Alzheimer’s disease (AD) gene expression data were obtained from 
the study of Blalock et al. [240]. All the three datasets (i.e. infected 
human proteins and expressed genes under MCI/AD) were compared 
to the Immunome database [241] and the common signatures 
between these datasets and the Immunome-derived dataset were 
extracted.	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7.2.4. Interaction network reconstruction 
We mapped our gene list from the query “HIV AND 
neurodegeneration” onto the brain interactome and obtained a 
network with 85 nodes and 58 edges. The network consists of a 
connected giant component with 37 nodes that bears the maximum 
number of total edges (54 out of 58). In order to build a dementia 
network model specific to human on a relevant and scientific basis, 
an OMIM-based dementia network was reconstructed by extracting 
the following descriptions from the OMIM Morbid Map [242] and 
pooling their corresponding genes into one union list after gene name 
normalization: dementia, Alzheimer, Parkinson, Lewy body, 
Huntington, and Creutzfeldt. These genes were fed into our text-
mining system and only 40 of them were found to have 2 or more 
reference publications in PubMed. We used these 40 genes as “seed 
genes” to reconstruct the protein-protein interaction network in the 
BIANA environment. The BIANA tool retrieves all possible 
interactions among these proteins and one or two levels of other 
neighboring proteins from a variety of databases and creates a 
network model around the specified seed genes. This network 
contains 886 nodes and 1264 edges.   	  
7.3. Results	  
7.3.1. Distinction between infection and neurodegeneration 
Dealing with virus-induced dementia raises the important question 
whether the current knowledge space surrounding AIDS-dementia 
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complex represents genes/proteins involved in HIV pathogenesis or 
the subsequent neurodegeneration. Comparison between the results 
of Q2 and human proteins interacting with HIV during the course of 
viral infection (data from VirusMINT database) showed only 7 
genes/proteins in common. This indicates that our query results are 
relevant to the neurodegeneration rather than the infection process. 
Gene list from Q2 was annotated by MSigDB tool 
(www.broadinstitute.org/msigdb) and it was found that this list is 
significantly enriched for the apoptosis, inflammatory pathways, and 
neurodegenerative diseases (Table 29).  
 
Table 29. Annotation results for the 88 genes obtained 
from the sub-corpus of HIV neurodegeneration 
Geneset Name Description No. of 
genes 
p-value 
Apoptosis pathway 
- 9 
1.52E-
08 
IL-10 pathway The cytokine IL-10 inhibits the 
inflammatory response by macrophages 
via activation of heme oxygenase 1. 6 
2.15E-
08 
Chemical pathway DNA damage promotes Bid cleavage, 
which stimulates mitochondrial 
cytochrome c release and consequent 
caspase activation, resulting in 
apoptosis. 7 
2.83E-
08 
Neurodegenerative 
diseases 
Genes involved in neurodegenerative 
diseases 8 
9.58E-
08 
HSP-27 pathway Hsp27 oligomers have molecular 
chaperone activity and protect heat-
stressed cells against apoptosis. 6 
9.60E-
08 
P53 pathway p53 induces cell cycle arrest or 
apoptosis under conditions of DNA 
damage. 6 
9.60E-
08 
CCR5 pathway CCR5 is a G-protein coupled receptor 
expressed in macrophages that 
recognizes chemokine ligands and is 
targeted by the HIV envelope protein 
GP120. 6 
2.16E-
07 
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HIV-NEF pathway HIV-infected CD4 helper T cells may 
express Fas ligand, which binds to the 
Fas receptors of uninfected cells and 
induces apoptosis. 9 
2.31E-
07 
IL1R pathway The cytokine IL-1 stimulates its 
primary receptor, IL-1R1, which 
induces transcription of inflammation-
related genes such as interferons. 7 
6.01E-
07 
Mitochondria 
pathway 
Pro-apoptotic signaling induces 
mitochondria to release cytochrome c, 
which stimulates Apaf-1 to activate 
caspase 9. 6 
6.03E-
07 
 	  
7.3.2. Relevance to neurodegeneration and dementia 
Currently there is no clear approach to measuring the contextual 
quality of the genes mentioned in the body of literature. For our 
purpose, we constructed a gene-literature bipartite network (out of 
the results of Q2) in which the genes and PMID of their reference 
publications are connected. The Eigenfactor value for each PMID 
was included as the weight of edges. Eigenfactor is a scoring metrics, 
which ranks scholarly journals according to the local citation 
information as well as considering the entire network of citations. 
Filtering out edges with the Eigenfactor values below 0.1 left a 
network of 45 genes, which are cited in the quality publications 
(Figure 40). These genes were submitted to the MSigDB for pathway 
enrichment analysis; the results indicate a significant enrichment for 
neurodegenerative and apoptotic pathways (Table 30).  
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Figure 40. Gene-literature bipartite graph. Nodes in red and 
blue represent genes and their paper references respectively. A 
connection between the red and blue nodes is made if the gene is 
referenced in the corresponding publication.  
 
Table 30. Pathway enrichment analysis of the 45 genes at 
the core of gene-literature bipartite network 
Geneset Name Description No. of 
genes 
p-value 
Neurodegenerative 
diseases 
Genes involved in 
neurodegenerative diseases 6 4.60E-07 
Chemical pathway DNA damage promotes Bid 
cleavage, which stimulates 
mitochondrial cytochrome c 
release and consequent caspase 
activation, resulting in 
apoptosis. 5 6.71E-07 
Apoptosis pathway Genes involved in apoptosis. 6 9.79E-07 
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Pancreatic cancer Genes involved in pancreatic 
cancer: 7 1.52E-06 
Alzheimer’s disease Genes involved in Alzheimer’s 
disease 5 2.40E-06 
D4GDI pathway D4-GDI inhibits the pro-
apoptotic Rho GTPases and is 
cleaved by caspase-3. 4 2.59E-06 
IL-10 pathway The cytokine IL-10 inhibits the 
inflammatory response by 
macrophages via activation of 
heme oxygenase 1. 4 2.59E-06 
HIV-NEF pathway HIV-infected CD4 helper T 
cells may express Fas ligand, 
which binds to the Fas 
receptors of uninfected cells 
and induces apoptosis. 6 5.84E-06 
HSP-27 pathway Hsp27 oligomers have 
molecular chaperone activity 
and protect heat-stressed cells 
against apoptosis. 4 6.45E-06 
To realize the extent of relevance the viral neurodegeneration might 
have to dementia disorders, we compared the gene lists that we had 
obtained from querying PubMed abstracts for Alzheimer’s dementia 
and Parkinson’s dementia with the gene list from Q2. Both gene-lists 
showed high overlaps with the Q2 results (68.18% and 43%, 
respectively) that did not match by chance (hypergeometric p-
values=5.0090e-13, and 9.7188e-22, respectively). Gene set 
enrichment analysis was performed on these overlapped gene sets for 
pathway annotation and for both overlapping sets similar pathway 
annotations were retrieved that include apoptosis, Alzheimer’s 
disease, and IL1 pathway.	  
7.3.3. Relevance to the inflammation and immune system 
activation 
In the pathway annotation of the 88-gene list obtained from the HIV 
neurodegeneration query, a predominant presence of inflammatory 
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pathway elements was observed with the IL10 pathway as the second 
most significant category. It is being discussed that inflammation is 
the hallmark of CNS disorders and its link to the activation of the 
immune system is established. To investigate the extent of relevance 
between neurodegeneration and the inflammatory induced immune 
response, we first determined which pro- and anti-inflammatory 
cytokines are mentioned in the literature to be active in the brain; 
using two keywords namely, “proinflammatory AND brain” and 
“anti-inflammatory AND brain”, the literature corpora were queried 
in SCAIView for those genes/proteins involved in the brain pro-
/anti-inflammatory processes. Both pro- and anti-inflammatory genes 
in the “brain” were identified by comparing the results of SCAIView 
queries against the Cytokina Database (Table 31). To the best of our 
knowledge, this is the first curated list of inflammatory 
genes/proteins reported in the human brain. 
 
Table 31. The list of brain-expressed pro- and anti-
inflammatory genes collected from the literature 
Pro-inflammatory CCL1, CCL17, CCL2, CCL20,CCL27, 
CCL3, CCL4, CCL5, CCL7, CCL8, 
CD40LG, CSF2, CSF3, CX3CL1, CXCL1, 
CXCL10, CXCL12, CXCL2, CXCL5, 
CXCL9, FASLG, IFNA1, IFNB1, IFNG, 
IL12A, IL15, IL17B, IL18, IL1A, IL1B, IL2, 
IL23A, IL6, IL8, LIF, LTA, OSM, TGFB1, 
TNF, TNFSF12 
Anti-inflammatory CSF3, EPO, IFNB1, IL10, IL11, IL13, IL4, 
TGFB1 
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Then, the MCI and AD expression data was used to see the activity 
range of these genes under disease conditions. After projection of 
expressions onto these inflammatory genes it was observed that none 
of the ‘anti-inflammatory’ genes was found amongst the MCI or AD 
over-expressed genes; however from ‘pro-inflammatory’ genes, 
IFNG and IL18 in mild cognitive impairment, and CXCL2, IL1A, 
IFNG, IL15, and TGFB1 in Alzheimer’s disease were found to 
become upregulated. These results imply that the homeostatic 
balance between pro- and anti-inflammatory pathways might be 
perturbed under neurodegenerative conditions.	  
7.3.4. Pathway-pathway interaction map 
In order to get a vision on the structure of the crosstalking pathways 
involved in the HIV-induced dementia, our gene list from the “HIV 
AND neurodegeneration” query was mapped onto the human protein 
interactome network as described in the Methods section. The giant 
component of the network was subjected to the pathway analysis by 
submitting its constituent genes to the MSigDB database. It is 
observed that the network is enriched for DNA damage pathways, 
apoptotic pathways, p53 pathway and neurodegenerative diseases 
pathways. The confirmation for relevance of the giant component to 
neurodegenerative diseases comes from the significant overlap of 
this component with our OMIM-based dementia network (55.88%, 
hypergeometric p-value= 1.2249e-14).        
Visualization of the interconnections among pathways in the giant 
component was performed in the Cytoscape environment using the 
PNmerger plugin [243]. This plugin annotates the network proteins 
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with the KEGG pathway information, extends the network to the full 
pathway membership and also presents the potential crosstalk 
elements among pathways (Figure 41). Identified pathways and their 
crosstalk partners are summarized in the Supplementary Table S8.     
 
	  
Figure 41. Extended network of the pathway crosstalks for 
HIV-induced neurodegeneration. Nodes in red color represent 
crosstalk proteins.	  
7.4. Discussion 
Accumulating evidence suggests the striking similarities between the 
long-term microbial after-effects on memory loss or cognitive 
decline and characteristic symptoms of AD, which is in favor of the 
“infectious agent” hypothesis [244]. Indeed, the results from a 
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randomized clinical trial investigating the effects of antibiotics on 
patients with AD indicated that a combination of two common 
antibiotics could delay the cognitive decline [245].   
In this study we applied our text mining technology to disease 
mechanism identification and pathway-pathway map reconstruction 
for virus-induced dementia with the focus on the HIV-associated 
neurodegeneration. The reason for choosing AIDS-dementia 
complex as the case study was two-fold: it is very well studied 
through extensive literature; and the manifestation of dementia in the 
course of disease is time-dependent.  
Dementia is a syndrome which can be commonly seen in a number 
of different neurological disorders and clinical conditions ranging 
from infectious diseases such as AIDS to neurodegenerative diseases 
like Alzheimer’s and Parkinson’s. Neuronal cell death or 
neurodegeneration is widely observed in all these disorders but the 
exact factors or cofactors that initiate this process are not well 
understood. There have been several hypotheses regarding the 
mechanism of the neurodegeneration in dementia including the 
inflammatory hypothesis of dementia, the oxidative stress 
hypothesis, and the cell cycle hypothesis. However, we show here 
that all these hypotheses capture related parts of the same disease 
mechanism, although none has proved to uncover the causative 
factors upstream the disease mechanism. Moreover, we demonstrate 
that Alzheimer’s and infection signaling pathways are connected in 
proximity to each other, which suggests that infection and dementia 
are probably associated at the molecular level.     
Chapter	  7.	  Modeling	  of	  the	  Immune	  Component	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   157	  
Our knowledge-based approach suggests that all the above-
mentioned hypotheses describe parts of a unified disease mechanism, 
which is initiated within the cytotoxic arm of the immune system. It 
is then speculated that microglia are activated by an unknown cause 
so that these resident innate immune cells in the brain in turn induce 
pro-inflammatory and oxidative stress pathways [246]. The latter 
pathway leads to DNA damage and consequently cell-cycle arrest 
through p53 and CDKNIA signaling pathways, which stimulates 
apoptosis and nerve cell death [247] (Figure 42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Schematic order of speculative events in HIV-
induced neurodegeneration. This schema represents a 
hypothetical flow of conceptual causes in ADIS-dementia based on 
accumulated evidence in the literature. 
Microglia	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It should be noted that this inference is highly speculative and is 
meant to elicit new mechanism-based hypotheses that fundamentally 
build on the infectious agent hypotheses of the AD etiology. 
Moreover, this inference does not explain the cause and initiation of 
AD but it merely builds on the molecular and pathway knowledge to 
guide how AD could potentially be initiated. With the availability of 
more data, it would be possible to test the proposed infection 
hypothesis and its link to AD through, e.g. systematic collection of 
external evidence (e.g. from GWAS studies) in the future.  
As shown in Figure 41, the pathway interaction map is enriched by 
the immune response (cytokine-cytokine receptor interaction, 
complementary cascade, leukocyte migration, antigen processing and 
presentation, pathogenic E. coli infection pathway, Toll-like receptor 
signaling pathway, and Natural killer cell mediated cytotoxicity) and 
the DNA-damage apoptotic response (MAPK signaling pathway, cell 
cycle, different types of cancer pathways, and apoptosis). However, 
our approach identified another over-represented, yet hidden 
pathway in the literature known as Kynurenine pathway, which is not 
annotated in any of popular pathway databases. The kynurenine 
pathway is characterized for involvement in neuroprotection and 
regulation of the immune tolerance in human neurons via catabolism 
of L-tryptophan [248]. We found one study that shows decreased 
levels of kynurenic acid in serum and red blood cells of Alzheimer’s 
disease patients [249]. Another earlier study concludes that 
activation of immune system increases the levels of kynurenines in 
the CSF of HIV-infected patients with neurological disorder [250]. 
Therefore, it will be encouraging to study the role and crosstalks of 
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the Kynurenine pathway in the context of neurodegenerative 
diseases.     
One important point that must be taken into consideration is the 
phenomenon of time-dependency in all dementia-spectrum disorders. 
The cumulative evidence indicates that the neurotoxicity mediated 
by overactivated microglia is of a ‘progressive’ nature, so that such 
microglial cells remain overactive for years and continuous yet 
cumulative loss of neurons occurs over time [251],[252],[253],[254]. 
Similarly, virus-associated dementia appears in the late phases of 
infection after many years latency. We hypothesize that an unknown 
mechanism instigates microglia to secrete pro-inflammatory 
elements constitutively, which leads to disruption of the existing 
feedback loops between pro- and anti-inflammatory pathways.  
Future investigations addressing this emerging hypothesis will be 
critical for the understanding of the causative agent or agents of 
dementia-spectrum diseases and the design of effective anti-dementia 
therapeutics.	  
7.5. Conclusion 
Since our text mining and knowledge extraction system outputs a list 
of genes, which are ranked according to their mutual information 
content, the gene list analysis can be treated similar to the gene lists 
obtained from the expression studies. The gene list obtained from 
PubMed abstracts in this way represents two parts of the knowledge 
domain: the well-known intensively-researched part and the less-
established recently-proposed part. Hereby, we used the former part 
as the backbone or layout of our framework to investigate the 
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relationships about the latter part. In this manner, disease-causing 
mechanisms can be studied in the context of pathway interaction 
networks, which may help generate novel hypotheses and identify 
those drug targets that are more likely to be involved in the causative 
effects of the disease. 
While we focused on a case study of HIV-associated 
neurodegeneration in this work, our approach can be applied to 
virtually all kinds of disease. Building integrative models such as the 
one studied here helps researchers bring dispersed pieces of 
knowledge together and get a holistic picture of the problem under 
study. Clearly, elucidating the disease-causing mechanism for a 
certain phenotype or clinical outcome, which is manifested over a 
range of diseases that share similar clinical symptoms, could guide 
researchers to the causative factors underlying the core of diseases in 
question. 	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CHAPTER 8. Modeling of the 
Neuroendocrine Component associated to 
Alzheimer’s Disease 	  
As explained in Chapter 6, the exploratory data analysis indicated 
that hormone-signaling pathways could be involved in the pathology 
of AD. In this chapter, a first attempt towards modeling the 
neuroendocrine component of the AD mechanism has been 
described, which has been also published in the journal of 
Translational Medicine [255].        
8.1. Background	  
The clinical hallmark of dementia-spectrum diseases including 
Alzheimer’s disease (AD) and frontotemporal dementia is the 
gradual memory loss and impairment of other cognitive functions, 
which has been attributed to the aggregation of amyloid fibrils, a 
process known as amyloidogenesis [256],[257],[258]. However, 
recent findings indicate that many peptide and protein hormones are 
stored in secretory granules in the form of functional amyloid fibrils 
and such an amyloid-like structure is necessary for their natural 
functioning as hormones[259].  
Moreover, observational studies on the beneficial effect of estrogen-
based hormone therapy on cognitive impairment have also reported 
conflicting results [260]. Indeed, gender-specific risk profiles 
observed for dementia in elderly men and women have drawn 
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attention to the impact that sex hormones, as risk factors, may have 
on progression from mild cognitive impairment (MCI) to dementia 
[261],[262]. The higher risk of AD and dementia incidence in 
women has been linked to high serum levels of endogenous estrogen 
[263] and it has been shown to be influenced by hormone 
replacement therapy [264],[265],[266],[267],[268], although a better 
cognitive performance after current hormone therapy was dependent 
on the duration and type of treatment [269].   
On the other hand, both basic and clinical research findings have 
consistently shown influence of a range of hormones on some 
cognitive functions in AD. For example, high levels of leptin in 
blood have been associated to a lower risk of AD [270] and leptin 
replacement therapy has been suggested as a novel therapeutic 
strategy for AD [271]. The loss of melatonin in cerebrospinal fluid 
has been observed in patients with dementia of Alzheimer’s 
suggesting that it may play a role in the pathogenesis of AD 
[272],[273],[274],[275]. A low thyroid hormone level has been also 
associated with AD [276],[277]; the administration of thyroid 
hormone in AD model mice prevented cognitive deficit and 
improved the neurological function [278]. In Alzheimer’s disease, a 
greater cognitive impairment has been found to be associated with 
lower CSF concentrations of corticotropin-releasing hormone 
[279],[280]. There is evidence that growth hormone (GH) declines 
with advancing age or in Alzheimer’s disease [281],[282],[283] and 
that daily treatment of healthy older adults with GH improves the 
cognition independent of gender [284]. A recent study also shows 
that GH can boost memory retention in rats [285].  
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There are several lines of evidence that point to the role of insulin 
signaling in AD; e.g. insulin levels in the CSF of AD patients is 
lower than healthy controls [286],[287], insulin receptor signaling is 
compromised in AD neurons [288], and insulin resistance is 
associated with reductions in cerebral glucose metabolic rate, which 
is a risk factor for developing AD dementia [289]. Interestingly, 
epidemiological findings indicate that type II diabetes mellitus is 
linked to developing and exacerbating AD pathology [290],[291] so 
that Alzheimer’s has been even proposed by some authors to be ‘type 
III diabetes’ [292],[293]. Similar neuroendocrine disturbances have 
been reported for Huntington’s disease under which the thyrotropic, 
somatotropic and gonadotropic axes are altered [294].  
All the above-mentioned evidence, including inconsistent results and 
disparate findings, suggests that there is a gap between the 
knowledge obtained from basic research and findings of clinical 
investigations on the association between hormones and cognition. 
Context-specific networks of molecular interactions provide a 
relevant framework for supporting translation of basic knowledge 
into clinically relevant information through integrative modeling of 
disease mechanism. Current Alzheimer’s disease maps, including the 
recent AlzPathway model [295], lack the focused representation of 
hormone signaling pathways. Therefore, this work describes the first 
attempt to characterize the hormone/hormone-receptor interactions 
relevant to dementia disorders under a unified framework of the 
interconnected hormonal components.	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8.2. Methods	  
Figure 43 summarizes the overall strategy used for this study. It 
demonstrates a top-down integrative (knowledge- and data-driven) 
approach to modeling the hormone protein interaction network. 	  
	  
Figure 43. Schematic representation of the methodology 
used for construction and analysis of dementia-related 
hormonal network. Details on literature mining and model 
construction and analysis have been provided below.  	  
8.2.1. Literature mining 
Our retrieval system was composed of two software components: the 
dictionary-based text-mining tool, ProMiner, and the semantic search 
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engine, SCAIView. PubMed abstracts were searched for all instances 
of genes and proteins, which are mentioned in the context of 
‘dementia’ as keyword (accessed as of 08.02.2011). The retrieved 
entities were manually checked for their true relevance to both 
hormones and dementia in the context of their abstracts.	  
8.2.2. Network reconstruction and annotation 
The results from text-mining were cross-checked with the contents of 
the EndoNet database [296] and the confirmed entities were used as 
seed proteins in the BIANA tool for reconstruction of the dementia-
related hormonal network (DHN) at level 2. The initial protein-
protein interaction network was constructed around the seed set. In 
order to reduce the dimensionality and increase the confidence, 
interactions that are only supported by the yeast two-hybrid method 
were removed and those interactions that are independently 
confirmed by two or more experimental methods were maintained. 
The network was visualized and statistically analyzed in the 
Cytoscape and Gephi environments [297]. G-lay clustering algorithm 
was used for modularity analysis [298].	  	  
8.2.3. Pathways used for the recovery test 
For the pathway recovery test, we obtained the following expert-
curated hormonal pathways, used them as gold standard, and mapped 
them onto the network: growth hormone pathway [299], insulin 
signaling pathway [299], leptin signaling pathway [300], thyroid 
hormone signaling [301], regulation of the estrogen receptor pathway 
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[299], corticotropin-releasing hormone pathway [302], and 
Melatonin signaling pathway [303].	  
8.2.4. Statistical analysis 
Gene set enrichment analysis was performed using the Molecular 
Signature Database (MSigDB). The DAVID functional annotation 
tool was used for annotation of differentially expressed genes in the 
network. 	  
8.2.5. Translational validation 
For establishing the clinical relevance of the core DHN model, 
knockout mouse phenotypes were retrieved from MGI database 
(http://www.informatics.jax.org/). For retrieval and extraction of 
putative biomarker information from the literature, the biomarker 
terminology developed and published by our team [204] was used. 
Pathway membership for each target was obtained from KEGG 
database (http://www.genome.jp/kegg/) and their association to 
disease was determined using genetic association database 
(geneticassociationdb.nih.gov). Information on brain tissue 
specificity of the targets was obtained from Tissue Distribution 
Database (genome.dkfz-heidelberg.de/menu/tissue_db/) but the 
higher resolution information at the cell type level was retrieved 
from the literaure using SCAIView search engine.  DrugBank was 
searched for the proteins of the core DHN as targets of approved 
drugs (http://www.drugbank.ca/). Then PubMed was searched for 
supporting evidence of positive off-target effects of non-dementia 
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drugs that showed potential implication of those drug-targets in 
improvement of dementia.	  
8.3. Results 
8.3.1. Enrichment of dementia-related proteins for hormone 
signaling activity  
Mining the knowledge space of the literature for proteins that are 
shown to play a role in dementia resulted in a list of 1960 entities, 
which were ranked based on their mutual information (see Methods). 
Due to the fact that high-dimensional information returned by 
retrieval systems inherits noise, the next step was to observe whether 
signals of hormonal proteins could be detected in this large list of 
entities. The gene set enrichment analysis (GSEA) of these proteins 
revealed under-represented signatures of hormone activities in 
pathway analysis as well as implicit but statistically significant 
presence of hormone-related regulatory gene sets in GO biological 
process annotations. However, at the level of GO molecular function, 
these signatures showed significant over-representation for hormone 
activity, neuropeptide hormones and hormone signaling pathways 
(Table 32). 
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Table 32. Analysis of the retrieved data based on 
enrichment for gene ontology, category of molecular 
function. The top five annotations indicate a significant enrichment 
of the results for hormone activity.  
Gene set name Description of annotation P-value 
Amine receptor activity 
GO:0008227: Combining with a 
biogenic amine to initiate a change in 
cell activity. 3.61E-05 
Hormone activity 
GO:0005179: The action characteristic 
of a hormone, any substance formed in 
very small amounts in one specialized 
organ or group of cells and carried 
(sometimes in the bloodstream) to 
another organ or group of cells in the 
same organism, upon which it has a 
specific regulatory action.  1.46E-04 
Copper ion binding 
GO:0005507: Interacting selectively 
with copper (Cu) ions. 3.40E-03 
Neuropeptide hormone 
activity 
GO:0005184: The action characteristic 
of a neuropeptide hormone, any peptide 
hormone that acts in the central nervous 
system. A neuropeptide is any of several 
types of molecules found in brain tissue, 
composed of short chains of amino 
acids.  6.55E-03 
Serotonin receptor 
activity 
GO:0004993: Combining with the 
biogenic amine serotonin, a 
neurotransmitter and hormone found in 
vertebrates, invertebrates and plants, to 
initiate a change in cell activity. 1.40E-02 
 
The results of this observation led us to raise the hypothesis that an 
endocrine interaction network may exist that substantially 
contributes to the pathology of the dementia-spectrum diseases. To 
investigate this hypothesis, we used text-mining and knowledge 
discovery technologies to narrow down our search for retrieval and 
extraction of instances of hormone proteins and their receptors, 
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which are cited in the literature (Medline abstracts) in relation to 
dementia. The focused search resulted in retrieval of 1329 
documents and 453 protein entities extracted from them. Finally, 89 
hormone/hormone-receptor entities were confirmed to play a role as 
hormone/hormone-receptor after crosschecking the retrieved entities 
with the contents of the EndoNet database as gold standard (see 
Methods). We use this initial set of proteins (seed set) as prior 
knowledge to build upon our integrative model.	  
8.3.2. Dementia-related hormone network (DHN) and its 
biological relevance 
The initial protein-protein interaction network comprises of 6966 
nodes (proteins) and 85997 edges (interactions) but after filtering the 
number of edges in DHN decreased to 83998. 6515 nodes form a 
giant connected component and the rest of 451 nodes are singletons 
without any connection; thus, for simplicity, we only consider the 
giant component for further analyses. Statistical analysis of the giant 
component of DHN shows that its node degree distribution could be 
fitted in the power law of the form y=1092.8x-1.17 with an acceptable 
goodness of fit (R-squared value=0.856, Correlation=0.996). This 
indicates that the network is of biological nature.  
The network clustering coefficient of 0.315 and immense distribution 
of the clustering coefficients around the nodes with more than 100 
neighbors is suggestive of a modular organization consisting of 
several interconnected functional modules. The modularity analysis 
of the network revealed four major modules whose functional 
annotation using GSEA supports the notion of modular organization 
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underlying the network (Figure 44): the largest module with 2037 
nodes (Figure 44A) is significantly enriched for regulation of 
transcription, the second module with 1540 interconnected proteins 
(Figure 44B) is significantly involved in hormone and receptor 
signaling, the third module with 1420 proteins (Figure 44C) is 
significantly annotated for GPCR signaling, and finally the fourth 
module containing 1312 nodes (Figure 44D) is enriched for protein 
translation and induction of apoptosis. These findings are consistent 
with the fact that hormone peptides are major ligands for GPCRs and 
through cellular signaling cascades, they regulate the transcription of 
target genes in the nucleus.	  
	  
Figure 44. An overview of modules detected in DHN. 19 
modules were detected in DHN out of which 4 modules represent ca. 
97% of the network. (A) The largest module is enriched for 
regulation of transcription. (B) The second module with 1540 
interconnected proteins representing hormone and hormone receptor 
signaling pathways. (C) The third module with 1420 proteins 
enriched for GPCR signaling. (D) The fourth module containing 
1312 nodes is enriched for protein translation and induction of 
apoptosis. 
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8.3.3. Evaluation of DHN by pathway recovery 
Both the biological relevance and the modularity were further 
evaluated by mapping the Alzheimer’s disease pathway from the 
KEGG database as well as hormone signaling pathways from other 
resources (see Methods). Mapping the Alzheimer’s disease pathway 
onto the network resulted in the recovery of all the proteins and their 
corresponding interactions in the pathway except for APH1A.  
Regarding hormone signaling pathways, the number of proteins 
involved in the actual signaling and the number of mapped proteins 
for each signaling pathway is shown in Table 33. For two pathways 
with 100% node recovery, i.e. insulin signaling pathway and growth 
hormone pathway, manual extraction of edges (interactions) from 
BioCarta and mapping them onto the network yielded 76% edge 
recovery (16 out of 21) for the growth hormone pathway and 90% 
edge recovery (19 out of 21) for the insulin signaling pathway.  
 
Table 33. List of dementia-related hormone signaling 
pathways that were recovered fully or partially in DHN 
Hormone 
signaling pathway 
No. of proteins 
in the original 
pathway 
No. of proteins present in 
the hormone-dementia 
network 
Estrogen receptor 
pathway 
30 25 (83% recovery) 
Insulin signaling 
pathway 
21 21 (100% recovery) 
Growth hormone 
pathway 
27 27 (100% recovery) 
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Leptin signaling 
pathway 
21 17 (80% recovery) 
Thyroid signaling 
pathway 
11 8 (72% recovery) 
Melatonin 
signaling pathway 
16 16 (100% recovery) 
Corticotropin-
releasing hormone 
signaling pathway 
17 16 (94% recovery) 
 
We also surveyed our network for the presence of hormone receptors 
by comparing them to known hormone receptors of genomic 
neuroendocrine hormones and were able to identify them for 
majority of these hormones. 	  
8.3.4. Hormonal convergence in DHN	  
After the completion of this individual pathway recovery test, we 
aggregated all the elements of these seven pathways and mapped 
them onto the giant component of DHN. The aim was to detect the 
core of DHN where the majority of hormone crosstalks occur. A 
subnetwork of 73 nodes and 133 edges was formed, representing the 
converged hormonal pathway interactions. Interestingly, 62 of these 
hormone peptides (ca. 86%) are densely interconnected and form the 
core of DHN. Besides, their interactions appeared to occur in 
different regions of the normal brain after adding the context of brain 
region annotations to each edge using the brain interactome (Figure 
45).  
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Figure 45. Elements of the seven hormonal signaling 
pathways form the core connected component of the brain 
interactome (normal state with all possible interactions). 
Pathway memberships are indicated by color codings; Green: 
estrogen signaling pathway; Red: insulin signaling pathway; Light 
blue: leptin signaling pathway; Dark blue: melatonin signaling 
pathway; Gray: thyroid signaling pathway; Brown: corticotropin-
releasing hormone pathway. Yellow color indicates common 
membership to two or more pathways and also embeds the elements 
of the growth hormone signaling pathway. 
 
Analysis of these annotations shows that the majority of the 
hormonal interactions occur in prefrontal cortex (ca. 93%), 
hypothalamus (ca. 92%) and cingulate cortex (ca. 90%), 
respectively. The finding that interactions of the converged network 
mostly occur in prefrontal cortex and cingulate cortex is consistent 
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with the neuroanatomical distribution of neurofibrillary tangles and 
plaques in the cerebral cortex of AD patients [304]. Moreover, the 
relevance of this finding to clinical attributes of the advanced AD 
pathology has been shown in several studies (Prefrontal cortex: 
[305],[306]; Cingulate cortex: [307]; Hypothalamus: [308],[309]. 
For example, it has been shown that prefrontal cortex, an important 
component for working memory, is the site of hormonal effects on 
cognition including estrogen [310], insulin [311], growth hormone 
[312], and thyroid hormone [313]. Thus, collective dysregulation of 
these pathways in prefrontal cortex of AD patients can lead to 
worsened memory impairment.  
As the pathway-wise color codings in the converged hormonal 
network in Figure 45 indicates, a strong convergence and close 
interplay of hormone signals can be observed at the molecular level 
of the brain interactome. The yellow nodes show the common 
membership of proteins in two or more of these pathways and are 
significantly enriched for Neurotrophin/Trk signaling (GSEA p-
value: 0e0, 14 genes in overlap), through which a variety of signaling 
cascades are connected and signals of neuronal development, 
survival as well as additional higher-order signals such as learning 
and memory are transmitted. The extended portion of estrogen 
signaling pathway in the core interactome is also noted.	  
8.3.5. Linking hormone-dementia hypothesis to mechanistic 
evidence 
Apart from above in silico analyses, we provide more solid support 
for the hormone-dementia hypothesis from an Alzheimer’s reference 
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expression data set [314], which has been processed and used for 
identification of a perturbed protein hub network in Alzheimer’s 
disease by Liang et al. (2012) [315]. The Alzheimer’s reference data 
set provides carefully phenotyped expression data set for six brain 
regions from late-onset AD patients (GSE5281) and lends support to 
the hypothesis that most of the differentially expressed genes in these 
six brain regions represent hub proteins in the hub network specific 
to Alzheimer’s disease. We compared the core DHN with the 
Alzheimer’s hub network derived from Alzheimer’s reference 
expression data set and found 18 hormone signaling proteins in the 
core DHN that overlap with the hub genes differentially expressed in 
the hub network of Alzheimer’s disease (Table 34). As table 34 
indicates, all hormone signaling pathways are perturbed in different 
brain regions, with the largest overlap between insulin and growth 
hormone signaling pathways. Among these proteins, ESR1 and IRS1 
exclusively represent two hormone signaling pathways, namely 
estrogen signaling pathway and insulin signaling pathway. 
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Table 34. Putative AD biomarkers in the core DHN 
supported by gene expression data and pathway 
membership. Red color indicates upregulation and green 
indicates downregulation of the corresponding genes, which 
are expressed in particular brain regions. Membership of those 
genes to their corresponding pathways are marked blue.   
 
8.3.6. Translational validation of the core DHN 
To our knowledge, except for hormone therapy with estrogen, there 
is no clinical trial describing the effect of other hormones on 
cognition improvement. Hence, in the absence of clinical trials, we 
propose a strategy for translational validation of the core DHN by 
showing the clinical relevance of the core DHN to dementia in the 
first step and then linking molecular signatures - through mouse 
model phenotypes - to their corresponding clinical manifestations. 
The clinical relevance of the core DHN to dementia can be 
established through biomarker-guided analysis, in which information 
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of putative molecular indicators of dementia is retrieved and 
extracted from the literature and further become enriched with 
pathway membership, disease association and tissue/cell type 
specificity data (Table 35). Of the proteins in the core DHN, four 
were found in the literature to be reported as potential biomarkers 
that show measurable activity under Alzheimer’s condition. These 
four proteins represent four different hormonal signaling pathways, 
namely growth hormone pathway (MAPK3), corticotropin-releasing 
hormone pathway (NOS1), melatonin signaling pathway (CREB1) 
and insulin pathway (JUN), whose measurable activities under AD 
condition suggest their mechanistic involvement in the pathology of 
AD dementia. 
 
Table 35. Clinical relevance of the core DHN to dementia 
through biomarker-guided analysis 
Target 
candidate 
Pathway 
membership 
Disease 
association 
Biomarker 
type 
Brain 
tissue 
specificity  
Cell-type 
specificity  
MAPK3 Alzheimer’s 
disease, Prion 
disease, Type 
II diabetes 
mellitus, 
Insulin 
signaling 
pathway, 
Long-term 
potentiation 
Autism CSF 
increased 
levels AD 
(PMID: 
22145083, 
19625747), 
Phosphorylati
on (PMID: 
19233276, 
16920298, 
17612901), 
Alterations in 
lymphoblasts 
of AD 
patients 
(PMID: 
19158936) 
Left 
ventricle, 
Right 
ventricle, 
Brain stem 
Microglia, 
Astrocytes, 
Neurons 
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NOS1 Alzheimer's 
disease, Long-
term 
depression, 
Calcium 
signaling 
pathway 
Parkinson's 
disease, 
Alzheimer's 
disease, 
Diabetes 
Mellitus 
type II 
Nitric oxide 
overproductio
n  (PMID: 
20804853), 
nNOS 
signaling 
initiated in 
interneurons 
(PMID: 
16758165), 
Increased 
expression of 
nNOS 
isoforms in 
astrocytes 
(PMID: 
12384247) 
Substantia 
nigra, 
Forebrain, 
cerebral 
white 
matter, 
Limbic 
system 
Astrocytes, 
Neurons 
CREB1 Huntington's 
disease, 
Cholinergic 
synapse 
Alzheimer's 
disease 
Impaired 
CREB 
phosphorylati
on 
(PMID:22119
240) 
Substantia 
nigra, Brain 
stem, Sub-
commissura
l organ, 
Brain 
ventricle, 
Cerebral 
gray matter, 
Cerebral 
white 
matter, 
Forebrain, 
limbic 
system 
Hippocamp
al neurons, 
Dendate 
gyrus 
JUN GnRH 
signaling 
pathway, 
Neurotrophin 
signaling 
pathway, 
MAPK 
signaling 
pathway 
Cognitive 
performance 
Prolonged 
expression of 
c-Jun 
(PMID:87744
39), Increased 
immuno-
reactivity 
(PMID:83139
43) 
Sub-
commissura
l organ, 
Brain 
ventricle, 
Cerebral 
gray and 
white 
matter 
Neurons, 
Microglia, 
Substantia 
nigra 
 
        
Next, we sought to investigate the translational value of DHN by 
linking hormone proteins in DHN to their corresponding knockout 
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mouse phenotypes. Table 36 summarizes 19 knockout mouse models 
representing 6 hormonal signaling pathways with phenotypes related 
to the nervous system. It also includes the ratio of knockout studies 
reporting an effect on the nervous system to studies reporting no 
effect on the nervous system.   
 
Table 36. Knockout mouse phenotypes observed for 
several proteins in the core DHN model 
Name Mutation 
category 
Observed effects on the 
nervous system 
Ratio of KO 
studies with CNS 
phenotypes to 
studies without 
CNS phenotypes Estrogen signaling 
Esr1tm1Ksk Targeted 
(knock-out) 
abnormal pituitary gland 
physiology    
abnormal hypothalamus 
morphology  
abnormal innervation 
4:8 (50%) 
Ncor2tm1Kjep Targeted 
(knock-out) 
abnormal cerebral cortex 
morphology  
abnormal neuron 
differentiation 
1:0 (100%) 
Hdac2tm1.2Rdp Targeted 
(knock-out) 
abnormal hippocampus 
CA1 region morphology 
abnormal dentate gyrus 
morphology 
abnormal hippocampus 
pyramidal cell 
morphology 
enhanced long term 
potentiation 
1:3 (34%) 
Ccnd1tm1Wbg Targeted 
(knock-out) 
absent Purkinje cell layer
  abnormal 
cerebellar granule layer
     
small cerebellum 
1:3 (34%) 
Crebbptm1Sis Targeted 
(knock-out) 
abnormal forebrain 
morphology 
3:4 (75%) 
Insulin signaling  
Juntm1Wag Targeted 
(knock-out) 
abnormal forebrain 
morphology 
1:2 (50%) 
Hras1tm1Grnt Targeted reduced long term 1:3 (34%) 
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(knock-out) potentiation 
Csnk2a1 Targeted 
(knock-out) 
abnormal telencephalon 
development 
1:2 (50%) 
Mapk3tm1Gpg Targeted 
(knock-out) 
reduced long term 
potentiation 
2:2 (100%) 
Leptin signaling pathway 
Leprtm1.2Chua Targeted 
(knock-out) 
abnormal inhibitory 
postsynaptic currents 
1:4 (25%) 
Stat3tm1Aki Targeted 
(knock-out) 
abnormal motor neuron 
morphology  
   
abnormal neuron 
physiology 
1:6 (17%) 
Hif1atm1.1Stom Targeted 
(knock-out) 
abnormal cerebrum 
morphology 
abnormal cerebral cortex 
morphology   
loss of cortex neurons 
  
abnormal occipital lobe 
morphology  
  
abnormal temporal lobe 
morphology   
loss of hippocampal 
neurons 
4:7 (57%) 
Thyroid signaling pathway 
Rxrbtm1Rev Targeted 
(knock-out) 
abnormal excitatory 
postsynaptic potential  
reduced long term 
potentiation  
absent long term 
depression 
2:3 (67%) 
Corticotropin-releasing pathway 
Gnaqtm1Soff Targeted 
(knock-out) 
abnormal glutamate-
mediated receptor currents 
absent long term 
depression 
1:2 (50%) 
Braftm1.1Sva Targeted 
(knock-out) 
increased neuron apoptosis
   
     
abnormal innervation  
    
     
thin cerebral cortex 
3:3 (100%) 
Nos1tm1Plh Targeted 
(knock-out) 
abnormal brain wave 
pattern    
   
abnormal long term 
potentiation  
3:4 (75%) 
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reduced long term 
potentiation  
   
absent long term 
depression    
   
decreased synaptic 
glutamate release  
   
abnormal peripheral 
nervous system 
regeneration  
Melatonin signaling pathway 
Gnai1tm1Drs Targeted 
(knock-out) 
abnormal long term 
potentiation 
1:1 (100%) 
Plcb1tm1Hssh Targeted 
(knock-out) 
loss of hippocampal 
neurons 
1:1 (100%) 
Creb1tm1Gsc Targeted 
(knock-out) 
abnormal CNS synaptic 
transmission  
reduced long term 
potentiation 
1:2 (50%) 
 
 
To establish the bridge between the observed mouse phenotypes and 
the clinical disease manifestation in human, we propose the novel 
concept of “mechanism discovery through serendipitous off-target 
effects” based on the secondary positive effect of approved drugs 
that leads to unexpected and serendipitous clinical observations. 
Many approved drugs that are routinely used for treatment of human 
diseases lead to manifestation of so-called ‘hidden phenotypes’ due 
to binding to unknown targets [316]. The revelation of hidden 
phenotypes points to the fact that off-target effects sometimes result 
in positive effects through novel mechanisms of action. The most 
prominent example is the positive effect of Sildenafil on erectile 
dysfunction while the drug had been originally developed against 
angina.   
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Here we have collected a number of drugs with reported 
serendipitous effects on cognition that target several proteins in the 
core DHN (Table 37). Interestingly, all the off-targets of these drugs, 
when compared to the knockouts in Table 36, correspond to a 
nervous system phenotype in mice. Landscape illustration of the off-
target effects in the core DHN model in Figure 46 shows that 
modulation of the estrogen signaling pathway by four drugs was 
more likely to lead to the serendipitous off-target effect on dementia 
and consequently, to improved cognitive functions observed in 
patients treated with these drugs.  
 
Table 37. Drugs with serendipitous off-target effects on 
cognition and memory 
Drug 
name 
Main 
indicati
on 
Positive side 
effect on 
cognition 
and memory 
Study 
subjects/ 
design 
Supporti
ng 
evidence 
(PMID) 
Target 
protein 
in core 
DHN 
Bexarotene 
(Targretin) 
Skin 
cancer 
Rapid 
reversal of 
cognition, 
social and 
olfactory 
deficits 
Mouse model 
of AD 
22323736 RXRA 
RXRB 
Tamoxifen Breast 
cancer 
Higher level 
of 
independence 
in activities 
of daily life 
and decision 
making; 
relationship 
of tamoxifen 
with a lower 
prevalence of 
AD 
Cross-
sectional study 
of women 
receiving 
tamoxifen 
11005221 ESR1 
Raloxifene Breast 
cancer 
Reduced risk 
of cognitive 
impairment in 
The Multiple 
Outcomes of 
Raloxifene 
15800139 ESR1 
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postmenopau
sal women 
Evaluation 
randomized, 
placebo-
controlled trial 
among 
postmenopaus
al women with 
osteoporosis 
Vorinostat Cutaneo
us T cell 
lympho
ma (skin 
cancer) 
Complete 
restoration of 
contextual 
memory 
Mutant 
APPswe/PS1d
E9 mice 
20010553 HDAC2 
HDAC3 
Lovastatin Hyperli
pid-
emia 
Reduction of 
Abeta 
formation and 
slowing the 
progression 
of AD 
Double-blind 
randomized 
study on 
human 
subjects  
11900994 HDAC2 
Resverat-
rol 
Aging Promoting 
clearance of 
Abeta 
peptides 
Various cell 
lines  
16162502 CSNK2
A1 
Sorafenib Renal 
cell 
carcino
ma 
Reversal of 
memory 
impairment 
Transgenic 
APPswe 
mouse model 
20201822 BRAF 
Naloxone Opioid 
overdos
e 
Improvement 
of learning 
and memory 
through 
enhancement 
of long-term 
potentiation 
Aged rats with 
declined 
memory 
14670637 
15805661 
CREB1 
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Figure 46. Schematic off-target landscape of 8 non-
dementia drugs in the core DHN model. This enriched model 
is a proof-of-concept demonstrator for the mechanistic relevance of 
hormone signaling pathways to pathology of dementia. 
To enlighten the usability of the DHN model, we performed a more 
general analysis by systematically searching for non-dementia drugs 
with targets of the core DHN model and retrieving published studies 
that support the positive, negative or neutral effect of those drugs on 
cognition or memory or learning. This analysis demonstrated that of 
62 proteins in the core DHN model, 21 (ca. 33%) have been already 
targeted by at least one drug out of which 18 drugs targeting 13 
proteins have shown positive effect, 3 drugs targeting 1 protein have 
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demonstrated negative effect, and 39 drugs targeting 18 proteins 
have not been investigated in relation to cognitive functions or have 
not been reported in the literature to have any observed effect on 
dementia. 21 proteins (ca. 33%) have been targeted by experimental 
compounds and 20 proteins (ca. 32%) have not been targeted by any 
drug or compound. These findings imply that hormone signaling 
pathways present a promising target space for drug discovery in the 
area of neurodegenerative brain disorders.	  
8.4. Discussion 
Integrative modeling approaches provide a suitable medium for 
fusion of complementary data derived from literature and 
experiments. Given the fact that molecular mechanism of disease 
risk factors is often unclear and the exact mode of action of most 
approved drugs is unknown in most cases, such models can be used 
to interpret disease mechanism and to predict drug mode of action. In 
particular, an integrative model allows for inference of crosstalks 
among components of the system, guidance of analysis to the core 
pathological pathways, and generation of further hypotheses on how 
risk factors or disease-modifying treatments at molecular level lead 
to manifestation of positive or negative clinical effects. Accordingly, 
our in silico approach to modeling hormone signaling pathways that 
underlie dementia pathology provided several novel insights beyond 
what is already known about hormone signaling pathways in 
dementia, as follows.  
The growing number of findings on the role of hormone signaling 
pathways in regulation of cognition and memory raises an immediate 
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question: how these bits and pieces of accumulating knowledge are 
being used to explain the contribution of hormones to improvement 
or exacerbation of dementia? The dementia-related hormonal 
network, presented in this paper, provided a first unified picture of 
the hormonal component underlying cognitive impairment. 
Convergence of genomic hormonal pathways in the DHN model 
uncovered tight molecular interconnections and crosstalks among 
hormone signaling pathways and regulatory pathways of neural 
growth, survival and differentiation. For instance, the observed 
convergence of estrogen and neurotrophin signaling pathways at the 
core of DHN has been shown to regulate an array of cytoskeletal and 
growth-associated genes in cerebral cortex, including tau 
microtubule associated protein, MAPT [317]. The implication of 
such hormone signals in the pathology of dementia is supported by 
the evidence that phosphorylation of MAPT, which leads to 
neurofibrillary tangle formation and ultimately neurodegeneration, is 
regulated by the signaling effects of insulin and estradiol [318],[319]. 
Similarly, the regulatory influence of thyroid hormone, melatonin, 
and corticotropin-releasing factors on hippocampal tau 
phosphorylation has been documented in the literature 
[320],[321],[322].  
The DHN model could guide the mechanism discovery analysis to 
those signaling pathways that constitute the core pathological 
processes. The modularity detected in the network implies that 
hormone receptors and hormone signals in concert with transcription 
factors may play a significant part in the disease mechanism. The 
molecular interconnection of insulin pathway to dementia pathology 
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- revealed by the DHN model – may provide a mechanistic 
explanation for the previous epidemiological studies on the 
contribution of diabetes mellitus and insulin resistance as risk factors 
to exacerbation of dementia (e.g. [323],[324],[325]). For instance, 
very recently, a 9-year prospective study on 3069 elderly adults 
without dementia demonstrated that patients who suffered diabetes 
had significantly worse cognitive decline in comparison with those 
who did not have the disease, suggesting the contribution of diabetes 
mellitus severity to accelerated cognitive impairment [326]. An 
interesting observation in our model is the co-occurrence of diabetes-
related proteins in the convergent core of DHN. Indeed, three 
members of this subnetwork (i.e. MAPK1, INSR, SOCS3) belong to 
the Type II diabetes mellitus pathway, which fall into the bigger 
insulin signaling pathway together with SHC1 and ELK1. As was 
shown by pathway recovery analysis, the insulin signaling pathway 
is present in the network with the highest number of nodes and edges 
amongst other signaling pathways. The presence of 
MAPK1/ELK1/CREBBP axis in the core subnetwork and its direct 
crosstalk to the insulin pathway is consistent with experimental 
observations that link insulin signaling and diabetes risk to the 
regulation of learning and formation of long-term memory 
[327],[328],[329].  
We showed that the DHN model could have more valuable 
implications beyond a sole portrait of networked signaling pathways 
by enabling high-resolution analysis of core molecular events. This 
was achieved through enhancement of the DHN model with 
knockout phenotype data and drug-target information. Genetically 
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engineered mouse models play an instrumental role in studying 
disease mechanism and translating preclinical studies to the clinic 
[330]. Thus, the knockout phenotypes are good candidates for 
establishing the link between the molecular mechanism and the 
disease clinical manifestation. One clear observation from knockout 
phenotypes is the prominent involvement of all hormone signaling 
pathways in long term potentiation (LTP) beside other biological 
processes. It is well known that long term potentiation of synaptic 
transmission substantially contributes to memory formation [331] 
and that LTP inhibitors also block memory and learning [332]. 
Hence, it can be inferred from the model that probably perturbation 
in hormone signaling pathways may affect LTP adversely. 
Interestingly, knockout models of three putative biomarkers for 
dementia, namely MAPK3, NOS1 and CREB1, show reduced LTP, 
which supports the notion, that hormone signaling pathways are part 
of the dementia pathology. It should be noted that these proteins 
generally exert multiple functions in the biology of nervous system 
by participating in different signaling pathways and thus, the core 
DHN model describes their contribution to the hormone-mediated 
signaling in the context of dementia.  
Since mouse knockout phenotypes alone might not be sufficient to 
concretely conclude about the translational value of our DHN model, 
introduction of the “serendipitous off-target effect” for linking DHN 
model to disease mechanism demonstrated to provide further 
validation for the DHN model. It was shown that inhibition of off-
targets belonging to hormone signaling pathways could lead to 
improvement of memory and learning in human or animal models. 
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Therefore, the enhanced DHN model can be used to predict novel 
targets out of off-targtes or to identify disease-modifying targets and 
pathways that partially regulate the pathology of disease. For 
example, HDAC2 knockout mouse models show enhanced LTP, 
which may indicate HDAC2 might be a potential therapeutic target; 
on the other hand, the clinical evidence is provided by the off-target 
effect of Lovastatin on HDAC2: originally designed against 
hypercholesterolemia, Lovastatin was tested during a double-blind, 
randomized clinical study on human subjects for its effect on 
progression of Alzheimer’s disease through reduction of amyloid-
beta formation[333]. The study found that Lovastatin decreases the 
risk of AD progression. Such an inference exemplifies how the novel 
knowledge on the mechanism of drug effect on disease-related risk 
factors can be derived from the enhanced integrative model of DHN. 
Although DHN provides a unified integrative map of possible 
hormone signaling mechanism in the context of dementia, it has its 
limitations. The inherent issue of network biology is that 
completeness of molecular network maps is limited to data 
availability and validity. The DHN model analyzed in this work may 
not cover all the hormone pathways involved in the pathogenesis of 
dementia but rather it focuses on the convergent hormone action by 
the most prominent ones. Furthermore, such models provide only a 
static picture and do not capture the dynamic behavior of the system. 
However, context-specific modeling, as the first step, makes it 
possible to simulate disease-specific perturbations after incorporation 
of quantitative data from high-throughput technologies. Such an 
integrative modeling approach may prove valuable for prediction of 
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potential biomarkers due to the fact that hormones are able to cross 
the blood-brain barrier by transmembrane diffusion or using 
transporters and their brain levels reflect blood levels [334]. We plan 
to keep the DHN model up to date – within the boundaries of 
available resources – by implementing an alert system that 
automatically collects new information published on the role of 
hormone signaling in dementia and enriches the model with the 
emerging knowledge. It is anticipated that, with the availability of 
more data, the resolution (i.e. specificity and sensitivity) of the 
model will increase so that new versions of the model will support 
translational scientists to make informed decisions.	  
8.5. Conclusions 
The integrated hormone interaction model presented in this study can 
be beneficial in correlating the information of genes, proteins, 
signaling pathways and the clinical manifestation of dementia in the 
context of endocrine system. Such models have great potential to 
support the process of identifying new targets and novel biomarkers 
and bear the potential to help pharmaceutical industry to increase the 
efficiency of their pipeline.	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CHAPTER 9. Modeling of the CNS 
Component and Temporal Progression of 
Alzheimer’s Disease 	  
Given the fact that efficient translation of valuable information 
embedded in brain scans into clinical application is of paramount 
scientific and public health importance, a strategy is proposed to 
bridge the current gap between imaging and molecular biology, 
particularly in AD. This work appeared in Nature Scientific Reports, 
November 2013 [335].   
9.1. Introduction 
Recent advancements in structural and functional neuroimaging 
techniques offer unprecedented opportunities to visualize brain 
structure and function, to non-invasively monitor the progression of 
a disease over time, or to track disease trajectories. Different types of 
imaging reveal different aspects of the brain complexity: Magnetic 
Resonance Imaging (MRI), Computerized Tomography (CT) and 
Diffusion Tensor Imaging (DTI) are designed to localize anatomical 
areas and structures (structural imaging techniques) whereas 
functional Magnetic Resonance Imaging (fMRI) and Positron 
Emission Tomography (PET) are used to capture neural activity at 
molecular level (functional imaging techniques) [336],[337]. Such 
imaging technologies have been used to identify structural and 
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functional changes associated with different stages of progressive 
neurodegenerative diseases such as Alzheimer’s disease (AD) [338].  
In AD patients, progressive loss of memory and cognitive abilities is 
attributed to the dysfunction and death of nerve cells in specific 
regions of the brain [339]. Imaging techniques have established the 
existence of such link between brain structural and functional 
changes by demonstrating the spatio-temporal patterns of cell death 
across affected brain regions. Differential patterns of brain atrophy 
observed in the brain of AD patients with the help of imaging 
techniques indicate that distribution of particular structural changes 
in specific regions of the AD brain may reflect the underlying 
pathology [340].  
Based on the above-mentioned capabilities of imaging technologies, 
a steadily increasing number of imaging studies has been published 
on diagnosis and prognosis of AD but the reported applications are 
still limited to clinical monitoring of anatomical lesions or injuries of 
brain in the course of the disease. On the other hand, the assessment 
of persons with brain disorders and diagnostic decision-making 
process for such patients is still highly dependent on the skills of 
examiner and the patient’s abilities, which shows the current 
limitations of brain imaging techniques for informing the diagnosis 
beyond the behavioral assessments [341]. Current automated 
methods for diagnosis of neuropsychiatric disorders make use of 
classification algorithms to classify the brain scans of participants 
based on measurements of local variation in the morphological 
features of the brain [342]. Accordingly, the diagnostic information 
derived from such imaging-based methods is often unspecific and the 
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knowledge behind the molecular mechanism underlying the 
measured imaging outcomes remains implicit or unknown. In fact, 
the challenge of linking clinical outcomes to their underlying 
molecular events has been long of interest to the scientific 
community and to the pharmaceutical industry as well. This is 
because it will help to obtain better understanding of the disease 
mechanism at molecular level, particularly for personalized medicine 
applications. The technique of molecular imaging using reporter 
molecules that provide information on particular molecular or 
cellular events has been around for some while but it is not in clinical 
use yet and its diagnostic as well as prognostic application will be 
limited to tracing of single cell or single cellular process [343].   
To the best of our knowledge, there is no suggestion in the scientific 
or patent literature preceding the present study how to facilitate 
diagnosis and prognosis of brain diseases by translating information 
from a plurality of brain scan images to underlying region-specific 
disease pathways. Therefore, it would be desirable to provide a 
method that is able to not only diagnose brain images more 
accurately with higher specificity to the disease but also improve 
prognosis by prescribing efficient and personalized therapies based 
on medical history of individual patients. Such a method could be 
potentially upgraded to a clinical decision-support system that would 
adjoin neuroimaging softwares. It could also support target 
identification and biomarker discovery efforts as well. 
The present work proposes a novel strategy using an integrative 
computational approach, which incorporates the information of 
imaging and potential protein biomarkers specific to disease into a 
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brain-specific protein interaction network. Enrichment analysis for 
known pathways further validated the method and unveiled the high 
impact of immune system on the pathology of AD.	  
9.2. Materials and methods	  
9.2.1. Information retrieval and extraction 
With the help of state-of-the-art text mining and knowledge 
discovery tools, ProMiner and SCAIView, PubMed abstracts were 
searched using our dedicated biomarker terminology. The queries 
were formulated and executed over the complete set of PubMed 
abstracts on 14.05.2013 in SCAIView search engine (accessible 
through http://bishop.scai.fraunhofer.de/scaiview/). An example of 
query formulation is shown below:  
(([MeSH Disease:"Alzheimer Disease"]) AND [BioMarker 
Ontology:"Diffusion tensor imaging"])      
Similarly, with the help of SCAIView and the biomarker 
terminology, the following query was performed to obtain a list of 
potential AD biomarkers: 
 (([MeSH Disease:"Alzheimer Disease"]) AND [BioMarker 
Terminology Node:"Evidence Marker"])      
The long list of retrieved potential AD biomarkers was filtered for 
expression evidence and was subjected to manual inspection of 
statements made in the paper abstracts. 
Imaging abstracts were manually screened so that context (relevance 
to both AD and imaging biomarker) as well as content (information 
detailing the type of imaging biomarker and the affected brain 
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region) of retrieved documents was checked and the relevant 
information was extracted.	  
9.2.2. Reconstruction of the temporal lobe subnetwork 
A brain-specific protein-protein interaction (PPI) network 
representing 15 brain regions was used (i.e. brain interactome). The 
PPI network was then filtered for the affected brain regions to obtain 
region-specific subnetwork for temporal lobe, based on the edge 
attributes using Cytoscape software.	  
9.2.3. Pathway enrichment analysis 
Since the affected region in the early stage was the same in the 
advanced stage, we only analyzed one subnetwork representing 
temporal lobe in this study. The subnetwork and corresponding 
mapped molecular biomarkers were subjected to pathway enrichment 
analysis (GSEA) in MsigDB. In order to normalize the pathway 
matching process, GSEA was performed on both potential 
biomarkers and subnetwork proteins using separate pathway 
annotation sets, namely BioCarta, KEGG, and Reactome. In order to 
make the more specific enrichment results from the small number of 
potential biomarkers comparable to the less specific but high 
dimensional enrichment results from the large number of subnetwork 
proteins, we considered the top 20 enrichment results for subnetwork 
proteins so that the sensitivity of the pathway matching process is 
preserved.	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9.3. Results 
The core methodology for translation of imaging readouts to 
molecular pathway maps consists of two steps:  
Step 1 intends to integrate the information of both imaging and 
molecular biomarkers into a brain-specific network model (so-called 
brain interactome), which represents experimentally confirmed 
protein interactions (i.e. network edges) in 15 anatomical regions of 
the human brain9. Since reports on brain imaging contain meta-
information about clinical specifications of patient subjects such as 
stage of the disease and the affected region of the brain, the idea is to 
ultimately generate specific disease subnetworks out of the brain 
interactome that represent protein interactions in affected regions of 
the diseased brain. This is achieved by mapping information of 
imaging outcomes onto the region-specific brain interactome (Figure 
47). For validation purposes, we have used imaging information 
reported in the literature on AD but the source of image-based 
diagnosis could in essence be extended to the clinician’s medical 
report or any other diagnostic annotation attached to images. 
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Figure 47. Generation of brain region-specific subnetwork 
models using imaging readouts. Region-specific diagnosis of 
brain injury can be matched with the region-specific subnetworks of 
the brain interactome to generate an interaction model specific to the 
injured region, in the first step.   
Step 2 involves extraction of identified subnetworks from the brain 
interactome based on the affected regions that are diagnosed by 
imaging and consequently their analysis for underlying pathways. 
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The pathway analysis is performed on both the entire subnetworks 
and potential biomarkers mapped onto these subnetworks separately. 
Afterwards, pathways that are derived from subnetworks and 
pathways that are derived from mapped biomarkers are being 
matched so that potential molecular biomarkers act as “pins” on the 
disease map to guide the analysis to the core biological processes 
deemed to drive the pathology of the disease (Figure 48). 
 
	  
Figure	   48. Enhancement of subnetwork models with the 
information of potential biomarkers. Region-specific 
subnetwork model generated based on the imaging diagnosis in the 
first step is subjected to biomarker-guided analysis by mapping 
potential biomarkers and pathway matching, as detailed below. 
 
9.3.1. Method validation using imaging readouts of 
Alzheimer’s patients 
Our semantic information retrieval system, SCAIView, retrieved 
5698 PubMed abstracts reporting clinical application of imaging 
techniques for diagnosis of AD (MRI: 3458, PET: 1989, DTI: 251) 
and containing information on both AD and affected brain regions 
(see Methods). After manual inspection of these abstracts and 
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information extraction, it turned out that the reported brain regions 
injured in AD could be assigned to three stages of the disease, 
namely early AD/mild cognitive impairment (MCI), moderate 
Alzheimer’s, and advanced Alzheimer’s. It was evident from the 
frequency of AD imaging publications that the majority of these 
studies reported the application of imaging methods to diagnosis of 
the early stage Alzheimer’s disease, reflecting the high priority that 
is assigned to finding early diagnostics for AD. Moreover, these 
efforts were heavily biased toward application of MRI techniques 
amongst others.   
Analysis of the diagnosed anatomical regions in AD brains indicated 
that both structural and functional techniques report limbic system 
and its anatomical components (i.e. temporal lobe, hippocampus, 
cingulate, thalamus and corpus callosum) as the affected regions 
across disease stages. Based on these readouts, a disease progression 
trend is observed so that it appears with progression of the disease 
from early to advanced stage, anatomical lesions extend from 
temporal lobe, entorhinal and precuneus cortices to prefrontal and 
cerebral cortices. These readouts suggest that temporal lobe lesion 
and dysfunction is persistent across disease stages. Therefore, we 
generated a temporal lobe subnetwork model out of the brain 
interactome and validated our proposed method on this model. The 
temporal lobe model is represented by a protein-protein interaction 
(PPI) subnetwork with 2323 nodes and 3587 edges.  	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9.3.2. Biomarker-pathway coupling for targeted enrichment 
analysis 
In order to spot pathways causally involved in the progression of AD 
in the temporal lobe subnetwork model, we searched for molecular 
indicators (potential biomarker candidates) of AD in the literature, 
extracted a list of such hypothetical AD biomarkers (see Methods) 
and mapped them onto the temporal lobe subnetwork. Biomarkers 
are molecular alterations that can be measured in human tissue, cells 
or fluids and represent direct steps in the causal pathways of a 
disease. As a result, 144 potential biomarkers, including 
inflammatory and non-inflammatory biomarkers, were mapped onto 
the temporal lobe subnetwork. Since these potential biomarkers 
indicate measurable molecular activities under the AD condition, this 
strategy helps us guide our analysis to those pathways that are more 
likely to be involved in the disease mechanism at the molecular 
level. Moreover, it overcomes the challenge of dealing with the large 
number of significant pathways that often result from pathway 
enrichment analysis algorithms, particularly when a large number of 
proteins participating in network models are submitted for analysis. 
To this end, we performed separate pathway enrichment analyses on 
both, the subnetwork proteins and the list of mapped biomarkers. 
Since the enrichment results from mapped biomarkers are used to 
guide the analysis on the subnetwork model, enrichment analysis on 
the biomarker list was performed using BioCarta, KEGG, and 
Reactome separately. The same analyses were performed on the 
subnetwork proteins. In this way, the same set of pathway 
annotations from each pathway database is used for pathway 
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comparison and the sensitivity of the pathway matching process 
between biomarker-derived pathways and subnetwork-derived 
pathways is maximized. The purpose is to find out which pathways 
are suggested by potential biomarkers to be perturbed in the 
subnetwork model and which pathways in the subnetwork model 
correctly represent the disease mechanism.  
Such a biomarker-guided pathway analysis showed that imaging 
biomarkers point to the involvement of six pathways in progression 
of AD, namely HIV-NEF pathway, FAS signaling pathway, IL2RB 
pathway, keratinocyte pathway, MAPK signaling pathway and 
immune system signaling (Table 38).  
 
Table 38. Matched results of pathway enrichment analysis 
on the temporal lobe subnetwork model 
Source Enriched pathways resulted from 
mapped biomarkers (FDR value) 
Matched pathways in the 
subnetwork (FDR value) 
BioCarta HIV-I NEF pathway (0 e0) 
FAS signaling pathway (2.41 e-14) 
IL2RB pathway (1.33 e-13) 
Keratinocyte pathway (4.94 e-11) 
HIV-I NEF pathway (0 e0) 
FAS signaling pathway (0 e0) 
IL2RB pathway (0 e0) 
Keratinocyte pathway (0 e0) 
KEGG MAPK signaling pathway (1.03 e-
14) 
MAPK signaling pathway (0 e0) 
Reactome Immune system (0 e0) Immune system (0 e0) 
 
Figure 49 illustrates HIV-NEF pathway spotted on the temporal lobe 
subnetwork model. In this model, there are two approved CNS drugs 
that target two proteins within the HIV-NEF pathway: Triflusal, 
which targets NFKB1 and is used for treatment of cerebral infarction 
and prevention of stroke; and Rasagiline, which targets BCL2 and is 
applied for treatment of idiopathic Parkinson’s disease. Such a drug-
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target-disease pathway landscape informs which therapies already 
target a disease pathway in a particular brain region. The specificity 
of the translated model increased even more when the expression 
information of mapped potential biomarkers (i.e. overexpressed or 
underexpressed) under AD conditions was also extracted from the 
literature and incorporated into the subnetwork model.  
 
	  
Figure 49. Representation of recovered HIV-NEF pathway 
and its first neighbor proteins in the temporal lobe 
network model. The model has been enhanced with drug-target 
and biomarker expression information. Circular nodes in yellow 
show membership to the HIV-NEF pathway; square nodes in pink 
are approved drugs targeting the recovered pathway; triangle nodes 
represent potential biomarkers color-coded for their expression levels 
in AD brain (red: over-expression; green: under-expression). 
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9.4. Discussion 
In spite of invaluable contribution of neuroimaging to the 
understanding of disease progression, its outcome can not be directly 
used in the context of molecular systems analyses for translational 
purposes. The presented methodology is a novel approach to 
integrating brain imaging readouts into a network model of brain 
molecular interactions, which was validated using the accumulated 
knowledge on diagnostic neuroimaging of Alzheimer’s disease in the 
literature. In this way, the pictorial information of brain scans that 
are not amenable to molecular analysis can be incorporated in a 
region-specific brain interaction network to analyze the resultant 
mechanistic models and to validate those models in the context of 
molecular pathways. Consequently, application of this approach to 
identifying drug targets can have important implications in CNS drug 
discovery by reducing the risk of drug failure in clinical trials, given 
the fact that it uses human imaging data instead of disease-
mimicking animal data. Even at the level of sample data, a clear 
advantage of imaging biomarkers over gene expression signatures in 
neurodegenerative disease research is that they refer to in-vivo 
observations of regions and tissues in the diseased brain that are 
directly involved in the disease initiation and progression whereas 
gene expression signatures only provide a snapshot of perturbed 
genes, suffer from heterogeneity of cell types and are limited to post-
mortem sampling. 
Pathway enrichment analysis on the image-translated molecular map 
of temporal lobe revealed several pathways that were not previously 
appreciated to be causally involved in the pathogenesis of AD. The 
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advantage of using pathway enrichment analysis is that the collective 
effect of reported molecular biomarkers under the disease condition 
is taken into account in the context of disease pathways. When taken 
together, these pathways unveiled an important aspect of 
Alzheimer’s pathology: immune system-driven apoptosis. 
Significant enrichment of temporal lobe subnetwork model and its 
mapped biomarkers for HIV infection pathway might indicate that 
signaling pathways to neuronal damage and apoptosis are elicited 
from the very early stage of AD, which persist over the period of 
advanced phase. The role of IL2RB and FAS signaling pathway in 
immune system-mediated apoptosis complements accumulated 
evidence that MAPK signaling pathways contribute to the 
pathogenesis of AD through regulation of neural apoptosis 
[344],[345],[346].  
Enhancing these translated models with drug-target and biomarker 
information – as shown for HIV-NEF pathway model in Figure 49 – 
can provide added value to physicians and researchers in several 
ways:  
- it may support more accurate diagnosis based on molecular 
etiology of the disease, particularly when measured biomarkers from 
patient are available and can be mapped onto the model to spot 
disease pathways. This has implications for the mechanistic 
diagnosis of diseases rather than conventional diagnosis solely based 
on often overlapping symptoms and signs.  
- it may improve prognostic tasks using the drug-target information 
that is associated to disease pathways. Patient’s therapeutic history 
can complement the model and support prognostic decision-making 
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through incorporation of individual risk factors such as susceptibility 
background (e.g. APOE genotype) or environmental risk factors (e.g. 
aging). 
- it may guide target identification through prediction of drug mode 
of action in the context of affected tissue, disease stage and perturbed 
pathway. Information of approved drugs and their targets in disease 
pathways that are already incorporated in the model can support the 
concept of polypharmacology for discovery and development of 
next-generation multi-targeting drugs.  
- it may be used for prediction of companion biomarkers that are 
mechanistically linked to disease etiology, on one hand, and to mode 
of action of approved or experimental drugs, on the other hand.       
In summary, the novel integrative methodology presented here 
provides insight into the underlying molecular mechanisms of 
disease progression by linking the clinical readouts of imaging 
techniques to their corresponding molecular events, but this approach 
has limitations. The inherent issue of network biology is that 
completeness of molecular network maps is limited to data 
availability and validity. Therefore, the specificity and sensitivity of 
the translation process is a function of the completeness of the brain 
interactome. Another limiting factor is the low resolution of the 
protein-protein interaction maps in terms of representing other 
molecular species than proteins and also directionality of the 
interactions. However, these shortcomings can be overcome through 
replacement of PPI networks with causal computational models 
based on BEL. BEL-based mechanistic models not only represent all 
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molecular species such as ions or metabolites but also preserve the 
directionality of interactions. 
This method is generic and can be applied to modeling other brain 
disorders. It can be foreseen that the extended algorithm of this 
methodology, when optimized and fully automated, has the potential 
to be used as a clinical decision-support tool for personalized 
diagnosis and prognosis of patients with brain disorders. 	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CHAPTER 10. Model-based Target 
Prediction for Alzheimer’s Disease 	  
10.1. Targetability versus druggability 
In the book “in silico technologies in drug target identification and 
validation”, Leon and Markel (2006) classify data-driven methods 
such a s expression profiling under the category of ‘target 
identification’ and assign text-mining and network/pathway analysis 
methods to the category of ‘target validation’ [347]. In this work, a 
hybrid approach to in silico identification and validation of drug 
targets in the context of AD has been introduced. The advantage of 
this hybrid approach, which combines data- and knowledge-driven 
strategies, is that it provides a unified framework for simultaneous 
identification and validation of potential target and biomarker 
candidates specific to the context of AD in silico.  
In the opinion of this author, it is important to distinguish between 
“targetability” and “druggability” features. While most of the studies 
have been focused on the druggability properties of the protein 
targets, less attention has been paid to the targetability properties of 
protein targets. This notion is supported by the fact that the primary 
target for 7% of approved drugs is not known and mode of action for 
18% of approved drugs is not defined [348],[349]. Druggability is 
defined as “the ability of a target to be modulated by potent, small 
drug-like molecules” [350], mostly reflects the structured-based 
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physicochemical properties of the target in the binding site [351], 
and is used in the target validation phase [352]. In contrast, there is 
no clear definition for targetability in the literature so far. 
Targetability can be defined as ‘the ability of a target to modify the 
path of disease or modulate disease-related phenotypes’. It is often 
used in the target identification phase [353]. 
The concept of targetability is being transformed from a ‘target-
based’ paradigm into ‘pathway-based’ paradigm, where network 
subgraphs and pathways emerge as targetable entities (e.g. 
[354],[355]). Rising attrition rates of new compounds in the past 
decade, which was highest (62%) during phase II [356], indicates the 
lack of efficacy and reflects the low predictive capacity of target-
based discoveries. Advantages of the pathway-based approach over 
the target-based approach are manifold [357]:  
a) the hypothesis behind a target’s mechanism of action in the 
context of the disease can be disproved (i.e. what if 
manipulation of target X fails to modify the disease process Y);   
b) the functional output of the target pathway can be predicted and 
linked to clinically relevant outcomes; and     
c) positive therapeutic off-target effects of approved or pipeline 
drugs can be predicted. 
Several studies have previously shown the effectiveness of using 
pathways as therapeutic targets in neurobiology. For example, 
measurement of hippocampal neurogenesis pathway by high-
throughput screening for approved drugs on mouse models showed 
that cholesterol lowering drugs can predict the stimulatory effect of 
these drugs on the adult neurogenesis pathway in animal models 
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[358]. In another study by the same group, lipopolysaccharide-
induced microglia proliferation pathway in the rat brain was 
subjected to HTS analysis and drugs were found that ameliorated 
clinical symptoms in the mouse models of Parkinson’s disease [359]. 
In a primary study based on pathway analysis, Cramer et al. (2012) 
found that FDA-approved anti-cancer drug, bexarotene, could 
rapidly reverse cognitive and olfactory deficits in Alzheimer’s mouse 
models [360]. Inspired by these results, Li and Lu (2013) have 
proposed a pathway-based drug repositioning prediction method, 
which considers all possible causal chains connecting drugs to 
diseases through molecular pathways and estimates transition 
likelihood of each causal chain in the network [361]. 	  
10.2. Application of the hybrid approach to target 
identification and validation for AD	  
As mentioned in Chapter 6, the triad of Brain, Immune, and 
Hormone signaling components create an inter-linked and complex 
system, which is an example of integrated and interactive system 
where nervous, immune/inflammatory, and endocrine components 
preserve complex crosstalks in order to guarantee the maintenance of 
the system’s homeostasis. Due to such a high level of integrity, 
dysregulation or malfunctioning of one component directly affects 
the neighbouring components. Separate hypotheses on the 
involvement of each component in the pathology of AD have been 
proposed but they all describe the impairment in components of the 
same system. Therefore, the collective results from modeling 
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components of the triad system should be taken into account when 
the identification of a targetable pathway is desired.  
The proposed hybrid approach provides a systems view on the 
involvement of the triad system in the pathology of AD. Interplay 
between the immune, nervous and endocrine components has 
attracted attention of researchers for many years and it is now well 
established that this triad interaction is mediated by cytokines, which 
regulate important processes such as cell proliferation and hormone 
secretion [362]. Accordingly, immunotransmitters transmit 
information from the immune component to the CNS component and 
interfere with the neuroendocrine component. This triad interaction 
may explain, at least in part, impairments in immunity against 
infections, reproductive functions, and brain atrophy, which occur in 
the pathophysiology of AD.      
 
 
 
 
 
 
Figure 50. The triad system hypothesized to be involved in 
the pathology of AD and repreentation of their 
interactions. 
CNS    (brain) 
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When analyzing the pathway enrichment for literature-derived 
proteins reported to be involved in dementia (Chapter 8), it came to 
the attention that the Biocarta’s cytokines and inflammatory response 
pathway is the most significant overrepresented pathway. On the 
other hand, modeling results from both AIDS-dementia complex and 
AD progression studies (Chapters 7 and 9, respectively) are 
indicative of the prominent role of the immune response signaling 
and cellular regulatory signaling pathways in the core pathology of 
AD. More weight should be given to the results of biomarker-guided 
pathway analysis in the AD staging study because in-vivo imaging 
biomarkers in combination with in-vitro measured molecular 
biomarkers reflect a more realistic picture of the disease 
development in AD patients.  
Comparison of the enriched pathways that resulted from modeling of 
each component implies that MAPK signaling pathway is common 
among all the three components. In the hormone-dementia study 
above, MAPK3, which regulates the growth hormone pathway, 
represents the MAPK signaling pathway. It has been shown that 
MAPK signaling pathway is pathologically involved in various 
human diseases including AD, PD and ALS [363]. This is because 
mitogen-activated protein kinases mediate intracellular signaling and 
regulate a diverse set of cellular activities. Besides, it has been 
shown that extra-cellular amyloid-beta activates MAPK signaling 
cascade via nicotinic receptors [364]. In AD, MAPK pathway 
enforces abnormal re-entry into the cell cycle, which in turn activates 
amyloid production pathways; more specifically, MAPK3 is 
activated by oxidative stress, which is a hallmark of 
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neurodegeneration [365]. MAPK signaling pathway has been 
suggested as a potential therapeutic target for neurodegenerative 
diseases because protein kinases are attractive modulators of brain 
inflammation and gliosis and MAPK inhibitors can be easily 
administered due to good bioavailability [366]. In comparison to the 
field of oncology where half of the drugs in the pipeline are kinase 
inhibitors, CNS disease indications appear to be lagging behind for 
kinase-targeted drugs. For example, Imatinib (Gleevec), which is 
used for treatment of multiple cancers, was first reported for its 
efficacy in 1995-6 and was ultimately approved and introduced to 
the market in 2001 whereas no kinase inhibitor exists to date for 
CNS diseases. In fact, the launch of Imatinib demonstrated the 
success of applying pathway approaches in target validation. 
However, there are several kinase inhibitors that are either at the 
preclinical or clinical phase of investigation for treatment of CNS 
disorders [367].      
Given the above results, however, an ideal therapeutic strategy seems 
to require modulating all the disease pathways underlying the triad 
system. So far, the mainstream of investigation for therapeutic 
interventions in AD has been focused on targeting amyloid 
production, accumulation, clearance, or toxicity associated with 
amyloid-beta plaques. Due to disappointments with these 
approaches, as discussed earlier, alternative approaches are under 
investigation, which include targeting oxidative stress, inflammation, 
and glutamate-mediated neurotoxicity; in addition, neurorestoration 
via neurotrophin pathway and hormone therapies are emerging 
approaches to modifying the path of AD [368]. Unfortunately, these 
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entire alternative approaches have been founded on the same old 
hypothesis of amyloidosis and each one of them represents a piece of 
the same puzzle. Acknowledging the complexity of AD, it becomes 
apparent that targeting single pathways through these approaches 
may not result in effective treatments for AD. Hence, it is proposed 
here that the concept of polypharmacology can be extended from the 
level of “multi-protein” targeting to the level of “multi-pathway” 
targeting.        
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CHAPTER 11. Conclusion and Outlook 	  
Deciphering disease mechanisms is an important mission in systems 
biology and drug discovery. When dealing with multi-factorial 
progressive diseases such as neurodegeneration, it is of utmost 
importance to firstly get a profound understanding and knowledge on 
molecular mechanisms because this will lend a more support to 
predictive models for target identification and validation.  
One of the biggest hurdles to finding novel biomarkers and 
therapeutics for brain diseases is the lack of deep understanding of 
the “etiological mechanism”. As an example, the current 
classification of diseases is solely based on anatomical, symptomatic 
and epidemiological criteria and does not take the etiological 
mechanism into account. At the same time, neurological disorders 
may share common disease mechanisms despite heterogeneous 
clinical symptoms. Thus, re-defining diseases based on their 
underlying molecular and environmental causes rather than on 
physical signs and symptoms is crucial for development of effective 
therapeutic strategies. In addition, the elucidation of disease 
mechanism may support discovery of new disease-specific 
biomarkers.  
Despite decades of research on various aspects of dementia, the 
mechanisms underlying neurodegeneration are yet far from being 
well understood. The fact is that years of pure data-driven 
approaches to delineating the complexity of disease mechanism in 
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dementia merely based on GWAS or gene expression results has not 
yielded a practical and impactful outcome. Polymorphism studies 
may be underpowered to detect rare variants, gene expression studies 
are highly sensitive to genetic, environmental, demographic and 
technical factors, and proteomic results – particularly in the 
biomarker discovery for dementia – are difficult to reproduce [369]. 
A general problem with most of data-driven methods is that they are 
devoid of proper disease-specific biological context; i.e. they ignore 
cell-type and tissue specificity, disease staging, and patient-specific 
risk factors at the time of sampling. The argument is that data-driven 
approaches alone simply are not amenable to understanding the 
complexity underlying NDDs, in general, and AD, in particular. 
Given the increasing amount of information density in the published 
knowledge space of literature, the task of knowledge-driven 
approaches is to bring context to multi-layered data-driven methods 
based on prior biological knowledge. This prior knowledge spans 
from published pathways and co-expression information to clinical 
parameters including age, comorbidities, and disease progression, to 
name a few.  
As shown throughout this thesis, a knowledge-based integrative 
approach to modeling neurodegenerative disease mechanism in AD 
was designed and utilized successfully to link molecular disease 
states to their corresponding clinical readouts. A substantial amount 
of time and effort was dedicated to groundbreaking work and 
development of semantic frameworks specific to dementia and AD, 
which did not exist before. Various ontologies and controlled 
vocabularies were generated, evaluated, and applied to support the 
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knowledge-driven approach to modeling AD dementia mechanism. 
The complementary nature of knowledge-driven and data-driven 
approaches allowed for combining experimental data with prior 
knowledge under a single modeling framework, which ultimately 
resulted in enhanced sematic resolution at biological scales, 
improved functional sensitivity at the molecular level, and increased 
disease specificity at clinical level.        
The results of disease modeling approach applied to AD in this work 
clearly show a deviation from the conventional amyloid-centered 
results. It appears that amyloid plaque formation and inflammation 
are secondary effects of an earlier damage to the neurons, which can 
be seen as a consequence of dysregulation in the immune system. 
Thus, the next wave of neurodegenerative research should be heavily 
directed towards investigation of the role of the immune system in 
susceptibility to and initiation of the disease. It is predictable that the 
next generation of computational disease models integrate medical 
histories and health outcomes of patients, for example in the form of 
co-morbidity analysis, so that deeper insights into the early events in 
the pathogenesis of NDDs is gained and preventive measures to 
modify the path of disease progression can be taken.  
The capacity of in silico disease models to be augmented with 
annotation of semantic and mechanistic information such as 
anatomic sites, knock-out phenotypes, pathways, drug targets and/or 
potential biomarkers provides a flexible framework for development 
of algorithms that support decision making in drug development, 
clinical diagnosis and prognosis of diseases. The proposed algorithm 
for translation of brain scans to their underlying region-specific 
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molecular maps is an example of such augmentation efforts, which 
uses the novel “biomarker-guided analysis” method and thereby 
opens a new opportunity to computationally validate the in silico 
models of the disease. In should be noted that the disease models 
presented in this work are correlation, unsigned network models, 
which have been built using protein-protein interaction data. An 
emerging alternative in computational disease model building 
integrates literature-derived ‘cause and effect’ relationships into a 
data-driven platform and produces casual network models. 
Moreover, BEL-based disease models go beyond modeling of 
‘single-entity interactions’ by including more biological entities as 
well as biological processes. An interesting feature of BEL models is 
the ability to identify the information flow between up-stream and 
down-stream of cellular processes [370]. Given this capability, it 
would be interesting to devise a strategy for reasoning over the BEL 
models aiming at simulating effects of hypothetical ligands or 
perturbations at the up-stream points and predicting outcomes at the 
down-stream endpoints. 
By now, the concept of polypharmacology has been restricted to 
targeting multiple proteins in a single unique pathway. However, as 
discussed earlier in this chapter, the paradigm shift from single-target 
to pathway-target strategy demands for extension of the 
polypharmacology concept to the pathway level. The rationale 
supporting this proposition is that NDDs manifest heterogeneous 
clinical symptoms in various pathological locations and, therefore, 
targeting multiple disease pathways at the same time is more likely 
to exert a greater modifying effect on the mechanism of disease. As 
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shown in the present study, pathway-based disease modeling can be 
used for building the bridge from drug discovery to clinical research 
by linking molecular specifications of the disease mechanism to 
corresponding clinical manifestations. There are both advantages and 
limitations associated to this approach. Advantages include offering 
an alternative successful route to the current conventional target 
identification and validation in the context of disease pathway 
models, placing single genes and proteins in the context of pathway 
signatures for development of responder-specific therapeutics, and 
increasing the druggable space. Nonetheless, target relationships 
between pathways due to cross-talk events in the same cell or tissue, 
and different species-specific signaling mechanisms between distinct 
pathway models are among limiting factors. Moreover, in the 
absence of data and with limited "direct" AD knowledge, this sort of 
"loose association mining" is imperative. However, it can be 
foreseen that integrative disease modeling methods will be improved 
with advancement of “concrete association mining” algorithms as 
more data and information becomes available. In addition, it is 
anticipated that these methods will be used in the future to link the 
mode of action for drug candidates to predictable side effects or to 
build connectivity between in-vivo and in-vitro biomarkers.	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